1 
 MTN -039 
 
  
A Phase 1 Open Label Safety and Pharmacokinetic Study of Rectal 
Administration of a Tenofovir Alafenamide/ Elvitegravir Insert  at Two Dose Levels  
   
Microbicide Trials Network  
  
Funding Agencies:  
Division of AIDS, US National Institute of Allergy and Infectious Diseases  
US Eunice Kennedy Shriver National Institute of 
Child Health and Human Development  
US National Institute of Mental Health  
US National Institutes of Health  
   
Grant Number : 
5UM1 AI068633  
 
DAIDS Protocol ID : 
38470  
 
IND Sponsor:  
DAIDS  
  
IND # TBD 
  
Protocol Chair:  Sharon Riddler , MD, MPH  
   
Version 1.0 
 
March 6, 201 9
 
 
    
 
 
MTN -039, Version 1. 0 2  March 6, 2019   
MTN -039 
 
A Phase 1 Open Label Safety and Pharmacokinetic Study of Rectal Administration of 
a Tenofovir Alafenamide/ Elvitegravir Insert  at Two Dose Levels 
 
TABLE OF CONTENTS  
 
LIST OF ABBREVIATIONS AND ACRONYMS  ..................................................................... 6  
PROTOCOL TEAM ROSTER  ............................................................................................. 11 
INVESTIGATOR SIGNATURE FORM  ................................................................................ 19 
PROTOCOL SUMMARY  ..................................................................................................... 20 
1 KEY ROLES  .................................................................................................................. 23 
1.1 Protocol Identification  ............................................................................................ 23 
1.2 Funding Agencies, Sponsor and Monitor Identification  ......................................... 23 
1.3 Medical Officer  ...................................................................................................... 24 
1.4 Laboratory Centers  ............................................................................................... 24 
1.5 Data Center  ........................................................................................................... 24 
1.6 Study Implementation  ........................................................................................... 24 
2 INTRODUCTION ........................................................................................................... 25 
2.1 Background of Rectal Microbicide Research and Study Rationale  ....................... 25 
2.2 Elvitegravir (EVG) – Description and Mechanism of Action  .................................. 25 
2.3 Non-Clinical Studies of Elvitegrav ir ....................................................................... 26 
2.4 Tenofovir Alafenamide (TAF) – Description and Mechanism of Action ................. 30 
2.5 Non-Clinical Studies of Tenofovir Alafenamide ..................................................... 31 
2.6 Non-Clinical Studies of Elvitegravir and Tenofovir Alafenamide  ........................... 33 
2.7 Clinical Studies of Elvitegr avir and Tenofovir Alafenamide  ................................... 36 
2.8 Study Hypotheses and Rationale for Study Design .............................................. 42 
3 OBJECTIVES ................................................................................................................. 43 
3.1 Primary Objectives  ................................................................................................ 43 
3.2 Secondary Objective ............................................................................................. 43 
3.3 Exploratory Objectives  .......................................................................................... 43 
4 STUDY DESIGN  ............................................................................................................ 44 
4.1 Identification of Study Design ................................................................................ 44 
4.2 Summary of Major Endpoints  ................................................................................ 44 
4.3 Description of Study Population  ............................................................................ 45 
4.4 Time to Complete Accrual  ..................................................................................... 45 
4.5 Study Groups  ........................................................................................................ 45 
4.6 Expected Duration of Participation  ........................................................................ 45 
4.7 Sites  ...................................................................................................................... 45 
5 STUDY POPULATION  ................................................................................................... 45 
5.1 Selection of the Study Population  ......................................................................... 45 
5.2 Inclusion Criteria  ................................................................................................... 46 
5.3 Exclusion Criteria  .................................................................................................. 47 
5.4 Co-enrollment Guidelines  ..................................................................................... 48 
6 STUDY PRODUCT  ........................................................................................................ 49 
 
 
MTN -039, Version 1. 0 3  March 6, 2019  6.1 Regimen ................................................................................................................ 49 
6.2 Administration  ....................................................................................................... 49 
6.3 Study Product Formulation and Storage  ............................................................... 49 
6.4 Study Product Supply and Accountability  ............................................................. 50 
6.5 Ancillary Study Supplies  ....................................................................................... 51 
6.6 Concomitant Medications  ...................................................................................... 51 
6.7 Prohibited Medications, Products and Practices  ................................................... 51 
7 STUDY PROCEDURES  ................................................................................................ 53 
7.1 Pre-screening  ........................................................................................................ 54 
7.2 Screening  .............................................................................................................. 54 
7.3 Enrollment (Day 0)  ................................................................................................ 55 
7.4 Follow -up Visits  ..................................................................................................... 56 
7.5 Follow -up Procedures for Participants Who Permanently Discontinue Study 
Product  ................................................................................................................. 61 
7.6 Interim Visits  ......................................................................................................... 62 
7.7 Protocol Counseling: Adherence and Contraception Counseling .......................... 62 
7.8 Clinical Evaluations and Procedures  ..................................................................... 62 
7.9 Behavioral Assessments  ....................................................................................... 63 
7.10  Pharmacokinetics (PK) and Pharmacodynamics (PD)  .......................................... 64 
7.11  Laboratory Evaluations  ......................................................................................... 64 
7.12  Specimen Management  ........................................................................................ 66 
7.13  DAIDS Laboratory Oversight ................................................................................. 66 
7.14  Biohazard Containment  ........................................................................................ 66 
8 ASSESSMENT OF SAFETY  ......................................................................................... 67 
8.1 Safety Monitoring  .................................................................................................. 67 
8.2 Clinical Data and Safety Review ........................................................................... 67 
8.3 Adverse Events Definitions and Reporting Requirements  .................................... 68 
8.4 Adverse Event Reporting Requirements  ............................................................... 70 
8.5 Pregnancy and Infant Outcomes  ........................................................................... 71 
8.6 Regulatory Requirements  ..................................................................................... 71 
8.7 Social Harms Reporting  ........................................................................................ 71 
9 CLINICAL MANAGEMENT  ............................................................................................ 71 
9.1 Grading System  .................................................................................................... 72 
9.2 Dose Modification Instructions  .............................................................................. 72 
9.3 General Criteria for Permanent Discontinuation of Study Product  ........................ 72 
9.4 Follow -up in Response to Observed Adverse Events  ........................................... 72 
9.5 Pregnancy  ............................................................................................................. 73 
9.6 Criteria for Early Termination of Study Participation  ............................................. 73 
10 STATISTICAL CONSIDERATIONS  ............................................................................... 73 
10.1  Overview and General Design .............................................................................. 73 
10.2  Study Endpoints  .................................................................................................... 74 
10.3  Primary Study Hypotheses .................................................................................... 74 
10.4  Sample Size and Power Calculations  ................................................................... 74 
10.5  Randomization Procedures  ................................................................................... 75 
10.6  Participant Accrual, Follow -up and Retention  ....................................................... 76 
10.7  Data and Safety Monitoring and Analysis  ............................................................. 76 
 
 
MTN -039, Version 1. 0 4  March 6, 2019  11 DATA HANDLING AND RECORDKEEPING  ................................................................. 77 
11.1  Data Management Responsibilities  ....................................................................... 77 
11.2  Source Documents and Access to Source Data/Documents  ................................ 78 
11.3  Quality Control and Quality Assurance  ................................................................. 78 
12 CLINICAL SITE MONITORING ...................................................................................... 78 
13 HUMAN SUBJECTS PROTECTIONS  ........................................................................... 79 
13.1  Institutional Review Boards/Ethics Committees  .................................................... 79 
13.2  Protocol Registration  ............................................................................................. 79 
13.3  Study Coordination  ............................................................................................... 80 
13.4  Risk Benefit Statement  ......................................................................................... 81 
13.5  Informed Consent Process .................................................................................... 84 
13.6  Participant Confidentiality ...................................................................................... 85 
13.7  Special Populations  .............................................................................................. 86 
13.8  Compensation  ....................................................................................................... 86 
13.9  Communicable Disease Reporting  ........................................................................ 86 
13.10  Access to HIV -related Care................................................................................... 86 
13.11  Study Discontinuation  ........................................................................................... 86 
14 PUBLICATION POLICY  ................................................................................................. 87 
15 APPENDICES  ................................................................................................................ 87 
APPENDIX I:  SCHEDULE OF STUDY VISITS AND EVALUATIONS ................................ 88 
APPENDIX II:  ALGORITHM FOR HIV TESTING FOR SCREENING AND FOLLOW -UP . 91 
APPENDIX III: SAMPLE INFORMED CONSENT FORM  (SCREENING, ENROLLMENT, 
LONG -TERM STORAGE AND FUTURE TESTING)  ........................................................... 92 
REFERENCE LIST ............................................................................................................ 115  
 
TABLE OF TABLE S AND FIGURES  
 
Table 1:  In vitro  Dissolution of 8 mg Elvitegravir Insert  ....................................................... 27 
Table 2:  Study design of the pharmacokinetic study of EVG/TDF vaginal inserts in 
pigtailed macaques  ............................................................................................................. 28 
Table 3:  Group Assignments in EVG Vaginal and Rectal Irritation Studies  ........................ 29 
Table 4:  In vitro  Dissolution of 20/16 mg TAF/EVG Insert  .................................................. 34 
Table 5:  Adverse Reactionsa (All Grades) Reported in ≥5% of Subjects with Chronic 
HBV Infection and Compensated Liver Disease in Studies Gilead Studies 108 and 1 10 
(Week 96 Analysisb) ............................................................................................................ 41 
Table 6:  Adverse Reactions (All Grades) Reported in ≥5% of HIV -1 Infected 
Treatment -Naïve Adults Receiving Genvoya or Stribild in Gilead Studies 104 and 111 
(Week 144 Analysis)  ........................................................................................................... 42 
Table 7: Study Product Regimen  ........................................................................................ 49 
Table 8: Prohibited CYP Inhibitors  ...................................................................................... 52 
Table 9: Prohibited CYP Inducers  ....................................................................................... 52 
Table 10:  Screening Visit  ................................................................................................... 54 
Table 11:  Enrollment Visit  .................................................................................................. 55 
Table 12: Dosing Procedures  .............................................................................................. 56 
Table 13:  24- hour Post-Dosing Visits  ................................................................................. 58 
Table 14:  Other Post- Dosing Visits  .................................................................................... 59 
Table 15:  Final Contact/Early Termination Visit  ................................................................. 60 
 
 
MTN -039, Version 1. 0 5  March 6, 2019  Table 16: Specimens to be Collected to Assess Safety, PK and Ex Vivo  Antiviral 
Activity ................................................................................................................................. 64 
Table 17: Analysis of Safety Event Frequency  .................................................................... 74 
Table 18: Exact 2- sided 95% Confidence Intervals Based on Observing a Particular 
Rate of Safety Endpoints among 20 Participants  ................................................................ 75 
 
Figure 1: MTN -039 Study Visit Schedule  ............................................................................ 21 
Figure 2: Study Product  ....................................................................................................... 50 
Figure 3: MTN -039 Study Visit Schedule  ............................................................................ 54 
 
  
 
 
MTN -039, Version 1. 0 6  March 6, 2019  MTN -039 
 
A Phase 1 Open Label Safety and Pharmacokinetic Study of Rectal Administration of 
a Tenofovir Alafenamide/ Elvitegravir Insert  at Two Dose Levels 
LIST OF ABBREVIATIONS AND ACRONYMS  
 
AE adverse event  
AIDS  Acquired Immunodeficiency Syndrome  
ALT alanine transaminase  
API active pharmaceutical ingredient  
ARV antiretroviral drugs  
AST aspartate aminotransferase  
AUC  area under the curve  
AUC inf area under the curve  extrapolated to infinity  
AUC last area under the curve  up to the last measurable concentration  
BID bis in die, or twice per day  
BPA bisphenol A  
BRWG  Behavioral Research Working Group  
BSWG  Biomedical Science Working Group  
BV bacterial vaginosis  
CASI  computer assisted self -interview  
CBC  complete blood count  
CD4 cluster of differentiation 4  
CDC  Centers for Disease Control and Prevention  
cDNA  complementary DNA  
CFR Code of Federal Regulations  
CI Confidence Interval  
Cmax maximum concentration  
CMRB  Clinical Microbicide Research Branch  
CNS  central nervous system  
COBI  cobicistat  
CRF case report form  
CRMS  Clinical Research Management System  
CRS  Clinical Research Site  
CT Chlamydia trachomatis, Chlamydia  
CTA Clinical Trial Agreement  
CVF cervicovaginal fluid  
CWG  Community Working Group  
CYP1A2  cytochrome P450 family 1, subfamily A 2 genetic locus   
CYP2C8  cytochrome P450 family 2, subfamily C8 genetic locus   
CYP2C9  cytochrome P450 family 2, subfamily C9 genetic locus   
CYP2C19  cytochrome P450 family 2, subfamily C19 genetic locus   
CYP2D6  cytochrome P450 family 2, subfamily D6 genetic locus   
CYP2E1  cytochrome P450 family 2, subfamily E1 genetic locus   
CYP3A  cytochrome P450, family 3, subfamily A genetic locus  
CYP3A4  cytochrome P450 family 3, subfamily A 4 genetic locus   
CYP450  cytochrome P450  
 
 
MTN -039, Version 1. 0 7  March 6, 2019  DAERS  DAIDS Adverse E xperience  Reporting System  
DAIDS  Division of AIDS  
DAIDS PRO  DAIDS Protocol Registration Office  
DAPY  di-amino -pyrimidine  
DLV delavirdine  
DNA  deoxyribonucleic acid  
DOD  directly observed dosing  
EAE expedited adverse event  
EC ethics committees  
EC 50 50% effective concentration  
EFV efavirenz  
ENR  enrollment  
EU European Union  
EVG  elvitegravir  
FDA (US) Food and Drug Administration  
FHCRC  Fred Hutchinson Cancer Research Center  
FMO  flavin -containing monooxygenase  
FTC emtricitabine  
g grams  
GC Neisseria gonorrhoeae, gonorrhea  
GCP  Good Clinical Practices  
GEE  generalized estimating equations  
GMP  Good Manufacturing Practices  
HBsAg  hepatitis B surface antigen  
HBV hepatitis B virus  
HCG  human chorionic gonadotropin  
HCV  hepatitis C virus  
HEC  hydroxyethylcellulose  
HEENT  Head, Eye, Ear, Nose and Throat Examination  
HHS  (U.S.) Department of Health and Human Services  
HIV Human Immunodeficiency Virus  
HIV-1 Human Immunodeficiency Virus type 1  
HIV-1 IIIB  Human Immunodeficiency Virus type 1, IIIB strain  
HPTN  HIV Prevention Trials Network  
HPV human papillomavirus  
HSV herpes simplex virus  
HSV-1/2 herpes simplex virus type 1/2  
hu-PBL human peripheral blood lymphocytes  
hu-SCID  humanized severe combined immunodeficient  
IATA  International Air Transport Association  
IB Investigator’s Brochure  
IC50 half maximal inhibitory concentration  
ICF informed consent form  
ICH International Conference on Harmonisation  
IDI In-Depth Interview  
IL Interleukin  
IND Investigational New Drug  
INR International normalized ratio  
INSTI  Integrase strand transfer inhibitor  
 
 
MTN -039, Version 1. 0 8  March 6, 2019  IoR Investigator of Record  
IRB Institutional Review Board  
IUD intrauterine device  
kg kilogram  
LC Laboratory Center  
LDMS  Laboratory Data Management System  
LLOQ  lower limit of quantification  
LOC Leadership and Operations Center  
μg microgram  
MDP  Microbicides Development Programme  
mg milligram  
mL milliliter  
mM millimolar  
MO Medical Officer  
mOsm  milliosmole  
MPA  medroxyprogesterone acetate  
mRNA  mitochondrial ribonucleic acid  
MT-2 human melatonin receptor 2  
MTN  Microbicide Trials Network  
MTT 3-(4,5-Dimethylthiazol -2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole  
n number  
N-9 nonoxynol -9 
NAAT  nucleic acid amplification test  
NF National Formulary  
ng nanogram  
nM nanomolar  
NIAID  National Institute of Allergy and Infectious Diseases  
NICHD  National Institute of Child Health and Human Development  
NIH National Institutes of Health  
NIMH  National Institute of Mental Health  
NL network laboratory  
NNRTI  non-nucleoside reverse transcriptase inhibitor  
NRTI  nucleotide analogue reverse transcriptase inhibitor  
NOAEL  no observed adverse effect level  
NOEL  no observed effect level  
NS normal saline  
NSAIDS  non-steroidal anti -inflammatory drugs  
NVP nevirapine  
OHRP  Office for Human Research Protections  
P24 protein 24  
PBL peripheral blood lymphocytes  
PBS phosphate -buffered saline  
PCR  polymerase chain reaction  
PD pharmacodynamics  
PEP post-exposure prophylaxis  
pH potential of hydrogen  
PI protease inhibitors  
PID pelvic inflammatory disease  
PK pharmacokinetics  
 
 
MTN -039, Version 1. 0 9  March 6, 2019  PMPA  9-[(R)-2-(phosphonomethoxy)propyl]adenine monohydrate  
PoR Pharmacist of Record  
PPD Pharmaceutical Product Development, Inc.  
PrEP  pre-exposure prophylaxis  
PRO  Protocol Registration Office  
PSP Prevention Sciences Program  
PSRT  Protocol Safety Review Team  
PSS polystyrene sulfonate  
PT prothrombin time  
PTID  participant identification  
PVC polyvinyl chloride  
QD quaque die, or once per day  
RAI receptive anal intercourse  
RE Regulatory Entity  
RF rectal fluid  
RG reduced -glycerin  
RNA  ribonucleic acid  
RSC  Regulatory Support Center  
RT reverse transcriptase  
RTI reproductive tract infection  
RT-PCR  real-time polymerase chain reaction  
Rx treatment  
SAE serious adverse event  
SCHARP  Statistical Center for HIV/AIDS Research & Prevention  
SCID  severe combined immunodeficient  
SCR  screening  
SDMC  Statistical Data Management Center  
SHIV  simian human immunodeficiency virus  
SMC  Study Monitoring Committee  
SOP  standard operating procedure  
SMS  short message service  
SSP study specific procedures  
STI sexually transmitted infection  
SubQ  subcutaneous  
SUSAR  suspected, unexpected serious adverse reaction  
TAF tenofo vir alafenamide  
TCID  tissue culture infective dose  
TDF tenofovir disoproxil fumarate  
TFV tenofovir  
TFV-DP tenofovir diphosphate  
TEAE  treatment emergent adverse event  
T1/2 half-life 
Tmax time at which C max is observed  
TPGS  tocopheryl polyethylene glycol succinate  
TV trichomonas vaginalis  
UA urinalysis  
ULN upper limit of normal  
UPMC  University of Pittsburgh Medical Center  
USA United States of America  
 
 
MTN -039, Version 1. 0 10  March 6, 2019  USP United States Pharmacopoeia  
UTI urinary tract infection  
WHO  World Health Organization  
w/w weight/weight  
 
 
MTN -039, Version 1. 0 11  March 6, 2019  MTN -039 
 
A Phase 1 Open Label Safety and Pharmacokinetic Study of Rectal Administration of 
a Tenofovir Alafenamide/ Elvitegravir Insert  at Two Dose Levels 
PROTOCOL TEAM ROSTER  
 
 
 
Protocol Chair  
 
Sharon A. Riddler, MD, MPH  
Keystone Building, Suite 510 
3520 Fifth Avenue 
Pittsburgh, PA 15213 USA  
Phone: 412- 383-1741 or 412- 383-1675  
Fax: 412- 383-2900  
Email: riddler@pitt.edu  
 
 
 
MTN -039, Version 1. 0 12  March 6, 2019  Site Investigator s  
 
Ken Ho, MD  
Site Investigator   
UPMC, Keystone Building, Suite 533  
3520 Fifth Avenue 
Pittsburgh, PA 15213 USA  
Phone: 412- 383-7178  
Fax: 412- 383-2900  
Email: hok2@upmc.edu   
 Craig Hoesley, MD  
Site Investigator  
University of Alabama at Birmingham  
1530 3rd Avenue South, VH 201 Birmingham, AL 35294 USA 
Phone: 205- 934-3365  
Fax: 205- 975-3232  
Email: choesley@uab.edu 
  
 
 
MTN -039, Version 1. 0 13  March 6, 2019  US National Institutes of Health (NIH) 
 
Roberta Black, PhD  
Chief, Clinical Microbicide Research Branch  
National Institute of Allergy and Infectious Diseases (NIAID), Division of AIDS 
(DAIDS)  
5601 Fishers Lane, Room 8B62, MSC 9831 
Rockvi lle, MD 20852 USA  
Phone: 301- 496-8199  
Email:  rblack@niaid.nih.gov  
 
Naana Cleland, MHCA  
Health Specialist, Clinical Microbicide Research Branch (CMRB)   
Prevention Sciences Program (PSP) DAIDS, NIAID  
National Institutes of Health (NIH) - U.S. Department of Health and Human 
Services (HHS)  
5601 Fishers Lane, Room 8B27  
Rockville, MD 20852 USA 
Phone: 240- 292-4779  
Email: clelandn@niaid.nih.gov    
 
Jeanna Piper, MD  
DAIDS Senior Medical Officer  
NIAID, DAIDS  
5601 Fishers Lane, Room 8B68, MSC 9831 
Rockville, MD 20852 USA  
Phone: 240- 292-4798  
Fax: 301- 402-3684  
Email:  piperj@niaid.nih.gov  
 
Dianne M. Rausch, PhD  
Director  
DAIDS Research, NIMH  
5601 Fishers Lane Room 8D20, MSC 9831 
Rockville, MD 20852 USA  
Phone: 240- 627-3874  
Fax: 240- 627-3467  
Email: draus ch@mail.nih.gov  
 
Teri Senn, PhD  
Chief, HIV Care Engagement and Secondary Prevention Program  
National Institute of Mental Health (NIMH)  
5601 Fishers Lane Room 9G29  
Rockville, MD 20852 USA  
Phone: 301- 761-7852  
Email: teri.senn@nih.gov  
  
 
 
MTN -039, Version 1. 0 14  March 6, 2019  Microbicide Trials Network (MTN) Leadership and Operations Center (LOC) - Pitt 
 
Jared Baeten, MD, PhD  
MTN Co -Principal Investigator  
University of Washington  
ICRC, Dept of Global Health  
325 Ninth Avenue, Box 359927 
Seattle, WA  98104  
Phone: 206- 520-3808  
Fax: 206- 520-3831  
Email: jbaeten@uw.edu 
 Devika Singh MD, MPH  
Protocol Safety Physician Box 359927, Dept. of Global Health, ICRC  
325 Ninth Ave.  
Seattle WA 98104 USA Phone: 206- 744-8311  
Fax: 206- 520-3831  
Email: devika@mtnstopshiv.org 
Katherine Bunge, MD  
Protocol Safety Physician Magee- Womens Hospital of UPMC  
300 Halket Street  
Pittsburgh, PA 15213 USA  
Phone: 412- 641-3464  
Fax: 412- 641-1133  
Email: kbunge@mail.magee.edu  
 Mei Song, PhD  
Protocol Specialist  
Microbicide Trials Network  
204 Craft Avenue  
Pittsburgh, PA 15213 USA  
Phone: 412- 641-2282  
Fax: 412- 641-6170  
Email: songm4@mail.magee.edu  
Sharon Hillier, PhD  
MTN Principal Investigator  
Microbicide Trials Network  
204 Craft Avenue  
Pittsburgh, PA 15213 USA  
Phone: 412- 641-8933  
Fax: 412- 641-6170  
Email: shillier@mail.magee.edu  
 Jennifer Thomas, MSc  
Protocol Development Manager  
Microbicide Trials Network  
204 Craft Avenue  
Pittsburgh, PA 15213 USA  
Phone: 412- 641-5579  
Fax: 412- 641-6170  
Email: thomasj15@mwri.magee.edu  
Cindy Jacobson, PharmD  
Director of Pharmacy Affairs  
Microbicide Trials Network  
204 Craft Avenue  
Pittsburgh, PA  15213 USA  
Phone: 412- 641-8913  
Fax: 412- 641-6170  
Email: cjacobson@mail.magee.edu  
  
 
 
MTN -039, Version 1. 0 15  March 6, 2019  MTN Laboratory Center (LC)  
 
Craig Hendrix, MD  
Pharmacology LC Principal Investigator  
Johns Hopkins University  
600 North Wolfe Street, Harvey 502  
Baltimore, MD 21287 USA 
Phone: 410- 955-9707  
Fax: 410- 955-9708  
Email: cwhendrix@jhmi.edu 
 
Ratiya Pamela Kunjara Na Ayudhya, MT, ASCP  
Laboratory Manager  
Microbicide Trials Network  
204 Craft Avenue, Room A541 Pittsburgh, PA  15213 USA  
Phone: 412- 641-6393  
Fax: 412- 641-6170  
Email: pkunjara@mwri.magee.edu  
 
Mark Marzinke, PhD, DABCC  
Johns Hopkins at Bayview  
Clinical Pharmacology Analytical Laboratory 
(CPAL)/Marzinke Lab  
4940 Eastern Avenue Mason F. Lord (MFL) Center Tower Suite 6000, Room 
621 Baltimore, Maryland 21224 
Office: 443- 287-7516  
CPAL Office: 410- 550-9703 
Fax: 410- 955-0767  
Email: mmarzin1@jhmi.edu 
 
John Mellors, MD  
MTN LC Co -Principal Investigator  
University of Pittsburgh  
3550 Terrace Street, Suite 818  
Pittsburgh , PA 15261 USA  
Phone:  412-624-8512  
Fax: 412-383-7982  
Email:  jwm1@pitt.edu  
 
Lisa C. Rohan, PhD  
MTN LC Co -Principal Investigator  
University of Pittsburgh  
Magee- Womens Research Institute & Foundation  
204 Craft Avenue, Room B509 
Pittsburgh, PA 15213 USA  
Phone:  412-641-6108  
Fax: 412-641-6170  
Email:  lrohan@mwri.magee.edu  
 
 
MTN -039, Version 1. 0 16  March 6, 2019  MTN LOC  – FHI 360 
 
Sherri Johnson, MPH  
Senior Clinical Research Manager  
FHI 360 
1825 Connecticut Avenue, NW  
Washington, DC 20009 USA  
Phone: 202- 884-8000, Ext. 18677  
Fax: 202- 884-8844   
Email: sjohnson@fhi360.org 
 Marcus Bolton , M.Ed.  
Senior Community Program Manager  
FHI 360 
359 Blackwell Street  
Suite 200  
Durham, NC 27701 USA  
Phone: 919 544- 7040, Ext. 11458  
Fax: 919- 544-0207  
Email: mbolton@fhi360.org 
 
Nicole Macagna , MA   
Clinical Research Manager  
FHI 360 
359 Blackwell Street  
Suite 200  
Durham, NC  27701 USA 
Phone:  919.544.7040 Ext.11717  
Fax: 919- 544-0207  
Email: nmacagna@fhi360.org  
 
   
 
 
MTN -039, Version 1. 0 17  March 6, 2019  MTN Statistical Data Management Center (SDMC)  
 
Elizabeth Brown, ScD  
SDMC Principal Investigator  
FHCRC- SCHARP  
1100 Fairview Avenue North, M2- C200 
PO Box 19024  
Seattle, WA  98109 -1024 USA  
Phone: 206- 667-1731  
Fax: 206- 667-4812  
Email: erbrown@fredhutch.org  Cliff Kelly, MS  
Senior Statistical Analyst  
FHCRC- SCHARP  
1100 Fairview Avenue North, M2- C200 
PO Box 19024  
Seattle, WA 98109- 1024 USA  
Phone: 206- 667-2502  
Fax: 206- 667-4378  
Email: cwkelly@scharp.org  
Julie Ngo, MPH  
Clinical Data Manager  
FHCRC – SCHARP  
1100 Fairview Avenue North, E3- 129  
PO Box 19024  
Seattle, WA 98109- 1024 USA  
Phone: 206- 667-2094   
Fax: 206- 667-4812  
Email: j hngo@scharp.org 
   
 
 
MTN -039, Version 1. 0 18  March 6, 2019  Working Group Representative s 
 
Jose A. Bauermeister, MPH, PhD  
Behavioral Research Working Group (BRWG) Representative University of Pennsylvania  
418 Curie Blvd., Suite 222L  
Philadelphia, PA 19104  Phone: 215- 898-9993  
Email: bjose@upenn.edu 
 
Craig Hendrix, MD  
Biomedical Science Working Group (BSWG) Representative 
Johns Hopkins University  
600 North Wolfe Street, Harvey 502  
Baltimore, MD 21287 USA Phone: 410- 955-9707  
Fax: 410- 955-9708  
Email: cwhendrix@jhmi.edu 
 Sherri J. Karas, MEd 
Community Working Group (CWG) Representative 
University of Pittsburgh  
Presbyterian University Hospital 
3520 Fifth Ave.  
Pittsburgh, PA 15213  
Phone: 412- 383-1313  
Email: sjk91@pitt.edu    
 
 
 
MTN -039, Version 1. 0 19  March 6, 2019  MTN -039 
 
A Phase 1 Open Label Safety and Pharmacokinetic Study of Rectal Administration of 
a Tenofovir Alafenamide/ Elvitegravir Insert  at Two Dose Levels  
INVESTIGATOR SIGNATURE FORM  
Version 1.0; March 6, 201 9 
 
A Study of the Microbicide Trials Network  
 
Funded by:  
Division of AIDS  (DAIDS) , US National Institute of Allergy and Infectious Diseases  
US Eunice Kennedy Shriver  National Institute of Child Health and Human Development  
US National Institute of Mental Health  
US National Institutes of Health (NIH)  
 
IND Holder:  
DAIDS (DAIDS Protocol ID: 38470 ) 
 
I, the Investigator of Record, agree to conduct this study in full accordance with the provisions 
of this protocol  and all applicable protocol -related documents. I agree to conduct this study 
in complia nce with United States (US) Health and Human Service regulations (45 CFR 46); 
applicable U.S. Food and Drug Administration regulations; standards of the International Conference for Harmonization Guideline for Good Clinical Practice (E6); Institutional Review 
Board/Ethics Committee determinations; all applicable in- country, state, and local laws and 
regulations; and other applicable requirements (e.g., NIH, DAIDS)  and institutional policies.  
 I agree to maintain all study documentation for at least two years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least two years have elapsed since the formal discontinuation of clinical development of the investigational product. These documents should be retained for a longer period, however, if required by the applicable regulatory requirements or by an agreement with the sponsor. DAIDS  will inform the 
investigator/institution as to when these documents no longer need to be retained  
 I have read and understand the information in the Investigator's Brochure(s), including the potential risks and side effects of the products under investigation, and will ensure that all associates, colleagues, and employees assisting in the conduct of the study are informed about the obligations incurred by their contribution to the study.  
 ____________________________  
Name of Investigator of Record (print)  
 ____________________________  ______________________________  
Signature of Investigator of Record  Date  
 
 
MTN -039, Version 1. 0 20  March 6, 2019  MTN -039 
 
A Phase 1 Open Label Safety and Pharmacokinetic Study of Rectal Administration of 
a Tenofovir Alafenamide/ Elvitegravir Insert  at Two Dose Levels  
 
PROTOCOL SUMMARY  
 
Short Title:   Safety and PK Study of TAF/ EVG Administered Rectally  
 Clinical Phase:  Phase 1  
 IND Sponsor:  DAIDS  
 Protocol Chair :  Sharon Riddler , MD , MPH  
 Sample Size:  MTN -039 will enroll approximately 20 participants.   
 Study Population:   HIV-uninfected individuals  18 years of age or older  
 Study S ites: Sites selected by MTN Executive Committee  
 Study Design:  Phase 1, multi -site, open -label, single arm, two- period study of 
rectal administration of one Tenofovir Alafenamide /Elvitegravir  
Insert, 20/16 mg and then two TAF/ EVG Inserts  
 Study Duration:  Approximately 6-13 weeks of follow -up per participant is planned 
with a projected accrual period of 6-8 months . The total duration of 
the study will be approximately 11 months .  
 
Study Products:  TAF/ EVG Insert, 20/16 mg  
 Study Regimen:  Participants will apply a single TAF/ EVG Insert  rectally and samples 
will be c ollected over a 3- day period. After a washout period of at 
least 7 days, participants will apply two TAF/ EVG Inserts rectally 
and samples will be taken over a 3- day period.  
  
 
 
MTN -039, Version 1. 0 21  March 6, 2019  Figure 1: MTN -039 Study Visit Schedule  
  
 
 
Primary Objective s:  
 
Safety  
• To evaluate the safety of the TAF/ EVG  Insert , 20/16 mg  administered rectally  at two dose 
levels: 1 insert and 2 inserts  
 Pharmacokinetics  
• To characterize the systemic and rectal  pharmacokinetics of the TAF/ EVG Insert , 20/16 
mg applied rectally at two dose levels: 1 insert and 2 inserts  
 Primary Endpoint s: 
 Safety  
• All Grade 2 and higher AEs  
 Pharmacokinetics  
• EVG  concentrations in: 
o Blood  
o Rectal fluid  
o Rectal mucosal tissue homogenates  
 
• TAF and TFV  concentrations  in  
o Blood  
o Rectal fluid  
 
• TFV-DP concentration in:  
o Rectal mucosal tissue homogenates  
o Rectal mucosal tissue cell  isolates  
 
 

 
 
MTN -039, Version 1. 0 22  March 6, 2019  Secondary Objective:  
 
Acceptability  
• To identify product attributes considered likely to challenge and/or facilitate future 
sustained use of the TAF/ EVG Insert applied rectally  
 Secondary Endpoint s:  
 Acceptability  
• Participant report of overall acceptability of the TAF/ EVG Insert  applied rectally   
 Exploratory Objective s:  
 
Ex Vivo  Efficacy  
• To assess the preliminary ( ex vivo)  efficacy of TAF/ EVG after product is inserted rectally  
 Pharmacokinetics  
• To characterize the cervicovaginal  pharmacokinetics of the TAF/ EVG Insert , 20/16 mg 
applied rectally at two dose levels: 1 insert and 2 inserts  
 Mucosal Safety  
• To evaluate mucosal safety of the TAF/ EVG Insert , 20/16  mg applied rectally  at two dose 
levels: 1 insert and 2 inserts   
 
Exploratory Endpoints:   
 Ex Vivo  Efficacy  
• Changes in HIV-1 replication in colorectal explant culture supernatant  
• Anti-HIV activity in rectal fluid  
• Anti-HIV activity in cervicovaginal fluid  
 
Pharmacokinetics  
• EVG , TAF and TFV  concentrations in cervicovaginal  fluid 
 
Mucosal Safety  
• Rectal h istology  
• Rectal proteomics   
• Rectal metabolomics  
• Rectal immunophenotype  
• Rectal microbiome 
• Cervicovaginal microflora  
 
 
MTN -039,  Version 1.0 23  March 6, 2019  1 KEY ROLES 
 
1.1 Protocol Identification 
 Protocol Title:   A Phase 1 Open Label Safety and Pharmacokinetic Study of Rectal Administration of a Tenofovir Alafenamide/ Elvitegravir 
Insert at Two Dose Levels  
 Protocol Number:  MTN -039 
 Short Title:  Safety and PK Study of TAF/ EVG Administered Rectally  
 Date:   March 6, 201 9 
 1.2 Funding Agencies, Sponsor and Monitor Identification  
 Funding Agencies:   US Division of AIDS (DAIDS)/National Institute of Allergy 
and Infectious Diseases (NIAID ) 
National Institutes of Health (NIH)  
5601 Fishers Lane  
Rockville , MD  20852 USA  
 
    US National Institute of Mental Health (NIMH)  
6001 Executive Boulevard Rockville, MD  20852 USA  
  US Eunice Kennedy Shriver  National Institute of Child Health 
and Human Development (NICHD)  
 Maternal and Pediatric Infectious Diseases (MPID) Branch  
6100 Executive Boulevard Rockville , MD  20852 USA 
 
IND Sponsor:  US Division of AIDS (DAIDS)/National Institute of Allergy 
and Infectious Diseases (NIAID ) 
National Institutes of Health (NIH)  
5601 Fishers Lane  
Rockville, MD  20852 USA  
 Monitor:  Pharmaceutical Product Development (PPD), Inc.  
929 North Front St.  
Wilmington, NC  28401 -3331 USA  
 
 
 
MTN -039,  Version 1.0 24  March 6, 2019  1.3 Medical Officer  
 
Medical Officer:   Jeanna Piper, MD  
5601 Fishers Lane, Room 8B68 , MSC 9831  
Rockville, MD 20852 USA 
 
1.4 Laborator y Center s 
 Network:   MTN Laboratory Center (LC)  
   204 Craft Ave.  
   Pittsburgh, PA 15213 USA  
 Pharmacology :  Johns Hopkins at Bayview  
   Clinical Pharmacology Analytical Laboratory/Marzinke Lab  
   4940 Eastern Avenue  
   Mason F. Lord (MFL) Center Tower Suite 6000  
   Room 621  
   Baltimore, M D 21224 USA 
 
1.5 Data Center  
MTN Statistical and Data Management Center (SDMC) 
Statistical Center for HIV/AIDS Research & Prevention 
(SCHARP)/Fred Hutchinson Cancer Research Center 
(FHCRC)  
   1100 Fairview Avenue N., LE -400 
   PO Box 19024  
   Seattle, WA 98109- 1024 USA  
 1.6 Study Implementation 
    MTN LOC - FHI 360  
   359 Blackwell Street, Suite 200  
   Durham, NC 27701 USA  
  
 
 
MTN -039,  Version 1.0 25  March 6, 2019  2 INTRODUCTION 
 
2.1 Background of Rectal Microbicide Research and Study Rationale  
 
Microbicides are products that are designed to be applied to the vaginal or rectal mucosa 
with the intent of preventing the acquisition of sexually transmitted infections (STIs) including the human immunodeficiency virus (HIV).
1 While the original impetus for vaginal 
microbicide development was to provide women with options for HIV prevention in settings where their partners were unwilling to use condoms for penile- vaginal 
intercourse, there is recognition that rectal microbicides are needed for men and women who practice receptive anal intercourse (RAI).  
 RAI is associated with the highest probability for sexual acquisition of H IV infection. 
Unprotected RAI is the sexual behavior with the highest per act risk of HIV acquisition conferring approximately 10 to 20 times more risk than unprotected receptive vaginal intercourse.
2,3 Globally, transgender females and men who have sex with men (MSM) are 
19 times more likely to be living with HIV compared with th e general population .4,5 
 Elvitegravir (EVG) is a human immunodeficiency virus -1 (HIV -1) integrase inhibitor that 
has shown potent activity against laboratory viral strains and clinical isolates of HIV -1 and 
against virus with resistance to nucleoside reverse transcriptase inhibitors (NRTI s), non -
nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PI s). 
Elvitegravir is FDA approved and currently available in single tablet combination formulations  for the treatment of HIV -1 infection.  
 Tenofovir alafenamide (TAF: formally known as GS -7340) is a prodrug of the antiviral 
acyclic nucleoside phosphonate tenofovir (TFV) with improved properties relative to tenofovir disoproxil fumarate (TDF). By enhancing stability in biological matrices while being rapidly activated in cells, TAF produces higher levels of intracellular TFV  
diphosphate, the pharmacologically active metabolite, in HIV -target cells at substantially 
reduced oral dose of TFV equivalents. It has been shown to have improved renal function 
and possibly reduced bone impairment compared to TDF .
6 TAF is US Food and Drug 
Administration ( FDA) approved and currently available as a single tablet formulation for 
the treatment of chronic hepatitis B  (Vemlidy®) and also co -formulated with other drugs 
for the treatment of HIV infection (Genvoya®, Odefsey® and Descovy®).  
 MTN -039 will evaluate the safety and pharmacokinetics (PK) of the TAF/EVG  Insert 
administered rectally at two dose levels.  Fast-dissolve topical inserts are an on- demand 
dosage form that is economical, discreet, user -friendly and user -initiated , factors that may 
encourage use in populations at risk for HIV  acquisition.  
2.2 Elvitegravir (EVG) – Descripti on and Mechanism of Action  
2.2.1  Description  
Elvitegravir (EVG) drug substance is a 2nd generation human immunodeficiency virus (HIV) integrase inhibitor. EVG is a white crystalline irregularly shaped material  and has 
an acidic pKa of 6.6 and Log D of 4.5 at pH 6.8. EVG is a poorly water soluble and highly 
 
 
MTN -039,  Version 1.0 26  March 6, 2019  permeable drug. It is considered a BCS class -2 compound. EVG (anhydrous crystalline 
form γ) is chemically stable in the solid state when exposed to heat, humidity and light.  
 
The chemical name of EVG is (S)-6- (3-chloro-2- fluorobenzyl) -1-(1-hydroxy -3-
methylbutan-2- yl)-7methoxy -4-oxo-1,4-dihydroquinoline-3- carboxylic acid . It has a 
molecular formula of C23H23ClFNO 5 and a molecular weight of 447.9 (free acid) . It has 
the following  structural formula:  
 
EVG is a white to off -white crystalline powder  with a solubility  of > 35μg/mL in aqueous 
buffers at pH 9.0. EVG  is stable for at least three  years at 30°C . 
2.2.2  Mechanism of action  
EVG is a n HIV-1 integrase strand transfer inhibitor (INSTI). Integrase is an HIV -1 encoded 
enzyme that is required for viral replication. Inhibition of integrase prevents the integration 
of HIV -1 DNA into host genomic DNA, blocking the formation of the HIV -1 provirus and 
propagation of the viral infection. EVG does not inhibit human topoisomerases I or II .7 
2.2.3  Strength of Study Product  
The doses of EVG proposed for use in MTN -039 are 16 mg in one insert and 32 mg in 
two inserts . 
2.3 Non-Clinical Studies of Elvitegravir  
2.3.1  In Vitro Studies  
2.3.1.1   Anti-HIV-1 Activity  
The antiviral activity of EVG against laboratory and clinical isolates of HIV -1 was 
assessed in T lymphoblastoid cells, monocyte/macrophage cells, and primary peripheral 
blood lymphocytes. The 50% effective concentration (EC 50) values ranged from 0.02 to 
1.7 nM. EVG  displayed antiviral activity in cell culture against HIV -1 clades A, B, C, D, E, 
F, G, and O (EC 50 values ranged from 0.1 to 1.3 nM) and activity against HIV -2 (EC 50 
value of 0.53 nM). The antiviral activity of EVG  with antiretroviral drugs in two- drug 
combination studies was not antagonistic when combined with the INSTI raltegravir, NNRTIs (efavirenz, etravirine, or nevirapine), NRTIs (abacavir, didanosine, emtricitabine, 
lamivudine, stavudine, tenofovir, or zidovudine), PIs (amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, or tipranavir), the fusion inhibitor 

 
 
MTN -039,  Version 1.0 27  March 6, 2019  enfuvirtide, or the CCR5 co- receptor antagonist maraviroc. EVG did not show inhibition 
of replication of HBV or HCV in cell culture.7 
 
The antiviral activity of EVG drug substance prepared at varying doses in suspension with 
insert formulation components  was tested in a cervicovaginal tissue explant model. 
Complete protection against HIV -1BAL infection was observed when EVG tissue 
concentrations were in the range of ~103-104 ng/g, whereas only partial protection was 
observed at ~102 ng/g. These data suggest that EVG tissue concentration of at least 1000 
ng/g will be efficacious prophylactically against HIV infection of cervicovaginal tissue and 
therefore were set as the target benchmark for drug development.8   
2.3.1.2  Resistance (HIV)  
HIV-1 isolates with reduced susceptibility to EVG  were selected in cell culture. Reduced 
susceptibility to EVG  was associated with the primary integrase substitutions T66A/I, 
E92G/Q, S147G, and Q148R. Additional integrase substitutions observed in cell culture selection included D10E, S17N, H51Y, F121Y, S153F/Y,  E157Q, D232N, R263K, and 
V281M .
7 
2.3.1.3   Cross -resistance (HIV)  
EVG -resistant viruses showed varying degrees of cross -resistance in cell culture to 
raltegravir in the INSTI class depending on the type and number of substitutions in HIV -
1 integrase.7 
2.3.1.4   Mutagenicity and Carcinogenesis  
EVG was not genotoxic in the reverse mutation bacterial test (Ames test) and the rat micronucleus assay. In an in vitro chromosomal aberration test, EVG was negative with metabolic activation; however, an equivocal response was observed without act ivation.
7 
2.3.1.5  In Vitro  Metabolism  
The metabolism of EVG is mediated primarily via intestinal and hepatic cytochrome P450 (CYP) 3A enzymes.
7 
2.3.1.6  In Vitro  Dissolution (EVG insert)  
An EVG insert offers rapid dissolution : an in vitro  96% dissolution is achieved within 15 
minutes (see Table 1).9  
Table 1:  In vi tro Dissolution of 8 mg Elvitegravir Insert  
Time (min)  Average (% release)  
N=3 %RSD  
N=3 
5 44.9 4.5 
10 76.1 3.9 
15 95.7 2.0 
30 99.9 1.1 
45 100.1  1.0 
60 100.1  0.9 
 
 
MTN -039,  Version 1.0 28  March 6, 2019  RSD – relative standard deviation  
2.3.2  Animal Studies  
2.3.2.1  Pharmacokinetics  
Oral EVG  
 
EVG displays modest bioavailability following oral administration in rats and dogs of 
34.1% and 29.6%, respectively, and systemic clearance values of 0.5 L/h/kg and 1.0 L/h/kg, respectively, representing low to intermediate values relative to hepatic blood flow in these species (3.5 and 2.6 L/h/kg, respectively). Maximum plasma concentrations (Cmax) were achieved in 0.5– 1.0 hour post -dose and terminal t½ (t½b) values were 2.3 
and 5.2 hours, respectively .
10 
EVG /TDF  Insert  – Macaque Study  
 A dose -ranging PK study of EVG -containing inserts administered vaginally to female 
pigtail macaques was conducted by CONRAD  (see Table 2 for study design) . Vaginal 
inserts containing a combination of 2.7 mg or 8  mg elvitegravir/tenofovir disoproxil 
fumarate (EVG/TDF) were administered to female pigtailed macaques to assess sys temic 
and local pharmacokinetics (PK). Blood, vaginal and rectal fluid, and/or vaginal tissue biopsy samples were collected at baseline, 0.5, 2, 6, and 24 hours, and 7 and 8 days following once weekly dosing for 4 weeks. Following a single dose of 8mg EVG/ TDF, 
samples were also collected at 3 and 7 days post -dose to assess the PK tail.  The samples 
were analyzed for concentrations of EVG. Study results can be found in the IB of the EVG insert .
8   
Table 2:  Study design of the pharmacokinetic study of EVG/TDF vaginal inserts in 
pigtailed macaques  
Group Treatment  Week(s) Dosed  Number  of 
Animals  
PK (2 -24 hours)  
1A 2.7mg EVG/TDF  1-4 3 
2A 2.7mg EVG/TDF  1-4 3 
1B 8mg EVG/TDF  1-4 3 
2B 8mg EVG/TDF  1-4 3 
PK Tail  
1A, 1B, 2A, and 2B  8mg EVG/TDF  1 12 
Note: The same animals used for the PK assessment were also used in the PK Tail assessment, following 
a 2 week rest period.  
 
EVG Insert – Vaginal Irritation Study of EVG in Rabbits  
 Twenty -four rabbits were involved in CONRAD Study 1645- 113, a vaginal irritation study 
of EVG to evaluate potential local irritation and determine the pharmacokinetics following 
once daily intravaginal  administration of EVG  in New Zealand White Hra:(NZW) SPF 
rabbits for 14 consecutive days – group assignments are shown in Table 3.
11The samples 
 
 
MTN -039,  Version 1.0 29  March 6, 2019  were analyzed for concentrations of EVG. Study results can be found in the IB of the EVG 
insert.8 
 
Table 3:  Group Assignments in EVG Vaginal and Rectal Irritation Studies  
Group 
Number  Treatment  Dose 
Level  Number of 
Animals in 
Vaginal Irritation 
study  Number of Animals in 
Rectal Irritation study  
Male  Female  
1  Reference Control 
(N-9)  4%  4  4  4  
2  Vehicle Control 
(PBS+5% glycerin)  0 mg  4  4  4  
3  Placebo Control  0 mg  4  4  4  
4  1X EVG * 2 mg  4  4  4  
5  3X EVG ** 6 mg  4  4  4  
6  10X EVG ** 20 mg  4  4  4  
N-9 = 4% nonoxynol -9; PBS= phosphate buffered saline  
* 1X EVG (8 mg active drug/4 mL vehicle) was prepared from ground elvitegravir insert powder formulated 
in PBS and glycerin  
** 3X EVG (24 mg active drug/4 mL vehicle) and 10X EVG (80 mg active drug/4 mL vehicle) was prepared 
from ground placebo insert powder and elvitegravir drug substance formulated in PBS and glycerin  
For vaginal irritation study:  Dose route was intravaginal for all animals; volume = 1 mL 
For rectal irritation study: Dose route was rectal for all animals; volume = 1 mL  
 
EVG Insert – Rectal Irritation Study of EVG in Rabbits  
 Forty -eight  rabbits were involved in CONRAD Study 1645 -114, a rectal irritation study of 
EVG to evaluate potential local irritation and determine the pharmacokinetics following 
once daily intrarectal administration of EVG  in New Zealand White Hra:(NZW) SPF 
rabbits for 14 consecutive days.  Group assignments are shown in Table 3. 
Pharmacokinetic s tudy findings  can be found in the IB of the EVG insert .
8  
 2.3.2.2  Toxicology
 
EVG Insert – Vaginal  Irritation Study of EVG in Rabbits  
CONRAD Study 1645 -113 assessed PK and potential for local irritation following once 
daily intravaginal  administration of EVG  in New Zealand White Hra:(NZW) SPF rabbits 
for 14 consecutive days . The assessment of toxicity in this study was made based on 
mortality, clinical observations, body weights, vaginal irritation scoring examinations, and anatomic pathology . There were no test article -related effects or definitive control article-
related eff ects observed for these parameters .
8  
EVG Insert – Rectal  Irritation Study of EVG in Rabbits  
CONRAD Study 1645 -114 assessed PK and potential for local irritation following once 
daily intrarectal  administration of EVG  in New Zealand White Hra:(NZW) SPF rabbits for 
14 consecutive days. The assessment of toxicity in this study was made based on mortality, clinical observations, body weights, and macroscopic and microscopic 
 
 
MTN -039,  Version 1.0 30  March 6, 2019  pathology of the rectum and surrounding tissues.  There were no test article- related effects 
or definitive control article- related effects observed for these parameters .8  
2.3.2.3  Mutagenicity and Carcinogenesis  
EVG was not genotoxic in the rat micronucleus assay.  Long -term carcinogenicity studies 
of oral EVG  were carried out in mice (104 weeks) and in rats (up to 88 weeks in males 
and 90 weeks in females). No drug -related increases  in tumor incidence were found in 
mice at doses up to 2000 mg per kg per day alone or in combination with 25 mg per kg 
per day ritonavir at exposures 3- and 14- fold, respectively, the human systemic exposure 
at the recommended daily dose of 150 mg. No drug -related increases in tumor incidence 
were found in rats at doses up to 2000 mg per kg per day at exposures 12- to 27- fold, 
respectively, in male and female, the human systemic exposure.7 
2.3.2.4  Pregnancy, Teratogenic Effects, and Lactation  
Oral EVG studies in animals have shown no evidence of teratogenicity or an effect on 
reproductive function. In offspring from rat and rabbit dams treated with E VG during 
pregnancy, there were no toxicologically significant effects on developmental endpoints. The exposures (AUC) at the embryo- fetal No Observed Adverse Effects Levels (NOAELs) 
in rats and rabbits were respectively 23 and 0.2 times higher than the exposure in humans at the recommended daily dose of 150 mg.
7 
Studies in rats have demonstrated that EVG is secreted in milk.7 
2.3.2.5   Reproductive Toxicity  
Oral EVG did not affect fertility in male and female rats at approximately 16- and 30- fold 
higher  exposures (AUC), respectively, than in humans at the therapeutic 150 mg daily 
dose. Fertility was normal in the offspring of rats exposed daily from before birth (in utero) through sexual maturity at daily exposures (AUC) of approximately 18- fold higher than 
human exposures at the recommended 150 mg daily dose.
7 
2.4 Tenofovir Alafenamide (TAF) – Description and Mechanism of Action  
2.4.1  Description  
Tenofovir alafenamide (TAF) is a nucleotide reverse transcriptase inhibitor and a prodrug of tenofovir. TAF is converted in vivo to tenofovir, an acyclic nucleoside phosphonate 
(nucleotide) analog of adenosine 5′ -monophosphate.
12 
 The chemical name of tenofovir alafenamide fumarate drug substance is L- alanine, N- 
[(S)-[[(1R)-2-(6-amino-9 H-purin-9- yl)-1-methylethoxy]methyl]phenoxyphosphinyl] -, 1 - 
methylethyl ester, (2E )-2-butenedioate (2:1). It has an empirical formula of 
C21H29O5N6P•½(C4H4O4) and a formula weight of 534.50. It has the following structural formula:  
 
 
MTN -039,  Version 1.0 31  March 6, 2019    
Tenofovir alafenamide fumarate is a white to off -white or tan powder with a solubility of 
4.7 mg per mL in water at 20 °C .12 
2.4.2  Mechanism of action  
TAF is a phosphonamidate prodrug of tenofovir (2’ -deoxyadenosine monophosphate 
analog). Plasma exposure to TAF allows for permeation into cells and then TAF is 
intracellularly converted to tenofovir through hydrolysis by cathepsin A. Tenofovir is subsequently phosphorylated by cellular kinases to the active metabolite tenofovir diphosphate (TFV -DP). TFV -DP inhibits HIV -1 replication through incorporation into viral 
DNA by the HIV reverse transcriptase, which results in DNA chain- termination.  
 TFV has activity that is specific to human immunodeficiency virus and hepatitis B virus. 
Cell culture studies have shown that both emtricitabine and tenofovir can be fully phosphorylated when combined in cells. T FV-DP is a weak inhibitor of mammalian DNA 
polymerases that include mitochondrial DNA polymerase γ and there is no evidence of 
mitochondrial toxicity in cell culture based on several assays including mitochondrial DNA analyses .
13 
2.4.3  Strength of Study Product  
The doses of TAF proposed for use in MTN -039 are 20 mg in 1 insert and 40 mg in 2 
inserts. 
2.5 Non-Clinical Studies of Tenofovir Alafenamide  
2.5.1  In Vitro Studies  
2.5.1.1  Anti-HIV-1 Activity  
 
The antiviral activity of TAF against laboratory and clinical isolates of HIV -1 subtype B 
was assessed in lymphoblastoid cell lines, peripheral blood mononuclear cells ( PBMCs ), 
primary monocyte/macrophage cells and CD4 -T lymphocytes. The EC50 values for TAF 
ranged from 2.0 to 14.7 nM. TAF displayed antiviral activity in cell culture against all HIV -
1 groups (M, N, O), including sub- types A, B, C, D, E, F, and G (EC50 values ranged from 
0.10 to 12.0 nM) and strain specific activity against HIV -2 (EC50 valu es ranged from 0.91 
to 2.63 nM) .13 

 
 
MTN -039,  Version 1.0 32  March 6, 2019  2.5.1.2  Resistance (HIV)  
 
HIV-1 isolates with reduced susceptibility to TAF have been selected in c ell culture. HIV -
1 isolates selected by TAF expressed a K65R substitution in HIV -1 RT, sometimes in the 
presence of S68N or L429I substitutions; in addition, a K70E substitution in HIV -1 RT was 
observed.13 
 
2.5.1.3  Cross -resistance (HIV)  
 
TFV resistance substitutions, K65R and K70E, result in reduced susceptibility to abacavir, 
didanosine, emtricitabine, lamivudine, and tenofovir. HIV -1 with multiple TAMs (M41L, 
D67N, K70R, L210W, T215F/Y, K219Q/E/N/R), or multinucleoside resistant HIV -1 with a 
T69S double insertion mutation or with a Q151M mutation complex including K65R, 
showed reduced susceptibility to TAF in cell cult ure.13 
 2.5.1.4  In Vitro  Metabolism  
 TAF is reportedly hydrolyzed within cells to form TFV, which is phosphorylated to the active metabolite, TFV -DP. In vitro, TAF is reportedly metabolized to TFV by 
carboxylestrase 1 in hepatocytes, by cathepsin A in PBMCs and macrophages, with minimal metabolism via CYP3A .
14  
 2.5.2  Animal Studies  
 
2.5.2.1  Pharmacokinetics  
 
Oral TAF – Dog Studies  
 
The hepatic  delivery  and metabolism of TAF in primary human hepatocytes in vitro and 
in dogs in vivo were evaluated in one study. Incubation of primary human hepatocytes with TAF resulted in high levels of the pharmacologically active metabolite TFV -DP, which 
persisted in the cell with a half -life of >24 h. Following oral administration of TAF to dogs 
for 7 days, TAF was rapidly absorbed. The appearance of the major metabolite TFV in plasma was accompanied by a rapid decline in circulating TAF. Consistent with the in vitro data, high and persistent levels of TFV -DP were observed in dog livers. Notably, 
higher liver TFV -DP levels were observed after administration of TAF than those given 
TDF.
15  
 To understand how TAF reduces first -pass clearance to be an effective  oral prodrug, its 
permeability and stability were characterized in vitro  and detailed pharmacokinetic studies 
were completed in dogs. TAF showed concentration- dependent permeability through  
monolayers of caco- 2 cells and dose- dependent oral bioavailability in dogs, increasing 
from 1.7% at 2 mg/kg to 24.7% at 20 mg/kg, suggesting saturable intestinal efflux transport. Consistent with the proposed role of intestinal efflux transport, coadminis tration 
of low dose GS -7340 with a transport inhibitor substantially increased GS -7340 exposure. 
The result of effective  oral absorption and efficient lymphoid  cell loading was reflected in 
the high and persistent levels of the pharmacologically active met abolite, TFV 
 
 
MTN -039,  Version 1.0 33  March 6, 2019  diphosphate, in peripheral blood mononuclear cells following  oral administration to 
dogs .16  
2.5.2.2  Mutagenicity , Carcinogenesis  and Impairment of Fertility  
 
Since TAF is rapidly converted to tenofovir and a lower tenofovir exposure in rats and 
mice is observed after TAF administration compared to TDF administration, carcinogenicity studies were conducted only with TDF. Long -term oral carcinogenicity 
studies of  TDF in mice and rats were carried out at exposures up to approximately 10 
times (mice) and 4 times (rats) those observed in humans at the 300 mg therapeutic dose of TDF for HIV -1 infection. The TFV exposure in these studies was approximately 167 
times (mi ce) and 55 times (rat) those observed in humans after administration of Genvoya 
treatment. At the high dose in female mice, liver adenomas were increased at tenofovir exposures 10 times (300 mg TDF) and 167 times (10 mg TAF in Genvoya) that in humans. In rats, the study was negative for carcinogenic findings .
13  
 
TAF was not genotoxic in the reverse mutation bacterial test (Ames test), mouse lymphoma or rat micronucleus assays.  
 There were no effects on fertility, mating performance or early embryonic development when TAF was administered to male rats at a dose equivalent to 155 times the human dose based on body surface area comparisons for 28 days prior to mating and to female rats for 14 days prior to mating through Day 7 of gestation.
13 
 2.5.2.3   Toxicology 
 
 
Minimal to slight infiltration of mononuclear cells in the posterior uvea was observed in 
dogs with similar severity after three and nine month administration of TAF; reversibility 
was seen after a three month recovery period. At the NOAEL for eye toxicity, the systemic exposure in dogs was 5 (TAF) and 15 ( TFV) times the exposure seen in humans at the 
recommended daily G envoya dosage.
13 
 2.6 Non-Clinical Studies of Elvitegravir and Tenofovir Alafenamide  
2.6.1  In Vitro  Studies  
 
2.6.1.1  In Vitro  Dissolution (TAF/EVG Insert)   
 A test of the in vitro dissolution of the TAF/EVG Insert was completed and the dissolution 
rate is listed in  Table 4. 
      
 
 
 
MTN -039,  Version 1.0 34  March 6, 2019  Table 4:  In vitro Dissolution of 20/16 mg TAF/ EVG Insert  
 
Time (min)  TAF EVG  
 Average (% release)  
N=6 %RSD  
N=6 Average (% release)  
N=6 %RSD  
N=6 
5 20 9.5 18 11.3 
10 41 10.3 38 11.2 
15 59 9.9 57 10.4 
30 90 5.3 87 5.3 
45 97 1.7 95 1.5 
60 97 1.6 95 1.5 
75 97 1.6 96 1.4 
RSD – relative standard deviation  
2.6.2  Animal Studies  
2.6.2.1  Pharmacokinetics  
 
TAF + EVG Solution – Mice Study  
 
A pharmacokinetic  and tissue distribution  study of drug -loaded nanoparticle (NP) was 
performed in female humanized CD34+-NSG mice to explore if a long -acting parenteral 
formulation of AVR may be an effective alternative to daily oral dosing. Mice received 
200 mg/kg each of TAF and EVG  as free drugs (TAF  + EVG solution) or as drug loaded 
NP (TAF  + EVG NP) formulation by subcutaneous (SubQ) administration. Plasma and 
tissue were collected to determine tenofovir  (TFV) and EVG concentrations using LC -
MS/MS. SubQ administration of TAF  + EVG  NP formulation resulted in long residence 
time and exposure for both drugs. The AUC (0-72h) of TFV and EVG was 14.1 ± 2.0, 
7.2 ± 1.8 μg × hr./mL from free drugs in solution and the AUC (0-14day) for the same drugs 
was 23.1 ± 4.4, 39.7  ± 6.7 μg × hr./mL from NPs. The observed elimination half -life (t 1/2) 
for TFV of free and NPs were 14.2  h, 5.1 days and for EVG 10.8 h, 3.3  days, 
respectively .17 
 
TAF/EVG Insert – Macaque Study  
 
CONRAD study 2708 evaluated the PK of TAF and EVG following administration of 
vaginal inserts containing a combination of TAF/EVG in female pigtailed macaques. Vaginal inserts containing 10/8 mg, 10/16 mg or 40/24 mg of TAF/EVG were administered to groups of 4 female macaques. One insert was administered vaginally to each macaque 5 times over an 8- week period with at least 1 week between doses. Animals were dosed 
on a single occasion at the 24h PK interval and on two separate occasions for both 2 and 4h PK intervals . Plasma, vaginal fluid and vaginal tissue biopsy samples were collected 
at 0.5 (blood only), 2, 4 and 24 hours post -dose. These samples were analyzed for 
concentrations of TAF, TFV and EVG. Vaginal biopsies were also evaluated for TFV -DP 
concentrations. The TAF/EVG insert did not result in adverse behavioral changes, 
physical changes in the vaginal vault or measurable systemic exposure to TAF, TFV or EVG in the macaques .
14 There was minimal dose proportionality between inserts for 
vaginal fluid or tissue concentrations. TFV and EVG in vaginal fluid after administration 
 
 
MTN -039,  Version 1.0 35  March 6, 2019  of TAF/EVG (20/16 mg) showed the most favorable PK and resulted in TFV -DP an d EVG 
tissue levels in range with those shown to provide in vivo protection against vaginal SHIV 
infection in macaques .18  
     
TAF/EVG Insert – Vaginal Irritation Study of EVG /TAF  in Rabbits  
 CONRAD Study 1645-1 16 evaluated the PK of TAF/EVG following once daily intravaginal 
administration of TAF/EVG formulated drug substance in female NZW SPF rabbits for 14 consecutive days.  5/4, 15/12 or 25/20 mg TAF/EVG formulated drug substance were 
administered to 5 groups of 4 female rabbits. The bioanalytical and PK assessments are summarized below .    
 Median peak EVG plasma concentrations were observed by 0.5 to 1 hour postdose on 
Days 1 and 13. M ean C
max values , ranging from 17.5 to 49.4 ng/mL,  for EVG appeared 
to increase with increasing dose across  the dose range on Days 1 and 13. M ean AUC 0-
24hr values appeared to increase with increasing dose across the dose range on Day 1 
and did not appear to increase with increasing dose on Day  13. Systemic exposure 
(AUC 0-24hr) to EVG did not appear to consistently change following repeated 
administration . Following the highest dose administered vaginally (25/20 mg TAF/EVG), 
mean EVG AUC 0-24hr was 441 hr*ng/ml on Day 1 and 366 hr*ng/ml on Day 13.    
 Median  peak TFV  plasma concentrations were observed by 0.5 and 1 hour postdose on 
Days 1 and 13. M ean C
max values , ranging from 41.0 to 354 ng/mL, for TFV appeared to 
increase with increasing dose across the dose range on Days 1 and 13.  Mean AUC 0-24hr 
values for TFV also appeared to increase with increasing dose across the dose range on 
Days 1 and 13. Systemic exposure (AUC 0-24hr) to TFV did not appear to consistently 
change following repeated admini stration. Following the highest dose administered 
vaginally (25/20 mg TAF/EVG), mean TFV  AUC 0-24hr was 861 hr*ng/ml on Day 1 and 1400  
hr*ng/ml on Day 13.19    
 
TAF/EVG Insert – Rectal Irritation Study of EVG/TAF in Rabbits  
 CONRAD Study 1645 -117 evaluated potential local irritation and determined the PK 
following once daily intrarectal administration of EVG  and TAF to male and female rabbits 
for 14 consecutive days. PK assessments and analysis are summarized below .  
 Median peak EVG plasma concentrations were observed by 0.5 hours postdose on Days  
1 and 13. M ean C
max values , ranging from 2.42 to 8.31 ng/mL,  for EVG appeared to 
increase with increasing dose across the dose range on Days 1 and 13.  Mean AUC 0-24hr 
values did not appear to increase with increasing dose on Day 1 and appeared to increase with increasing dose across the dose range on Day 13.  Systemi c exposure (AUC
0-24hr) to 
EVG did not appear to consistently change following repeated administration of 4 mg EVG in combination with 5 mg TAF, however, appeared to increase following repeated administration of 12 and 20 mg EVG in combination with 15 and 25 mg TAF, respectively . 
Following the highest dose administered rectally (25/20 mg TAF/EVG), mean EVG AUC
0-
24hr was 22.1 hr*ng/ml on Day 1 and 58.2 hr*ng/ml on Day 13.20  
   
 
 
MTN -039,  Version 1.0 36  March 6, 2019  Median peak TFV plasma concentrations were observed by 0.5 hours postdose on Days 
1 and 13. Mean C max values , ranging from 13.6 to 128,  for TFV appeared to increase with 
increasing dose across the dose range on Days 1 and 13. Mean AUC 0-24hr values for TFV 
also appeared to increase with increasing dose across the dose range on Days 1 and 13. 
Systemic exposure (AUC 0-24hr) to TFV generally appeared to increase following repeated 
administration of EVG in combination with TAF.  Following the highest dose administered 
rectally (25/20 mg TAF/EVG), mean TFV AUC 0-24hr was 11.6 hr*ng/ml on Day 1 and 33.9  
hr*ng/ml on Day 13.    
 
2.6.2.2  Toxicity  
 
TAF/EVG Insert – Vaginal Irritation Study of EVG /TAF  in Rabbits  
 
CONRAD Study 1645 -116 evaluated potential local irritation and determined the PK 
following once daily intravaginal  administration of EVG and TAF to female rabbits for 14 
consecutive days . 24 female rabbits were randomized to 6 groups: vehicle control, 
placebo control, referenc e control (N -9), or 4/5, 12/15, or 20/25 mg EVG/TAF.  The 
assessment of toxicity in this study was made based on mortality, clinical observations, 
body weights, vaginal irritation scoring, micro and macroscopic pathology of reproductive tissues. Results can  be found in the TAF/EVG insert IB .
14 
 
TAF/EVG Insert – Rectal Irritation Study of EVG /TAF in Rabbits  
 CONRAD Study 1645 -117 evaluated potential local irritation and determined the PK 
following once daily intrarectal administration of EVG  and TAF to male and female rabbits 
for 14 consecutive days. 24 male and 24 female rabbits were randomized to 6 groups for drug administration at a dose level of 4/5, 12/15, or 20/25 mg (EVG/TAF). The assessment of toxicity in this study was made based on mortality, clinical observations, body weights and body weight change.  All animals survived to study termination on Day 
14. There were no test article- related or definitive control article- related effects observed 
on study for the following parameters evaluated: bodyweights, clinical observations, macroscopic or microscopic pathology of tissues. TAF/EVG insert was generally safe and  
well tolerated by the rabbits in the study .
21  
All macroscopic findings were considered incidental changes as they lacked microscopic  
correlates, had no dose relationship in incidence or severity, occurred at a low incidence or as a single occurrence, or are known background incidental findings for the species. 
Both edema and mucosal hyperplasia were noted in males and females in the vehicle control, placebo control, and all test article- treated groups . These findings are considered 
most likely to be related to the procedure of intrarectal administration. There was a slight increase in severity in edema within the 12/15 and 20/25 mg EVG/TAF groups, but this 
was not considered test article related given the low incidence and variation in appearance of edema within the tissues .
21  
2.7 Clinical Studies of Elvitegravir and Tenofovir Alafenamide  
 
2.7.1  Resistance (HIV)  
 
 
 
MTN -039,  Version 1.0 37  March 6, 2019  2.7.1.1  EVG 
 
Pooled resistance analysis was performed on virus samples from subjects receiving EVG -
containing regimens in 6 clinical trials of EVG  (as single drug in combination with a 
regimen containing a protease inhibitor/ritonavir or as the fixed dose combination STRIBILD). Development of substitutions T66A/I/K, E92G/Q, T97A, S147G, Q148H/K/R, and N155H in the HIV -1 integrase protein was primarily associated with resistance to 
EVG . In addition to these primary EVG  resistance- associated substitutions, E92A, 
F121C/Y, P145S, Q146I/L/R, and N155S were also occasionally observed and were shown to confer reduced susceptibility to EVG . Substitutions at positions E92 and N155 
were the most frequently observed (39% and 27% of those evaluated subjects, respectively). In virus isolates harboring the observed primary EVG  resistance- associated 
substitutions, additional substitutions in integrase were detected including H51Y, L68I/V, G70R, V72A/N, I73V, Q95K/R, S119R, E138A/K, G140A/C/S, E157Q, K160N, E170A,S230R, and D232N .
7 
2.7.1.2  TAF 
 
In Treatment -Naïve Subjects:  
 In a pooled analysis of antiretroviral -naïve subjects receiving GENVOYA in Studies 104 
and 111, genotyping was performed on plasma HIV -1 isolates from all subjects with HIV -
1 RNA greater than 400 copies per mL at confirmed virologic failure, at Week 144, or at time of early study drug discontinuation. As of Week 144, the development of genotypic resistance to elvitegravir, emtricitabine, or TAF was observed in 12 of 22 subjects with evaluable resistance data from paired baseline and GENVOYA treatment -failure isolates 
(12 of 866 subjects [1.4%]) compared with 13 of 20 treatment -failure isolates from 
subjects with evaluable resistance data in the STRIBILD treatment group (13 of 867 subjects [1.5%]). Of the 12 subjects with resistance development in the GENVOYA group, the resistance- associated substitutions that emerged were M184V/I (N=11) and K65R/N 
(N=2) in reverse transcriptase and T66T/A/I/V (N=2), E92Q (N=4), E138K (N=1), Q148Q/R (N=1) and N155H (N=2) in integrase. Of the 13 subjects with resistance development in the STRIBILD group, the resistance- associated substitutions that 
emerged were M184V/I (N=9), K65R/N (N=4), and L210W (N=1) in reverse transcriptase and E92Q/V (N=4), E138K (N=3), Q148R (N=2), and N155H/S (N=3) in integrase. In both treatment groups, most subjects who developed substitutions associated with resistance to elvitegravir also developed emtricitabine resistance- associated substitutions. These 
genotypic resistance results were confirmed by phenotypic analyses .
13  
 
In Virologically Suppressed Subjects :  
 Three virologic failure subjects were identified with emergent genotypic and phenotypic 
resistance to GENVOYA (all three with M184I or V and one with K219Q in reverse transcriptase; two with E92Q or G in integrase) out of 8 virologic failure subjects with resistance data in a clinical study of virologically -suppressed subjects who switched from 
a regimen containing emtricitabine/TDF and a third agent to GENVOYA (Study 109, N=959) .
13 
 
 
 
MTN -039,  Version 1.0 38  March 6, 2019  2.7.2  P harmacokinetics of EVG and TAF  
Oral EVG  
 
Oral EVG must be co- administered with a pharmacokinetic booster to ensure adequate 
serum concentrations and facilitate once- daily dosing . Following oral administration of 
EVG and ritonavir with food , in HIV -1 infected subjects, peak EVG plasma concentrations 
were observed approximately 4 hours post -dose. EVG plasma exposures  increased in a 
less than dose proportional manner, likely due to solubility -limited absorption.22 
 As EVG is metabolized by CYP3A, drugs that induce CYP3A activity are expected to increase the clearance of EVG. EVG undergoes primarily oxidative metabolism via CYP3A, and is secondarily glucuronidated via UGT1A1/3 enzymes.  The median terminal 
plasma half -life of EVG following administration of EVG and ritonavir was approximately 
8.7 hours .
22 
 
Oral TAF  
 A single -center , open- label, dose- ranging PK study investigated a single TAF d ose in 24 
healthy, premenopausal HIV seronegative female volunteers 18- 49 years old. They were 
given 5, 10 or 25mg of TAF and each participant provided plasma, PBMC and cervical, 
vaginal and rectal tissue samples over 14 days. For each group, median (IQR) tenofovir plasma AUC
0–14 days was 52.8 (49.5 –59.6), 78.1 (68.2 –86.9) and 169.7 (131.2- 211.4) 
ng-h/mL and tenofovir -dp PBMC AUC 0–14 days was 2268 (1519- 4090), 4584 (3113- 5734) 
and 9306 (6891- 10785) fmol -h/106 cells, respectively. Tenofovir was quantifiable in 52% 
and 92% of FGT and GI tissues, whereas tenofovir -dp was quantifiable in only 5% and 
19% of  female genital tract and lower gastrointestinal tissues, respectively. Plasma 
tenofovir and PBMC tenofovir -dp were dose proportional  (90% CI  0.87- 1.15 and 0.62-
1.02, respectively) .23  
 In a study of safety, antiviral activity, and pharmacokinetics  of TAF, n on-cirrhotic, 
treatment -naïve subjects with chronic  hepatitis B were randomized (1:1:1:1:1) to receive 
TAF 8, 25, 40, or 120 mg, or TDF 300 mg for 28 days and assessed for safety, antiviral 
response,  and pharmacokinetics, followed- up by off -treatment for 4 weeks.  Following 
single dose administration on day 1, concentrations of  TAF in plasma increased in 
proportion to dose, reaching maximum  concentrations within 30-4 0 min utes. Consistent  
with the short elimination half -life of TAF (<45 min),  plasma concentrations of the drug 
were below the limit of quantification 6- 8 hours following dosing . TAF was completely  
undetectable in trough (pre- dose) plasma samples,  collected over the 28 day dosing 
period. At each of the dose levels evaluated, mean plasma TFV concentrations  following 
administration of TAF were substantially  lower than those following TDF dosing . Relative 
to the  mean TFV exposure (AUC
inf) with TDF 300 mg (2267 ng -h/ml), percentage 
reductions in mean TFV exposures for TAF  of 97%, 92%, 81%, and 33%, were seen 
following TAF doses of 8,  25, 40, and 120 mg, respectively .24 
 In another study of pharmacokinetics, safety and antiviral activity of 40 or 120 mg of TAF 
compared  with 300 mg of TDF, TAF and TDF were administered as monotherapy once 
daily for 14 days in 30 HIV-1-infected, treatment -naive subjects . Administration of 40 mg 
 
 
MTN -039,  Version 1.0 39  March 6, 2019  TAF resulted in lower tenofovir Cmax (13 versus  207 ng/mL) and lower systemic 
exposures  (AUC 0–t, 383 versus 1810 ng -h/mL) compared with subjects who received 
TDF. There were higher intracellular tenofovir concentrations within peripheral  blood 
mononuclear cells with both 40 mg (8.2 uM) and 120 mg (16.9 uM) of TAF  compared with 
300 mg of TDF (0.9 uM).25  
 
A phase 1b, randomized, partially blinded, active- and placebo- controlled, dose- ranging 
study  was also conducted with 38 t reatment -naive and experienced HIV -1–positive adults  
currently off antiretroviral therapy. Participants were randomized to receive 8, 25,  or 40 
mg TAF, 300 mg TDF, or  placebo, each once daily for 10 days.  After administration of 8, 
25, or 40 mg TAF, TAF was  rapidly absorbed (median Tmax  ~0.50 hours), displayed a 
short plasma half -life (t½ ;0.40 hours), and was below  the limit of quantitation in plasma 
by ~5 hours post -dose.  After administration of 8, 25, or 40 mg TAF or 300 mg TDF, the 
highest TFV plasma concentrations were observed with TDF. At steady  state, 8, 25, and 
40 mg TAF yielded mean TFV plasma exposures  AUC tau of 97%,  86%, and 79% lower, 
respectively, as compared with the TFV  exposures observed with 300 mg TDF. For 25 
and 40 mg TAF,  the mean intracellular peripheral blood mononuclear cell tenofovir -dp 
AUC tau was ~7-fold and ~25-fold higher  relative to 300 mg TDF .26 
 
Oral EVG and TAF in combination therapy  
 A singl e-arm, open- label study was conducted in 50 treatment -naïve adolescents with 
HIV aged 12- 18 years from ten hospital  clinics in South Africa, Thailand, Uganda, and the 
USA. The study aimed to assess safety, pharmacokinetics, and efficacy of the single -
tablet,  fixed -dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir 
alafenamide (Genvoya
®). The mean AUC tau for EVG was 23840 ng -h per mL (CV 25. 5%), 
and the mean AUC last for TAF was 189 ng -h per mL (CV 55 .8%). Both the AUC las and 
Cmax of TAF in adolescents were similar to those noted in adults after  administration of  
Genvoya. Notably, tenofovir  exposure in adolescents following this administration  was 
more than 90% lower than tenofovir exposure  following this administration in adults .27 
 In a single -arm, multicenter, open- label Phase 3 study, Genvoya was administered once 
daily to 242 virologically suppressed HIV -1-infected  participants with renal impairment to 
assess it safety and efficacy. Plasma PK parameters was measured in a subset of 
patients who participated in the intensive PK  substudy (n = 30) . The EVG and cobicistat 
(COBI) PK parameters were in the range of historical data after administration of Genvoya 
in HIV  infected  patients without renal impairment.  TAF PK parameters were consistent 
with historical data in nonrenally impaired patients. Additionally,  the TAF metabolite TFV  
was higher in patients in this study vs historical TAF  data in nonrenally impaired patients 
but was well below the TFV exposures from TDF -containing regimens .
28  
 Two controlled, double -blind , Phase 3 studies  were conducted to compare the safety and 
efficacy of E/C/F/TAF versus E/C/F/TDF in 1733 treatment -naive HIV -infected patients 
from 178 outpatient cent ers in 16 countries.  Participants were randomly assigned (1:1) to 
receive once- daily oral tablets containing 150 mg elvitegravir, 150 mg  cobicistat, 200 mg 
emtricitabine, and 10 mg tenofovir alafenamide (E/C/F/ TAF) or 300 mg teno fovir 
disoproxil fumarate (E/C/F/ TDF) with matching placebo.  65 participants participated in the 
intensive pharmacokinetic Substudy . Of those, 35 patients  participated in the PBMC 
 
 
MTN -039,  Version 1.0 40  March 6, 2019  substudy. Plasma tenofovir exposure AUC tau after administration of E/C/F/ TAF was 91% 
lower than tenofovir exposure  achieved with E/C/F/ TDF. The PBMC tenofovir -dp AUC tau 
was 4.1 times higher in participants  receiving E/C/F/ TAF than in those receiving 
E/C/F/ TDF.29 
 
Insert: Placebo and Drug -containing (TFV/FTC)  
CONRAD 117 was a randomized, double blind, placebo- controlled, Phase 1 trial 
designed to evaluate safety, PK/PD, and disintegration time after a single use of a vaginal 
insert containing TFV and/or FTC and during and after 14 days of once- daily use. 49 
women were randomized 1:1:1:1 to use inserts containing 40 mg TFV, 40 mg FTC, 40 mg TFV + 40 mg FTC, or placebo.  Participants self -administered one insert per day for 
14 days.  The TFV levels in vaginal aspirate were similar to those after TFV 1% vaginal 
gel administration associated with protection in a previous clinical study, and levels of TFV-DP in vaginal tissue associated with protection in a nonhuman primate study. Levels  
of FTC in aspirate and FTC -TP in genital tissue appeared to be at least as high as those 
seen after oral dosing in women and macaques. Systemic levels of both TFV and FTC were low.
14    
 
TAF/EVG Vaginal Insert  
 CONRAD will conduct A18 -146, a Phase 1 clinical trial of the TAF/EVG vaginal insert. 
This will be the first -in-human study for the vaginally administered TAF/EVG insert and 
will evaluate the safety, tolerability, PK, and PD after a single dose. The study w ill recruit 
healthy, non- pregnant women aged 18- 50 years who are not at risk for pregnancy and at 
low risk for sexually transmitted infections. Participants will use a single TAF/EVG insert in the clinic and will be randomized to 1 of 2 sample collection groups (2 and 48 hours after dosing or 24 and 72 hours after dosing). Plasma, cervicovaginal fluid and cervical tissue for PK will collected. It is expected that much lower plasma concentrations will be obtained for all drugs and aid in demonstrating systemic safety and refuting the need for further or extensive systemic PK characterization.
14 CONRAD will keep MTN apprised of 
any serious AEs t hat occur in this study.  
      
2.7.3  Safety  of EVG and TAF   
Oral EVG is currently approved for use as part of combination therapy. For the treatment of HIV infection, oral TAF is also approved for use as part of combination therapies. Therefore, l arge scale studies examining the safety and tolerability of EVG and TAF are 
limited to clinical trials where EVG or TAF were administered in combination with other 
ARVs.  
 
Oral EVG  
Gilead  Study GS-US-183-0101  demonstrated minimal AEs with the use of oral EV G. The 
study was a randomized, double- blind, placebo controlled, monotherapy phase 1/2 trial 
with 40 HIV -1 infected participants – a mix of both treatment naïve and treatment 
experienced (but not currently receiving ARV therapy) individuals. Participants r eceived 
EVG or placebo for 10 days at 5 dosage levels: 200 mg  BID, 400  mg BID , 800 mg QD, 
800 mg BID, or 50 mg + 100 mg ritonavir QD.   TEAEs of grade 2 or 3 were reported in 
 
 
MTN -039,  Version 1.0 41  March 6, 2019  27% of participants receiving EVG and 40% of those receiving placebo; no participants 
reported serious AEs, dosage interruptions, or discontinued from the study.8 
Oral TAF  
The safety of TAF( Vemlidy®) was assessed based on pooled data through the Week 96 
data analysis from 1298 subjects in two randomized, double- blind, active -controlled trials  
(Gilead Study 108 and Study 110) , in adult subjects with chronic hepatitis B and 
compensated liver disease.  The most common adverse reaction (all Grades) reported in 
at least 10% of subjects in the TAF group was headache. The proportion of subjects who 
discontinued treatment with TAF or TDF due to adverse reactions of any severity was 
1.5% and 0.9%, respectively.  Table 5 displays the frequency of the adverse reactions (all 
Grades) greater than or equal to 5% in the TAF group.12  
 
Table 5:  Adverse Reactionsa (All Grades) Reported in ≥5% of Subjects with Chronic HBV 
Infection and Compensated Liver Disease in Studies Gilead Studies 108 and 110 (Week 96 
Analysisb) 
Adverse reaction  Tenofovir 
alafenamide (TAF)  
N=866  Tenofovir Disoproxil 
Fumarate (TDF)  
N=432  
Headache 12% 10% 
Abdominal painc 9% 6% 
Cough  8% 8% 
Back pain 6% 6% 
Fatigue  6% 5% 
Nausea  6% 6% 
Arthralgia  5% 6% 
Diarrhea 5% 5% 
Dyspepsia  5% 5% 
a. Frequencies of adverse reactions are based on all treatment -emergent adverse events,  
regardless of relationship to study product.  
b. Double- bind phase  
c. Grouped term including abdominal pain upper, abdominal pain, abdominal pain lower,  
and abdominal tendernes s.  
 
EVG and TAF in Combination Therapy  
Additional clinical trials of EVG or TAF in HIV -infected individuals were conducted with 
EVG and TAF as part of combination therapy, administered in combination with other 
antiretrovirals ; thus it is not possible to attribute individual AEs to EVG  or TAF .8  Genvoya 
is a four drug combination that includes EVG, cobicistat, emtricitabine and TAF.   
 
In clinical trials in antiretroviral treatment -naïve HIV -infected adults, the primary safety 
assessment of Genvoya was based on Week 144 pooled data from 1733 subjects from two randomized, double- blind, active- controlled trials – Gilead Studies 104 and 111. A 
total of 866 subjects received one tablet of Genvoya once daily.  
 
 
MTN -039,  Version 1.0 42  March 6, 2019  The most common adverse event (all grades) reported in at least 10% of subjects in the 
Genvoya group was nausea. The proportion of subjects who discontinued treatment with Genvoya or Stribild due to AEs (regardless of severity)  was 1% and 2%, respectively.  The 
majority of AEs were grade 1. See Table 6 for the frequency of AEs (all grades) ≥5% in 
the Genvoya group.  
Table 6:  Adverse Reactions (All Grades) Reported in ≥5% of HIV -1 Infected Treatment -
Naïve Adults Receiving Genvoya or Stribild in Gilead Studies 104 and 111 (Week 144 
Analysis)  
Adverse reaction  Genvoya  
N=866  Stribild  
N=867  
Nausea 11% 13% 
Diarrhea 7% 9% 
Headache 6% 5% 
Fatigue  5% 4% 
 
Insert: Placebo and Drug -containing  (TFV/FTC)  
In CONRAD 134 , an open- label study that assessed in- vivo disi ntegration time, safety, 
and product acceptability of 4 placebo vaginal inserts in 32 women aged 18- 50 who were 
not at risk of pregnancy  – placebo inserts were found to be safe, with one mild AE reported 
that was subsequently assessed as being unrelated to study drug. The optimized insert 
prototypes were found to disintegrate faster and have higher acceptability over first 
generation inserts .8,30  
In CONRAD 117, the first-in-human study of vaginal microbicide inserts using TFV and/or 
FTC containing vaginal inserts - treatment -emergent adverse events (TEAEs) were 
minimal; only one TEAE met the pre- specified criterion for the safety endpoint, but this 
event was in the placebo group. Colposcopy and physical exam findings were minimal, as were changes in microflora and systemic laboratory values .
8 
2.7.4  Efficacy  
Efficacy data for EVG  or TAF containing antiretroviral regimens is summarized in the IB, 
and in the package inserts for EVG/COBI/FTC/TDF (Stribild, Gilead Sciences, Inc.) and 
EVG/COBI/FTC/TAF (Genvoya, Gilead Sciences, Inc.) .13 
2.8 Study Hypotheses and Rationale for St udy Design  
 
2.8.1  Study  Primary Hypotheses  
It is hypothesized that the two dose levels of the TAF/ EVG Insert in this study will be safe 
when applied to the rectum and well -tolerated among healthy individuals who have a 
history of receptive anal intercourse (RAI).  
 
 
MTN -039,  Version 1.0 43  March 6, 2019  2.8.2  Rationale for Study Design  
Rectal microbicides are needed for individuals at risk of acquiring HIV infection through 
unprotected RAI. It is important to expand the rectal microbicide pipeline with the addition 
of products from different classes such as EVG , an integrase inhibitor , and TAF, a 
nucleotide reverse transcriptase inhibitor . 
Rationale for the Dosing and PK Sampling Schedule  
 MTN -039 is the first study to assess the safety and PK of the TAF/ EVG Insert applied 
rectally. Antiviral activity studies of EVG in tissue explant model s have shown that an 
EVG tissue concentration of at least 1000 ng/g will be efficacious prophylactically agains t 
HIV infection . Previous vaginal PK/PD studies  suggested that a concentration of 1000 
fmol/mg TFV -DP in tissue could be a good predictor of high efficacy against HIV 
infection.
31 Based on the preclinical and animal data collected to date, the TAF/ EVG insert 
with 20 mg TAF and 16 mg EVG doses will achieve the target tissue concentration of 
1000 ng/g EVG and 1000 fmol/mg TFV -DP in humans.  
 
The PK sampling schedule in this study will provide valuable information regarding the 
rectal TAF/ EVG PK profile in humans.  This wil l provide guidance for  ongoing product 
development efforts to develop a combination topical insert containing TAF and EVG.  
   
 
3 OBJECTIVES  
 
3.1 Primary Objective s 
 
Safety  
• To evaluate the safety of the TAF/ EVG  Insert , 20/16 mg  administered rectally at two 
dose levels: 1 insert and 2 inserts  
 
Pharmacokinetics  
• To chara cterize the systemic and rectal  pharmacokinetics of the TAF/ EVG Insert , 
20/16 mg  applied rectally at two dose levels: 1 insert and 2 inserts  
 
3.2 Secondary Objective 
 
Acceptability  
• To identify product attributes considered likely to challenge and/or facilitate future 
sustained use of a TAF/ EVG insert applied rectally  
 
3.3 Exploratory Objective s 
 
Ex Vivo  Efficacy  
• To assess the preliminary ( ex vivo)  efficacy of TAF/ EVG after product is inserted 
rectally  
 
 
 
MTN -039,  Version 1.0 44  March 6, 2019  Pharmacokinetics  
• To characterize the cervicovaginal  pharmacokinetics of the TAF/ EVG Insert , 20/16 mg  
applied rectally at two dose levels: 1 insert and 2 inserts  
 
 Mucosal Safety  
• To evaluate mucosal safety of the TAF/ EVG Insert , 20/16 mg applied rectally  at two 
dose levels: 1 insert and 2 inserts    
 
 
4  STUDY DESIGN 
4.1 Identification of Study Design 
 MTN -039 is a phase 1, multi -site, open- label, single arm, two -period study of rectal 
administration of one TAF/ EVG Insert , 20/16 mg and then two TAF/ EVG Inserts .  
 
4.2 Summary of Major Endpoints  
 Primary Endpoint s: 
 Safety  
• All Grade 2 and higher AEs  
 Pharmacokinetics  
• EVG  concentrations in:  
o Blood  
o Rectal fluid  
o Rectal mucosal tissue homogenates  
 
• TAF and TFV concentrations in:  
o Blood  
o Rectal fluid  
 
• TFV-DP concentration in:  
o Rectal mucosal tissue homogenates  
o Rectal mucosal tissue cell  isolates  
 
Secondary Endpoint:  
 
Acceptability  
• Participant report of overall acceptability of the TAF/ EVG Insert  applied rectally   
Exploratory Endpoint s:  
 Ex Vivo  Efficacy  
• Changes in HIV-1 replication in colorectal explant culture supernatant  
• Anti-HIV activity in rectal fluid  
• Anti-HIV activity in cervicovaginal fluid  
 
 
MTN -039,  Version 1.0 45  March 6, 2019   
Pharmacokinetics  
• EVG , TAF and TFV concentrations  in cervicovaginal  fluid 
 
Mucosal Safety  
• Rectal histology  
• Rectal proteomics   
• Rectal metabolomics  
• Rectal immunophenotype  
• Rectal microbiome 
• Cervico vaginal microflora 
 
4.3 Description of Study Population 
 
The study population will consist  of HIV-uninfected  individuals 18 years of age or older  
who meet the criteria outlined in Sections  5.2 and 5.3. 
 
4.4 Time to Complete Accrual  
 The time to complete accrual is anticipated to be approximately  6-8 months .   
 
4.5 Study Groups  
 MTN -039 will enroll approximately  20 evaluable participants .  
 
4.6 Expected Duration of Participation  
 Each participant will be on study for approximately 6-13 weeks . The total duration of the 
study will be approximately 11 months.  
 
4.7 Sites 
 Sites selected by the MTN Executive Committee . 
  
5 STUDY POPULATION  
 
5.1 Selection of the Study Population  
 The inclusion and exclusion criteria in Sections 5.2 and 5.3
 will be used to ensure the 
appropriate selection of study participants.  
 5.1.1  Recruitment  
 Participants will be recruited from a variety of sources, including outpatient clinics, universities and community -based locations.  Recruitment materials will be approved by 
 
 
MTN -039,  Version 1.0 46  March 6, 2019  site Institutional Review Boards (IRBs) prior to use.   
 
5.1.2  Retention  
 Once a participant is enrolled in MTN -039, study site s will make every effort to retain the 
participant in follow -up to minimize possible bias associated with loss -to-follow -up. Sites 
will be responsible for dev eloping and implementing local standard operating procedures 
(SOPs)  to target and ensure high rates of retention.  
 
5.2 Inclusion Criteria  
 
Individuals who meet the following criteria are eligible for  study  inclusion:  
1) Individuals who are 18 years of age or older  at Screening , verified per site SOP  
 
2) Able and willing to provide written informed consent  to be scre ened for and enrolled 
in MTN -039 
 
3) HIV-1/2 uninfected at Screening and Enrollment, per applicable algorithm in  
Appendix 
II and willing to receive HIV test results  
 
4) Able and willing to provide adequate locator information, as defined in site SOP  
 5) Able to communicate in spoken and written English 
 
6) Available for all visits and able and willing to comply with all study procedural 
requirements  
 
7) In general good health at Screening and Enrollment, as determined by the site IoR or designee  
 
8) At Screening, history of consensual RAI at least once in lifetime  per participant report  
 
9) Willing not to take part in other research studies involving drugs, medical devices, 
genital or rectal products, or vaccines  for the duration of study participation (including 
the time between Screening and Enrollment)  
 
10) Willing to  comply with abstinence and other protocol requirements as outlined in 
Section 6. 7
 
 
11) For participants  of childbearing potential:  a negative pregnancy test at Screening and 
Enrollment  
 
12) For participants  of childbearing potential: Per participant report at Enrollment, using 
an effective method of contraception for at least 30 days (inclusive) prior to Enrollment  
and intending to use an effective method for the duration of study participation . 
Effective methods  include:   
• Hormonal methods  
• Intrauterine device (IUD) inserted at least 30 days prior to Enrollment (but not 
past the maximum length of recommended usage according to package 
instructions)  
• Sterilization  (of participant  or partner, as defined in site SOPs)   
 
 
MTN -039,  Version 1.0 47  March 6, 2019  • Sexually abstinent as defined by abstaining from penile- vaginal intercour se for 
90 days prior to Enrollment and intending to remain abstinent for the duration 
of study participation; this includes having sex exclusively with individuals 
assigned female sex at birth  
 
5.3 Exclusion Criteria  
 Individuals who meet any of the following  criteria will be excluded from the study :   
 
1) At Screening:  
a) Hemoglobin Grade 1 or higher*  
b) Platelet count Grade 1 or higher*  
c) Aspartate aminotransferase (AST) or alanine transaminase (ALT) Grade 1 or 
higher*  
d) Serum creatinine >1.3× the site laboratory upper limit of normal (ULN)  
e) International normalized ratio (INR) >1.5× the site laboratory ULN  
f) History of inflammatory bowel disease by participant report  
 
*As per the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events 
Corrected Version 2.1, July 2017.  
Note: Otherwise eligible participants with an exclusionary test result (other than HI V) can 
be re- tested during the screening process. If a participant is re- tested and a non -
exclusionary result is documented within 45 days of providing informed consent for 
screening, the participant may be enrolled.  
 
2) Anticipated use of and/or unwillingnes s to abstain from the following medications 
during study participation:  
a) Anticoagulant medications   
b) Non-study rectally -administered medications  and any products containing N -9 
 
3) Known adverse reaction to any of the components of the study product     
 4) Use of pre- exposure prophylaxis (PrEP) for HIV prevention within 3 month s prior to 
Enrollment , and/or anticipated use and/or unwillingness to abstain from PrEP during 
trial participation  
 5) Use of post -exposure prophylaxis (PEP) for potential HIV exposure within 6 months 
prior to Enrollment  
 6) Condomless  RAI and/or penile- vaginal intercourse with a partner  who is known to be 
HIV-positive or whose status  is unknown in the 6 months  prior to Enrollment  
 
7) History of transactional sex  in the 12 months prior to Enrollment  
 8) Non-therapeutic injection drug use or use of non- therapeutic, non- injection stimulant 
drugs in the 12 months prior to Enrollment  
 
9) Participation in research studies involving drugs, medical devices, genital or rectal products, or vaccines  within 30 days of the Enrollment Visit  
 
 
 
MTN -039,  Version 1.0 48  March 6, 2019  10) Per participant report, medical records, clinical diagnosis and/or diagnostic testing at 
either Screening or  Enrollment:  
 
a. Diagnosis or treatment of an anogenital STI  in the 3 months prior to enrollment  
(including window between Screening and Enrollment) . 
 
b. Symptoms, clinical or laboratory diagnosis of active pharyngeal, anorectal, or  
reproductive tract infection (RTI) requiring treatment per current CDC guidelines (http://www.cdc.gov/std/treatment).  
  
c. Current symptomatic urinary tract infection ( UTI). 
 
Infections requiring treatment include Neisseria gonorrhea (GC), Chlamydia 
trachomatis (CT) infection, syphilis, active herpes simplex virus (HSV) lesions, or symptomatic genital warts, chancroid, pelvic inflammatory disease (PID), bacterial vaginosis (BV), symptomatic vaginal candidiasis, and trichomoniasis.  
Note:   Otherwise eligible participants with an exclusionary UTI, BV and/or candida finding 
may be re -tested during the screening process.  
 
11) For participants  of childbearing potential: Pregnant or breastfeeding at either  
Screening or Enrollment or planning  to become pregnant during study participation  
Note:  A documented negative pregnancy test performed by study staff is required for 
inclusion; however, a self -reported pregnancy is adequate for exclusion from 
screening/enrollment into the study.  
 12) For participants  of childbearing potential: Last pregnancy outcome 90 days or less 
prior to Screening  
 
13) Has any other condition that, in the opinion of the IoR/designee, would preclude 
informed consent, make study participation unsafe, complicate the interpretation of 
study outcome data, or otherwise interfere with achieving the study objectives including any significant uncontrolled active or chronic medical condition.  
 
5.4 Co-enrollment Guidelines  
 As indicated in Sections 5.2 and 5.3
, participants must not take part in other research 
studies involving drugs, medical devices, rectal and genital  products, or vaccines after 
the Screening Visit and while taking part in MTN -039 unless approved by the Protocol 
Safety Review Team ( PSRT ). Participation in the following types of studies may be 
allowed at the discretion of the IoR/designee:  
 
• Participants  may take part in ancillary studies if approved by MTN -039 PSRT  
 Should any participant report concurrent participation in contraindicated studies after enrolling in MTN -039, the IoR/designee will consult the PSRT regarding ongoing product 
use and other potential safety considerations associated with co- enrollment.  
  
 
 
MTN -039,  Version 1.0 49  March 6, 2019  6 STUDY PRODUCT 
6.1 Regimen  
 
The product being used in this study is Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Vaginal Insert 20/16 mg. This product was initially developed for a study (A18- 146) 
involving vaginal administration, however rectal administration of the product is now being studied in this trial. Therefore, the product can simply be referred to as “TAF/EVG Insert” for this study. Each insert for rectal administration contains 20 mg tenofovir alafenamide 
(TAF) and 16 mg elvitegravir (EVG).  
 Participants will self -administer a saline enema at home the evening prior to a clinic 
dosing visit. Each participant will receive a single TAF/EVG Insert for  rectal 
administration . After a washout period of at least 7 days, participants will  each receive
 
two TAF/ EVG Inserts  for rectal administration. After each  dose is administered in the 
clinic, PK and PD sampling will be conducted  over a three- day period.  
 
Table 7: Study Product Regimen  
       
 
6.2 Administration  
 
Participants will be instructed to present to the clinic for each of the 2 doses of rectally 
administered TAF/ EVG  Inserts . Administration of the TAF/ EVG Insert(s) will be performed 
by study staff . 
 6.3 Study Product Formulation and Storage  
 Normal Saline Home Enemas  
 Participants will be provided with t wo 120 mL sealed cups of sterile USP normal saline  
(NS) solution for home enema administration. The participant will use a 60 mL oral syringe 
(provided) to transfer the entire content of the NS cup to the enema bottle. Although all  of 
the solution should be transferred to the enema bottle, the participant will be instructed to discard any unused solution remaining in the original container . The NS solution should 
be stored at room temperature 25ºC (77° F). Additionally, participants will be instructed to 
dispose the prepared saline enema if not used within 24 hours of filling.  
 Each participant will receive a sheet of instructions which will outline the process for preparing the enema, disposing unused solution and enema administration. A review of these instructions will be conducted with the participant at the clinic prior to providing the  
enema kit to be administered at home.    Visit 3  
 Visit 7 
1 TAF/ EVG Insert  
   
 
7-49 days following 
tissue sampling  2 TAF/ EVG  Inserts  
 
 
 
MTN -039,  Version 1.0 50  March 6, 2019   
TAF/EVG Inserts  
 TAF/EVG Inserts  have been formulated into white to off -white uncoated bullet shaped 
inserts containing 22.40  mg of TAF Fumarate (equivalent to 20 mg  TAF free base) and 
16 mg of EVG .
 TAF is a nucleotide reverse transcriptase inhibitor (NRTI) and a prodrug 
of Tenofovir (TFV ) and EVG is an integrase inhibitor. Both the active pharmaceutical 
ingredients (APIs) are supplied by Gilead Sciences, Inc.   
 
Figure 2: Study Product  
 
 
 
In addition to TAF and EVG this insert contains the following inactive excipients:  
povidone, magnesium stearate, polaxomer (also known as Kolliphor  P188), polyethylene 
glycol , mannitol, and lactose anhydrous. The insert dimensions are: length: 1.5 cm (0.6 
inches), width: 0.7 cm (0.28 inches), height: 0.6 cm (0.23 inches). Each insert is 
approximately 500 mg in weight. The TAF/EVG  Insert should be stored as supplied in a 
white induction- sealed HDPE bottle of 20 inserts along with polyester coil and a desiccant 
at room temperature (20° - 25°C) (68° - 77°F) until dispensed for use. Excursions between 
15 ° - 30°C  (59° - 86°F)  are allowed. 
 6.4 Study Product Supply and Accountability  
6.4.1  Study Product Supply  
 
CONRAD (the organization that supplies the rectal insert) will oversee the manufacture 
and analysis/release (Patheon, Whitby, ON, Canada) of the study product under current 
Good Manufacturing Practices ( cGMP).  
 
Sealed cups containing 120 mL USP normal saline and USP are supplied by Nurse 
Assist, Inc, Fort Worth . The enema bottles used in this study are commercially available 
125 mL enema bottles that meet  US Pharmacopeia  (USP) standards  and contain no 
heavy  metal s, no phthalates,  and are bisphenol  A (BPA) free.  
6.4.2  Study Product Dispensing 
 

 
 
MTN -039,  Version 1.0 51  March 6, 2019  TAF/ EVG  Inserts will be dispensed to clinic staff on behalf of the participant, upon receipt 
of a written prescription from an authorized prescriber. An authorized prescriber includes 
the IoR or a licensed clinician directly responsible to the IoR as noted on the Form FDA 
1572.  
6.4.3  Study Product Accountability  
 
Each Clinical Research Site (CRS) Pharmacist of Record (PoR) is required to maintain a 
complete r ecord of all TAF/ EVG Inserts received and subsequently dispensed. All unused 
TAF/ EVG Insert s must be returned to the MTN Pharmacist after the study is completed 
or terminated unless otherwise instructed by the MTN Pharmacist. The procedures to be  
followed are provided in the MTN -039 Pharmacy Study Product Management  Procedures 
Manual.  
 
6.5 Ancillary Study Supplies  
 
Clinic staff will provide male condoms to all participants.  Lubricant will be provided at each 
dosing for ease of administration (if needed).  
 6.6 Concomitant Medications  
 Enrolled study participants may use concomitant medications during study participation 
except for  medications and products not permitted per the inclusion and exclusion criteria 
and listed in Section 6.7
 below . All concomitant medications reported throughout the 
course of the study will be recorded in the study database. Concomitant medications 
include all prescription medications, over -the-counter preparations, vitamins, nutritional 
supplements, and herb al preparations .  
 
6.7 Prohibited Medications, Products and Practices  
6.7.1  Prohibited Medications and Products  
 Several concomitant medications/practices will not be permitted. Participants are  
prohibited from using strong and moderate CYP3A inhibitors and inducers. These 
medications are not  permitted because EVG is a CYP3A substrate.  A listing of these 
specific prohibited agents is provided below (see Table 8 and Table 9) and in the MTN -
039 SSP Manual available at www.mtnstopshiv.org . Mild inducers/inhibitors are permitted 
as long as stable dose is anticipated throughout the study.  
         
 
 
MTN -039,  Version 1.0 52  March 6, 2019  Table 8: Prohibited CYP  Inhibitors  
Strong  Inhibitors  
≥ 5-fold increase in AUC  
or > 80% decrease in CL Moderate Inhibitors 
≥2 but < 5- fold increase in 
AUC or 50-80% decrease in CL 
Antibiotics: 
clarithromycin, telit hromyc in 
 
Antidepressants: 
nefazo done 
 
Azole Antif ungals :  
ketoconazol e, itraco nazo le, 
posac onazole, vor icona zole 
 
Pharmacokinet ic Enhanc ers:  
cobicistat 
 
Protease Inhibit ors:  
ritonavir , indinavir, lopinavir/rito navir, 
nelfin avir, saquinavir, boce previr, 
telaprevir 
 
Rever se Transc riptas e Inhibit ors: 
delavirdine 
 
Vasopressi on Recept or Antagonis ts: 
conivaptan Antiarrhythmics: 
drone darone 
 
Antibiotics :  
erythromycin , 
ciprofloxac in 
 
Antiemetics: 
aprepita nt 
 
Antineoplastics: 
imatin ib 
 
Azole Antif ungals: 
flucona zole, mic onazo le 
 
Calcium Channel Blockers: 
verapami l, diltiazem 
 
Protease Inhibit ors:  
atazanav ir, darunavir/rito navir, 
fosam prenav ir 
 
Table 9: Prohibited CYP  Inducers  
Strong  Indu cers 
≥ 80% decrease in AUC Moderate Inducers 
50-80% decrease in AUC 
Antic onvu lsants/Mood Stabilizers: 
phenytoin, c arbamaz epine 
 
Antic onvu lsants/Barbiturates: 
primidone 
 
Antituberculars: 
rifamp in 
 
Barbiturates: 
phenobarbital, butalbital 
 
Glucoc orticoids: 
dexa methasone 
 
Herbal S upplements : 
St. John’s wort^ 
 
Protease Inhibit ors: 
tipranavir (alone)  Antibiotics: 
nafcillin 
 
Antihy pertensives: 
bosentan 
 
Antituberculars: 
rifabutin 
 
CNS  Stimulants: 
modafin il 
 
Rever se Tran scriptase I nhibitors: 
efavi renz, etravirine, nevirapine  
^The effec t of St . John’s w ort and echina cea varies wi dely and is preparation- dependent. 
 
 
 
 
MTN -039,  Version 1.0 53  March 6, 2019    
The use of study product concurrently with PEP and PrEP is prohibited during study 
participation. Individuals who need PEP or PrEP due to known or potential HIV exposure 
will permanently discontinue study product use. S ee Section  9.3 for additional 
information. Use of rectally -administered medications  and products, including  N-9 
products , is also prohibited.  
 
Use of anticoagulants or blood- thinners (such as heparin, Lovenox®, warfarin, Plavix® 
[clopidogrel bisulfate]) is also prohibited during study participation. See Section 9.3 for 
additional information.  
 Participants will be counseled to abstain from using aspirin (greater than 81 mg) and non-steroidal anti -inflammatory drugs (NSAIDS) within 72 hours prior to and following a tissue 
sample collection visit. Should a participant report taking any of the medications noted above, which may increase risk of bleeding, or report the use of rectal medications or 
products within 72 hours prior to tissue collection, the visit should be rescheduled within 
the visit window, if possible. If it is determined that rescheduling the visit within the window is not possible, the visit may proceed at IoR discretion after proper participant counseling has occurred.  
6.7.2  Prohibited Practices  
 
All participants are to abstain from inserting any non-study  products (including rectal 
medications, enemas, lubricant and sex toys) into the rectum , rectal stimulation with 
fingers, receptive oral  anogenital  stimulation  and receptive anal intercourse for 72 hours 
prior to and following clinic visits. Participants should abstain from inserting anything into 
the vagina for 72 hours prior to each clinic visit, including fingers, spermicides, vaginal 
medications (including hormones), vaginal douches, lubricants and moisturizers, sex toys (vibrators, dildos, etc.) and vaginal intercourse.  
 If desi red, the IoR may request rapid PSRT consultation to assist in making the 
determination as to whether or not to proceed with the visit at that time or to reschedule an interim visit. If the decision is made to reschedule an interim visit, any missed procedures (including biopsy collection) should be performed during the interim visit.  
   
7 STUDY PROCEDURES 
An overview of the study visit and evaluations schedule is presented in Appendix I .  
Presented in this section is additional information on visit -specific study procedures.  
Detailed instructions to guide and standardize procedures as well as information regarding the study visit windows are provided in the MTN -039 SSP Manual available at 
http://www.mtnstopshiv.org . 
 
 
 
MTN -039,  Version 1.0 54  March 6, 2019  Figure 3: MTN -039 Study Visit Schedule  
 
 
  
7.1 Pre-screening  
 
As part of participant outreach and recruitment strategies, study staff can pre- screen 
potential study participants at either on- site or off -site locations. During these interactions, 
study staff may explain the study to potential participants and ascertai n elements of 
presumptive eligibility to be confirmed at an on- site screening visit. Process information 
(e.g., number of potential participants contacted, number presumptively eligible) may be recorded and stored at study sites in the absence of written i nformed consent from 
potential participants, provided the information is collected in such a manner that it cannot be linked to participant identifiers, unless a waiver is granted from the local IRB. At each 
site, procedures and documentation will comply with local IRB requirements.  
 
7.2 Screening 
  
A Screening Visit will take place up to  45 days prior to the Enrollment Visit (Day 0).  
Multiple visits may be conducted to complete all required screening procedures, if necessary. Written informed consent for Screening/Enrollment will be obtained before any screening procedures are initiated. For participants who do not meet the eligibility 
criteria, s creening will be discontinued once ineligibility is determined.   
 NOTE: Participants  who fail their first screening attempt may be re- screened one time.  
 
Table 10:  Screening Visit  
Screening Visit  - Visit 1  
Component  Procedures  
Administrative and 
Regulatory  
 • Obtain written informed consent  
• Assign a unique Participant Identification (PTID) number  
• Assess eligibility  
• Collect demographic information  
• Collect locator information 
• Provide reimbursement  
• Schedule next visit/contact*  
Behavioral/Counseling  • HIV pre - and post -test counseling  
• HIV/STI risk reduction counseling 
• Protocol counseling  

 
 
MTN -039,  Version 1.0 55  March 6, 2019  Clinical  • Collect concomitant medications  
• Collect medical history  
• Perform physical examination 
• Perform genital examination*  
• Perform pelvic examination* ▲ 
• Perform rectal examination 
• Treat or prescribe treatment for RTI/UTI, or STIs*  
• Provide  available test results  Laboratory  
 Pharyngeal  • NAAT for GC/CT  
Urine  • NAAT for GC/CT ▼ 
• Urine dipstick/culture*  
• Pregnancy test  ■ 
Blood  • CBC with differential and platelets  
• Chemistries (AST/ALT/c reatinine)  
• Syphilis serology   
• HIV-1/2 test  
• Coagulation (PT/INR)  
Pelvic ▲ • NAAT for GC/CT/TV  
Anorectal  • NAAT for GC/CT  
Study Product/Supplies  • Offer condoms  
* If indicated  ▲Participants assigned female sex at birth and if  anatomy allows  ▼If pelvic GC/CT cannot 
be performed  ■ Participants  of childbearing potential   
 
7.3 Enrollment (Day 0)  
 
The Enrollment Visit can occur up to 45 days after the Screening Visit. All Enrollment 
procedures must occur on the same day.  
 
Participants will be assigned to one of two groups to obtain samples : Group 1 will have 
biopsies , rectal fluid and cervicovaginal fluid (if applicable)  collected at 2 hours (Visits 3 
and 7) and 48 hours (Visits 5 and 9) following each administration  of product; participants 
in this group will also have rectal and cervicovaginal fluid collected at 6 hour post -dose at 
Visits 3 and 7. Group 2 will have biopsies, rectal fluid and cervicovaginal fluid (if applicable) collected  at 24 hours (V isits 4 and 8) and 72 hours  (Visits 6 and 10) following 
each administration  of product ; participants in this group will also have rectal and 
cervicovaginal fluid collected at 4 hours post -dose at Visits 3 and 7. Both groups will have 
blood collected at eac h visit  from Visit 3 through Visit 10. At least three participants 
assigned female sex at birth should be enrolled and assigned to each group.  
 
Table 11:  Enrollment Visit  
Enrollment Visit – Visit 2  
Component  Procedures  
Administrative and Regulatory  
 • Assess and confirm eligibility  
• Review/update locator information  
• Random assignment to  sampling schedule  
• Provide reimbursement  
• Schedule next visit/contact*  
Behavioral/Counseling  • HIV pre - and post -test counseling  
 
 
MTN -039,  Version 1.0 56  March 6, 2019  • HIV/STI risk reduction counseling 
• Protocol counseling 
• Behavioral assessment  (CASI)  
Clinical  • Review/update  concomitant medications  
• Review/update medical history  
• Perform physical examination 
• Perform genital examination*  
• Perform pelvic examination* ▲ 
• Perform rectal examination 
• Treat or prescribe treatment for RTI/UTI, or STIs*  
• Provide  available test results  Laboratory  
 Pharyngeal  • NAAT for GC/CT*  
Urine  • NAAT for GC/CT* ▼ 
• Urine dipstick/culture*  
• Pregnancy test  ■ 
Blood  • CBC with differential and platelets*  
• Chemistries (AST/ALT/c reatinine)*  
• Syphilis serology*  
• Plasma  for archive  
• HIV-1/2 test 
• Blood for PK  
Pelvic ▲ • NAAT for GC/CT/TV*  
• CVF for PD  
• CVF for microflora  
Anorectal  • Rectal fluid for PD  
• Rectal fluid for micro biome  
• Rectal enema  prior to biopsy collection 
• Rectal tissue for PD  
• Rectal tissue for biomarkers  
• NAAT for GC/CT*  
Study Product/Supplies  • Offer condoms  
• Provide home enema kit 
* If indicated  ▲ Participants assigned female sex at birth and i f anatomy allows   ▼If pelvic GC/CT cannot 
be performed  ■ Participants  of childbearing potential  
 
7.4 Follow -up Visits  
 
7.4.1  Dosing – Visits 3 and 7 
 
The first dosing visit (Visit 3) should occur at least  7 days after the Enrollment Visit. The 
second and final dosing  visit (Visit 7) should occur at least 7 days  after the last tissue 
sampling visit following Dose 1  (following Visit 5 or 6 with a 1- to 7-week washout period).  
 
Table 12 : Dosing Procedures 
Dosing Procedures – Visits 3 and 7  
Component  Procedures  
 
 
MTN -039,  Version 1.0 57  March 6, 2019  Administrative and Regulatory  
 • Review/update locator information  
• Provide reimbursement  
• Schedule next visit/contact  
Behavioral/Counseling  • HIV pre - and post -test counseling*  
• HIV/STI risk reduction counseling*  
• Protocol counseling  
Clinical  • Review/update medical history  
• Review/update concomitant medications  
• Perform targeted physical examination*  
• Perform genital examination*  
• Perform pelvic examination* ▲ 
• Perform rectal examination 
• Treat or prescribe treatment for RTI/UTI, or STIs*  
• Provide available test results  
• Collect /update  AEs Laboratory  Pharyngeal  • NAAT for GC/CT*  
Urine  • NAAT for GC/CT* ▼ 
• Urine dipstick/culture*  
• Pregnancy test* ■ 
Blood  • CBC with differential and platelets*  
• Chemistries (AST/ALT/c reatinine)*  
• Syphilis serology*  
• HIV-1/2 test*  
• Blood for PK   
Pelvic ▲ • CVF for PK ** 
• CVF for PD ♣  
• CVF for microflora  ♣   
• NAAT for GC/CT/TV*  
Anorectal  • Rectal fluid for PK ** 
• Rectal fluid for PD  ♣  
• Rectal fluid micro biome  ♣  
• Rectal tissue for PK  ♣ 
• Rectal tissue for PD ♣ 
• Rectal tissue for biomarkers  ♣ 
• NAAT for GC/CT*  
Study Product/Supplies  • Administration  of study product  
• Offer condoms  
• Offer lubricant  
* If indicated ▲ Participants assigned female sex at birth and i f anatomy allows ▼If pelvic GC/CT cannot 
be performed  ■ Participants  of childbearing potential    
 All participants will have blood collected at 1, 2, 4, and 6 hours following product administration.   
♣ Group 1 only  at 2 hours post -dose  
** Group 1: 2 and 6 hours post -dose; Group 2: 4 hours post -dose  
 
 
 
 
MTN -039,  Version 1.0 58  March 6, 2019  7.4.2  Post -Dosing Visits  – Visits 4  and 8 
 
The 24 -hour Post -Dosing Visits (Visits 4 and 8) should occur between 22 and 26 hours 
(+/- 2 hours) after each dosing visit.  
 
Table 13:  24-hour Post -Dosing Visits  
24-Hour Post -Dosing Visits - Visits 4 and 8 
Component  Procedures  
Administrative and Regulatory  
 • Review/update locator information  
• Provide reimbursement  
• Schedule next visit/contact   
Behavioral/Counseling  • HIV pre - and post -test counseling*  
• HIV/STI risk reduction counseling*  
• Protocol counseling 
• Behavioral assessment  (Brief CASI)  
Clinical  • Review/update medical history  
• Review/update concomitant medications  
• Perform targeted physical examination*  
• Perform genital examination*  
• Perform pelvic examination* ▲ 
• Perform rectal examination 
• Treat or prescribe treatment for RTI/UTI, or STIs*  
• Provide available test results  
• Collect/update  AEs Laboratory  Pharyngeal  • NAAT for GC/CT*  
Urine  • NAAT for GC/CT* ▼ 
• Urine dipstick/culture*  
• Pregnancy test* ■ 
Blood  • CBC with differential and platelets * 
• Chemistries (AST/ALT/c reatinine) *  
• Syphilis serology*  
• HIV-1/2 test*  
• Blood for PK    
Pelvic ▲ • CVF for PK ☼ 
• CVF for PD  ☼ 
• CVF for microflora  ☼ 
• NAAT for GC/CT/TV*  
Anorectal  
 • Rectal fluid for PK  ☼ 
• Rectal fluid for PD  ☼ 
• Rectal fluid for micro biome ☼ 
• Rectal tissue for PK  ☼ 
• Rectal tissue for PD ☼ 
• Rectal tissue for biomarkers  ☼  
• NAAT for GC/CT*  
Study Product/Supplies  • Offer condoms  
 
 
MTN -039,  Version 1.0 59  March 6, 2019  * If indicated ▲ Participants assigned female sex at birth and i f anatomy allows ▼If pelvic GC/CT cannot 
be performed  ■ Participants  of childbearing potential  ☼ Group 2 only  
7.4.3  Other Post -Dosing Visits  – Visits 5, 6, 9, and 10  
 
The 48 -hour Post -Dosing Visits (Visits 5 and 9) should occur between 44 and 52 hours 
(+/- 4 hours) after each dosing visit. The 72 -hour Post -Dosing Visits (Visits 6 and 10) 
should occur between 66 and 78 hours (+/ - 6 hours) after  each dosing visit.    
 
Table 14:  Other Post -Dosing Visits  
Other Post -Dosing Visits -  Visits 5, 6, 9, and 10   
Component  Procedures  
Administrative and Regulatory  
 • Review/update locator information  
• Provide reimbursement   
• Schedule next visit/contact   
Behavioral/Counseling  • HIV pre - and post -test counseling*  
• HIV/STI risk reduction counseling*  
• Protocol counseling 
• Behavioral In -Depth Interview (IDI) (Visit 10 only)  
Clinical  • Review/update medical history  
• Review/update concomitant medications  
• Perform targeted physical examination*  
• Perform genital examination*  
• Perform pelvic examination* ▲ 
• Perform rectal examination 
• Treat or prescribe treatment for RTI/UTI, or STIs*  
• Provide available test results  
• Collect /update  AEs Laboratory  Pharyngeal  • NAAT for GC/CT*  
Urine  • NAAT for GC/CT* ▼ 
• Urine dipstick/culture*  
• Pregnancy test* ■  
Blood  • CBC with differential and platelets * (required at Visit 
10) 
• Chemistries (AST/ALT/c reatinine) * (required at Visit 
10) 
• Syphilis serology*  
• HIV-1/2 test*  (required at Visit 10)  
• Blood for PK    
Pelvic ▲ • CVF for PK ⌂   
• CVF for PD  ⌂  
• NAAT for GC/CT/TV*  
 
 
MTN -039,  Version 1.0 60  March 6, 2019  Anorectal  
 • Rectal fluid for PK  ⌂   
• Rectal fluid for PD  ⌂  
• Rectal enema prior to biopsy collection ⌂  
• Rectal tissue for PK  ⌂  
• Rectal tissue for PD ⌂  
• NAAT for GC/CT*  
Study Product/Supplies  • Offer condoms  
• Provide home enema kit (Visit 6 only)  
* If indicated ▲ Participants assigned female sex at birth and i f anatomy allows ▼If pelvic GC/CT cannot 
be performed  ■ Participants  of childbearing potential    
⌂ Group 1 will have biopsies, rectal fluid and cervicovaginal fluid (if applicable) collected at 48 hours (Visits 
5 and 9) following each administration of pr oduct;  
Group 2 will have biopsies, rectal fluid and cervicovaginal fluid (if applicable) collected at 72 hours (Visits 
6 and 10) following each administration of product .  
 
 
7.4.4  Final Contact /Early Termination Visit  
 
The Final Contact (Visit 11) should occur approximately 3-7 days following Visit 10 and 
may be conducted over the phone. This contact will also serve as the participant’s study 
termination.  Participants who permanently discontinue study product and follow -up visits  
prior to study completion will be asked to complete an Early Termination Visit , if willing .   
 
Table 15:  Final Contact /Early Termination Visit    
Final Contact /Early Termination Visit  - Visit 11 
Component  Procedures  
Administrative and 
Regulatory  • Review/update locator information  
• Provide reimbursement  
• Schedule next visit/contact*  
Behavioral/Counseling  • HIV pre - and post -test counseling*  
• HIV/STI risk reduction counseling*  
Clinical  • Review/update medical history  
• Review/update concomitant medications  
• Perform targeted physical examination*  
• Perform genital examination*  
• Perform pelvic examination* ▲ 
• Perform rectal examination* 
• Treat or prescribe treatment for RTI/UTI, or STIs*  
• Provide available test results  
• Collect /update AEs Laboratory  Pharyngeal  • NAAT for GC/CT*  
Urine  • NAAT for GC/CT* ▼ 
• Urine dipstick/culture*  
• Pregnancy test* ■ 
 
 
MTN -039,  Version 1.0 61  March 6, 2019  Blood  • CBC with differential and platelets*  
• Chemistries (AST/ALT/creatinine)*  
• Syphilis serology*  
• HIV-1/2 test*  
Pelvic ▲  • NAAT for GC/CT/TV*  
Anorectal  • NAAT for GC/CT*  
Study Product/Supplies  • Offer condoms * 
* If indicated ▲ Participants assigned female sex at birth and i f anatomy allows ▼If pelvic GC/CT cannot 
be performed ■Participants  of childbearing potential  
 
7.5 Follow -up Procedures for Participants Who Permanently Discontinue Study 
Product  
 
7.5.1  Participants Who Become Infected with HIV -1 
 
If a partic ipant tests positive for HIV -1 after the Enrollment Visit, the participant  will be 
referred  to local care and treatment services and may return to the research clinic for 
additional counseling and other support services, as needed. Continued study participation would be of no added benefit  to the participant, thus follow -up visits will be 
discontinued , study product use will cease,  and the participant will be considered 
terminated from the study.  An Early Termination Visit will occur and additional laboratory testing ( including  HIV RNA and HIV drug resistance testing)  will be conducted for  
participants who have received one or more doses of study product. Please reference the MTN -039 SSP Manual for additional details (www.mtnstopshiv.org).  
 7.5.2  Participants Who Become Pregnant  
 If a participant becomes pregnant, the participant will be referred to local health care 
services and may return to the research clinic for additional counseling, as needed. Continued study participation would be of no added benefit to the participant, thus product 
use, follow -up visits and procedures will be discontinued,  and the participant will be 
considered terminated from the study. An Early Termination Visit will be conducted, if the participant is willing. A participant who is pregnant at study termination will continue to be followed until the pregnancy outcome is ascertained, see Section 9.5
 for additional 
details.  
 For p articipants who become pregnant while on study product , the study site will make 
every reasonable effort to contact participants and collect infant outcome information at 
approximately one year after delivery for those pregnancies that result in live birth. For 
additional details regarding obtaining pregnancy and infant outcomes, please reference the MTN -039 SSP Manual (www.mtnstopshiv .org). 
 
7.5.3  Participants Who Permanently Discontinue Study Product for Other 
Reasons  
 
For participants who permanently discontinue study product use for any reason other than HIV seroconversion or pregnancy, site investigators may, after consultation with the 
 
 
MTN -039,  Version 1.0 62  March 6, 2019  PSRT and MTN -039 Management Team, decide to discontinue study follow -up visits and 
procedures . Participants will, however, be asked to complete the procedures scheduled 
to occur at the Early Termination Visit (Visit 11), if willing.  In the event study follow -up is 
continued, participants will have the protocol -specified visits through Final Contact . Sites 
should contact the PSRT and management team to determine whether the participant 
should be followed on study and what study procedures should be compl eted.  
 Participants who permanently discontinue study product use due to an AE must continue to be followed in the study, if willing, until resolution (return to baseline) or stabilization of the AE is documented.  
  
7.6 Interim Visits  
 Interim visits may be performed at any time during the study, and any visit procedures may be conducted as indicated. All interim contacts and visits will be documented in participants' study records. If a participant misses a visit (e.g., presents to the clinic outside of the visit window), the participant  can return for an interim visit to make up 
certain missed visit procedures and specimen collections. Refer to the MTN -039 SSP 
Manual for additional details.  
 All interim contacts and visits will be documented in participants' study records.   
 
7.7 Protocol Counseling: Adherence and Contraception Counseling  
 
At the Dosing Visit, participants will receive study product counseling appropriate to the visit. Study staff will document administration  of study product and that the counseling 
was provided. Study product counseling will be provided to study participants upon 
enrollment into the study. Contraception counseling will be provided to participants  of 
childbearing potential  beginning at the Screening Visit. Protocol adherence counseling 
will be provided beginning at the Screening Visit. Counseling will be provided in accordance with standard study methods. Counseling also will include reminders regarding concomitant medication and behavioral restrictions prior to and following 
collection of biopsies.   
 
7.8 Clinical Evaluations and Procedures  
 
Physical Examination  
The physical examination will include the following assessments:  
• General appearance  
• Weight *  
• Vital signs  
− Temperature  
− Pulse  
− Blood pressure  
− Respirations  
• Height*  
• Abdomen*  
 
 
MTN -039,  Version 1.0 63  March 6, 2019  • Head, Eye, Ear, Nose and Throat (HEENT) Examination*  
• Oral mucosa*  
• Lymph nodes*  
• Neck*  
• Heart*  
• Lungs*  
• Extremities*  
• Skin*  
• Neurological*  
• Other components as indicated by participant symptoms  
 
 * = May be omitted after Enrollment Visit  
 
Anor ectal Examination  
The ano rectal examination may include the following:  
• Visual exam  
• Digital exam  
• Anoscopy  
• Flexible sigmoidoscopy  
 
Note:  Detailed information regarding the rectal and genital examination, as well as the associated procedures required for collecting specimens at each visit, can be found in the MTN -039 SSP Manual.  
 Additional clinical assessments may be performed at the discretion of the examining clinician in response to  symptoms or illnesses present at the time of the exam.  
 
7.9 Behavioral Assessments 
 Participants will respond to brief computer administered self -interviews (CASI) at the 
Enrollment visit (Visit 2), and at the post-dose visits (Visit s 4 and 8). The baseline 
assessment, done at Enrollment, will include, among other topics, questions on 
participants’ prior experience and comfort using rectal products as well as douching or other rectal hygiene practices. The follow -up assessments will explore reactions to 
product and administration method. These assessments will allow us to identify product attributes likely to challenge and/or facilitate future sustained use when applied rectally by participants (secondary objective: acceptability). Suggestions for product impr ovement 
will also be collected.  
 An in -depth interview  is planned at Visit 10 . The in -depth interviews will include, among 
other topics, questions on user acceptability of the product, user -centered suggestions 
for product design and delivery, and experiences with the direct application method. The 
interview notes, recording and transcript  from the in- depth interview will be considered as 
source documentation. Major components of these assessments to be used have been 
validated in prior rectal microbicide trials (e.g., MTN- 006, MTN -007, MTN -017) and on-
going trials (MTN -026, MTN -033, and MTN -037).  
 
 
 
MTN -039,  Version 1.0 64  March 6, 2019  7.10 Pharmacokinetics (PK) and Pharmacodynamics (PD) 
 
The MTN -039 cohort will provide samples  for PK and PD  throughout the study from  Visits 
2 through 10 . At study randomization, participants will be assigned to one of two 
schedules  for collection of rectal tissue  (collected with flexible sigmoidoscopy) , rectal fluid, 
and cervicovaginal fluid (if applicable) : 
Group 1: Visit s 3, 5, 7 , and 9 
Group 2: Visits 4, 6, 8, and 10 
Note : Both g roups  1 and 2 will provide blood at Visits 3- 10. At Visits 3 and 7, both groups 
will provide rectal fluid and cervicovaginal fluid (if applicable) – Group 1 at 2 and 6 
hours post -dose, and Group 2 at 4 hours post -dose.  All sampling times are 
approximate; allowable windows and detailed instructions are provided in the MTN -
039 SSP Manual.  
 
Table 16: Specimens to be Collected to Assess Safety, PK and Ex Vivo  Antiviral Activity  
Study Visit  Specimens collected for PK, PD and mucosal safety  
 Blood  Rectal Fluid  Rectal Tissue  CVF  
Visit 2 - 
Enrollment   • Blood for PK  
 • RF for micro biome   
• RF for PD  
 • 7 samples for biomarkers  
o 1 histology  
o 1 proteomics  
o 1 metabolomics  
o 4 flow cytometry  
• 4 samples for PD  • CVF for microflora  
• CVF for PD  
Visit 3  & Visit 7 -  
Samples 
collected at 1, 2, 
4 and 6 hours    • Blood for PK  
 
  Group 1 at 2 -hour  
• RF for micro biome   
• RF for PK  
• RF for PD  
 
Group 1 at 6 -hour  
• RF for PK  
 
Group 2 at 4 -hour  
• RF for PK  
 Group 1 only at 2 -hour  
• 7 samples for biomarkers  
• 4 samples for PD  
• 11 samples for PK  
o 1 for EVG  
o 1 for TFV/TFV -DP 
o 1 for backup  
o 8 for MMC isolat ion Group 1 at 2 -hour  
• CVF for microflora   
• CVF for PK  
• CVF for PD  
 
Group 1 at 6 -hour  
• CVF for PK  
 
Group 2 at 4 -hour   
• CVF for PK  
 
Visits 4 & 8 -  
24 hour  • Blood for PK  
 Group 2 only   
• RF for micro biome 
• RF for PK  
• RF for PD  
 Group 2 only 
• 7 samples for biomarkers  
• 4 samples for PD  
• 11 samples for PK  
 Group 2 only   
• CVF for microflora   
• CVF for PK  
• CVF for PD  
 
Visits 5 & 9 -  
48 hour  • Blood for PK  
 Group 1 only   
• RF for PK  
• RF for PD  
 Group 1 only 
• 4 samples for PD  
• 11 samples for PK  
 Group 1 only   
• CVF for PK  
• CVF for PD  
 
Visits 6 & 10 -  
72 hour  • Blood for PK  
 Group 2 only   
• RF for PK  
• RF for PD  
 Group 2 only 
• 4 samples for PD  
• 11 samples for PK  
 Group 2 only   
• CVF for PK  
• CVF for PD  
 
 
7.11 Laboratory Evaluations  
 
 
MTN -039,  Version 1.0 65  March 6, 2019   
Local Laboratory  
The local laboratory will run the following, as indicated:  
 
• Pharyngeal specimens  
o NAAT for GC/CT  
• Vaginal specimens  
o NAAT for GC/CT/TV  
• Urine specimens  
o hCG 
o NAAT for GC/CT  
o Dipstick/culture  
• R ectal specimens  
o Rectal fluids for:  
 NAAT for GC/CT  
o Rectal tissue for:  
 PD (MTN LC approved)  
• Blood specimens  
o HIV-1/2 testing, with confirmatory testing as needed  
o CBC with differential and platelets  
o Chemistries (AST/ ALT/creatinine) 
o Syphilis serology  
o Coagulation (PT/INR)  
 
Network Laboratory Center (LC)  
• Cervicovaginal specimens  
o Fluid for PK  (Pharmacology Core)  
o Fluid for PD  (Pharmacodynamics Core)  
o Fluid for microflora   
• Blood specimens  
o PK (Pharmacology Core)  
o Plasma archive 
• R ectal specimens  
o Rectal fluids for:  
 PK (Pharmacology Core)  
 PD (Pharmacodynamics  Core)  
 Microbiome   
o Rectal tissue for:  
 PK (Pharmacology Core)  
 Biomarkers  
 
Once all required study analyses of collected specimens are complete, any remaining sample may be shipped to the MTN LC for use in study -related quality assurance and  
quality control testing. If study samples will be used for assay validation or proficiency testing that is not study related, all participant identifiers (PTID) will be removed from the samples prior to use. Specimens obtained from participants who do not  consent to long 
term storage will not be used for assay validation or proficiency testing purposes.  
 
 
 
MTN -039,  Version 1.0 66  March 6, 2019  7.12 Specimen Management  
 
Study sites will adhere to the standards of good clinical laboratory practice (https://www.niaid.nih.gov/sites/default/files/gclp.pdf ), in accordance with current US 
Division of AIDS (DAIDS) Laboratory Requirements, MTN -039 Study Specific Procedures 
Manual ( http://www.mtnstopshiv.org/studies ) and site standard operating procedures for 
proper collection, processing, labeling, transport, and storage of specimens to standardize procedures.  Specimen collection, testing, and storage at the site laboratories 
will be documented when applicable using the Laboratory Data Management System (LDMS).  In cases where laboratory results are not available due to administrative or 
laboratory error, the site is permitted to re- draw specimens. Further, as part of quality 
control, researchers may need to look at short pieces of non- coding repetitive DNA 
sequence (3- 7 base pairs) from blood in the event of sam ple mix -up. This test will only let 
researchers know the number of times this short segment is repeated and not specific genes or specific sequences of base pairs.  This sequence element does not contain any 
information about genes, therefore researchers will not be able to identify if participants are predisposed to specific diseases or any other genetic information based on this information.  This test will be an important tool for distinguishing whether two samples 
collected at the same or different time points are likely from the same person.  The test 
will only be used as part of a sample investigation with the knowledge of the site in situations where a known or suspected sample mix -up has occurred. No genetic testing 
(limited or genome- wide) is planned on leftover samples that are stored for the purposes 
of future research.  
 
7.13 DAIDS Laboratory Oversight  
 All laboratories participating in DAIDS Sponsored and/or Funded Laboratories in Clinical Trials will adhere to the DAIDS Laboratory Policy . 
(https://www.niaid.nih.gov/research/daids -clinical- research- policies -us-labs) 
 
7.14 Biohazard Containment  
 As the acquisition of HIV and other blood- borne pathogens can occur through contact 
with contaminated needles, blood, and blood products, appropriate blood and secretion precautions will be employed by all personnel in the drawing of blood and shipping and handling of all specimens for this study as recommended by the CDC and National Institutes of Health (NIH). All biological
 specimens will be transported using packaging 
mandated by Code of Federal Regulations (CFR) 42 Part 72. All dangerous goods materials, including diagnostic specimens and infectious substances, must be  
transported according to instructions detailed in the International Air Transport Association (IATA) Dangerous Goods Regulations. Biohazardous waste will be contained according to institutional, transportation/carrier, and all other applicable regulations . 
  
 
 
MTN -039,  Version 1.0 67  March 6, 2019  8 ASSESSMENT OF SAFETY  
 
8.1 Safety Monitoring 
 
Site IoRs are responsible for continuous close safety monitoring of all study participants and for alerting the Protocol Team if unexpected concerns arise. A sub- group of the 
Protocol Team, including the Protocol Chair, DAIDS Medical Officer, a CONRAD representative, and MTN Protocol Safety Physicians will serve as the PSRT. The MTN Statistical Data and Management Center (SDMC) prepares routine AE and clinical data reports for review by the PSRT, which meets via conference call approximately once per 
month or as needed throughout the period of study implementation to review safety data, discuss product use management, and address any potential safety concerns.  
 
8.2 Clinical Data and Safety Review  
 A multi- tiered safety review process will be followed for the duration of this study. The 
study site investigators are responsible for the initial evaluation and reporting of safety information at the participant level and for alerting the PSRT if unexpect ed concerns arise. 
Participant safety is also monitored at the Network level through a series of routine reviews conducted by the SDMC, the PSRT and study sponsors. Additional reviews may be conducted at each of these levels as dictated by the occurrence of certain events.  
 MTN SDMC staff will review incoming safety data on an ongoing basis. Events identified as questionable, inconsistent, or unexplained will be queried for verification. AE reports submitted in an expedited manner to the DAIDS Safety Office will be forwarded to the DAIDS Medical Officer , SDMC Clinical Safety & Coding Group staff , and CONRAD 
representative for review.  
 The PSRT will meet approximately every month via conference call to review clinical data reports generated by the MTN SDMC. The content, format and frequency of the clinical data reports will be agreed upon by the PSRT and the SDMC in advance of study implementation. In addition to the routine safety data reviews, the PSRT will convene on an ad hoc basis to make decisions regarding the handling of any significant safety concerns. If necessary, experts external to the MTN representing expertise in the fields of microbicides, biostatistics, HIV acquisition and medical ethics may be invited to join the PSRT safety review. A re commendation to pause or stop the trial may be made by the 
PSRT at this time or at any such time that the team agrees that an unacceptable type and/or frequency of AEs has been observed.  
 The Study Monitoring Committee (SMC) will review participant safety data as part of their regular reviews (see Section 10
), since no Data and Safety Monitoring Board oversight is 
planned for MTN -039. The SMC may recommend that the study proceed as designed, 
proceed with design modifications, or be discontinued. Members of the SMC will be 
independent investigators with no interest (financial or otherwise) in the outcomes of this study. If at any time a decision is made to discontinue enrollment and/or study product use in all participants, DAIDS  will notify the FDA as necessary and Site IoRs will notify 
the responsible IRB expeditiously.  
 
 
MTN -039,  Version 1.0 68  March 6, 2019   
In addition to the safety monitoring, the MTN SMC will conduct interim reviews of study progress, including rates of participant accrual, retention, completion of primary and main secondary endpoint assessments, and study or lab issues. These reviews will take place approximately every 4 -6 months, or as needed. At the time of these reviews, or at any 
other time, the SMC may recommend that the study proceed as designed, proceed with design modifications, or be discontinued.  
 
8.3 Adverse Events Definitions and Reporting Requirements  
 8.3.1  Adverse Events 
 An AE is defined as any untoward medical occurrence in a clinical research participant administered an investigational product and which does not necessarily have a causal relationship with the investigational product. As such, an AE can be an unfavorable or unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally  associated with the use of an investigational product, whether or not 
considered related to the product. This definition is applied to all study groups, and is applied to all groups beginning at the time of enrollment (i.e., once a participant is randomiz ed) through the termination visit. The term “investigational product” for this study 
refers to the TAF/EVG Insert, 20/16 mg .   
 Study participants will be provided instructions for contacting the study site to report any untoward medical occurrences they m ay experience. In cases of potentially life-
threatening events, participants will be instructed to seek immediate emergency care. Where feasible and medically appropriate, participants will be encouraged to seek evaluation where a study clinician is based,  and to request that the clinician be contacted 
upon their arrival. With appropriate permission of the participant, whenever possible, records from all non- study medical providers related to untoward medical occurrences 
will be obtained and required data elements will be captured in the study database. All participants reporting an untoward medical occurrence will be followed clinically until the occurrence resolves (returns to baseline) or stabilizes.  
 
Study site staff will document in source documents and in the study database all AEs 
reported by or observed in enrolled study participants regardless of severity and 
presumed relationship to study product. AE severity will be graded per the DAIDS Table 
for Grading Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017 and/or 
Addenda 1, 2 and 3 (Female Genital [Dated November 2007], Male Genital [Dated 
November 2007] and Rectal [Clarification Dated May 2012] Grading Tables for Use in 
Microbicide Studies).  
 
Please note:  
• Asymptomatic BV and asymptomatic candidiasis will not be reportable AEs;  
Note : Asymptomatic BV and asymptomatic candidiasis will be captured on the 
CRF that captures STI results . 
• Fetal losses (e.g., spontaneous abortions, spontaneous fetal deaths, stillbirths) will 
not be reported as AEs;  
Note : Fetal loss data will be captured on the Pregnancy Outcome CRF.  
 
 
MTN -039,  Version 1.0 69  March 6, 2019  • Untoward maternal conditions that either result in or result from fetal losses are 
reported as reproductive system AEs.  
 
Bleeding at the time of anoscope, flexible sigmoidoscope insertion/removal, and/or biopsy  
collection that is judged by the clinician to be within the range of what is normally 
anticipated will not be reportable as an AE. Bleeding of greater quantity or longer duration 
than what is typical, per clinician assessment, will be reportable as an AE.  Fecal urgency, 
bloating and flatulence associated with rectal procedures deemed to be within the range 
of what is normally expected will not be reportable as AEs.  
 
8.3.2  Serious Adverse Events 
 An SAE will be defined by the Manual for Expedited Reporting of Adverse Events to DAIDS (Version 2.0, January 2010), as an AE that:  
 
• Results in death  
• Is life -threatening  
• Results in persistent or significant disability/incapacity  
• Is a congenital anomaly/birth defect  
• Requires inpatient hospitalization or prolongation of existing hospitalization Note: Per ICH SAE definition, hospitalization itself is not an AE, but is an outcome 
of the event. Thus, hospitalization in the absence of an AE is not regarded as an 
AE and is not subject to expedited reporting. The following are examples of hospitalization that are not considered to be AEs:  
o Protocol -specified admission (e.g., for procedure required by study 
protocol)  
o Admission for treatment of target disease of the study, or for pre- existing 
condition (unless it is a worsening or increase in frequency of hospital admissions as judged by the clinical investigator)  
o Diagnostic admission (e.g., for a work -up of an existing condition such as 
persistent pretreatment lab abnormality)  
o Administrative admission (e.g., for annual physical)  
o Social admission (e.g., placement for lack of place to sleep)  
o Elective admission (e.g., for elective surgery)  
 Important medical events that may not result in death, be life- threatening, or require 
hospitalization may be considered a serious adverse drug experience when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may req uire 
medical or surgical intervention to prevent one of the outcomes listed above.   
 8.3.3  Adverse Event Relationship to Study Product  
 
Relatedness is an assessment made by a study clinician of whether or not the event is 
related to the study agent. Degrees of relatedness will be categorized according to current DAIDS -approved guidelines. Per the Manual for Expedited Reporting of Adverse Events 
to DAIDS (Version 2.0, January 2010), the relationship categories that will be used for this study are:  
 
 
 
MTN -039,  Version 1.0 70  March 6, 2019  • Related:  There  is a reasonable possibility that the AE may be related to the study 
agent(s)  
• Not Related:  There is not a reasonable possibility that the AE is related to the study 
agent(s)  
 
8.4 Adverse Event Reporting Requirements  
 
8.4.1  Expedited Adverse Event Reporting to DAIDS  
 
Requirements, definitions and methods for expedited reporting of AEs are outlined in 
Version 2.0 of the DAIDS EAE Manual, which is available on the DAIDS RSC website at  
https://rsc.niaid.nih.gov/clinical -research- sites/manual -expedited- reporting -adverse-
events -daids.  
 The DAIDS Adverse Experience Reporting System (DAERS), an internet -based reporting 
system, must be used for expedited adverse event (EAE) reporting to DAIDS. In the event of system outages or technical difficulties, EAEs may be submitted usi ng the DAIDS EAE 
Form. This form is available on the DAIDS RSC website at  
https://rsc.niaid.nih.gov/clinical -research- sites/paper -eae-reporting .  
 DAIDS will be responsible for  all FDA correspondence and for all site and DAIDS 
reporting. DAIDS will inform CONRAD of any reportable events and send a copy of all FDA correspondence to CONRAD. For questions about DAERS, please contact NIAID CRMS Support at CRMSSuppo rt@niaid.nih.gov . Please note that site queries may also 
be sent from within the DAERS application itself.  
 For questions about expedited reporting, please contact the DAIDS RSC Safety Office at 
DAIDSRSCSafetyOffice@tech -res.com . 
 8.4.2  Reporting Requirements for this Study        
 
The SAE Reporting Category, as defined in Version 2.0 of the DAIDS EAE Manual, will 
be used for this study. The study agent for which expedited reporting is required is: Tenofovi r Alafenamide ( TAF)/Elvitegravir ( EVG) Insert, 20/16 mg .            
                     
8.4.3  Grading Severity of Events 
 The grading of severity of events and the reporting period will be the same as for all AEs, as described in Section 8.3.1
. The most current Division of AIDS Table for Grading Adult 
and Pediatric Adverse Events, Corrected Version 2.1, July 2017 and Addenda 1, 2 and 3 
(Female Genital [Dated November 2007], Male Genital [Dated November 2007] and Rectal [Clarification Dated May 2012] Grading Tables for Use in Microbicide Studies) will be used and are available on the RSC websi te at https://rsc.niaid.nih.gov/clinical -
research- sites/daids -adverse- event -grading -tables .   
 
 
 
MTN -039,  Version 1.0 71  March 6, 2019  8.4.4  Expedited AE Reporting Period  
 
The EAE reporting period for this study begins at enrollment (i.e., randomization)  and 
continues through the participant’s termination from the study.  
 
After the protocol -defined AE reporting period, unless otherwise noted, only Suspected, 
Unexpected Serious Adverse Reactions (SUSARs) as defined in Version 2.0 of the EAE 
Manual will be reported to DAIDS if the study staff become aware of the events on a passive basis (from publicly available information).  
 
8.5 Pregnancy and Infant Outcomes  
 Pregnant women are excluded from this study.  
 A participant who becomes pregnant after enrollment will continue to be followed until the  
end of  pregnancy and, if applicable, infant outcome is ascertained, see Section 9.5
 for 
additional details. Pregnancy and infant outcomes will be reported on relevant CRFs . 
Pregnancy outcomes will not be expeditiously reported to CONRAD or the DAIDS Medical 
Officer (MO) unless there is an associated AE in the pregnant participant that meets expedited reporting criteria or the pregnancy results in a congenital anomaly meeting the Manual for Expedited Reporting of EAEs to DAIDS (Version 2.0, January 2010) guidelines for expedited reporting.  
 
8.6 Regulatory Requirements  
 Information on all reported AEs will be included in reports to the FDA and other applicable government and regulatory authorities. Site IoRs/designees will submit AE and any relevant safety information in accordance with local regulatory requirements.  
 
8.7 Social Harms Reporting 
 Although study sites will make every effort to protect participant privacy and confidentiality, it is possible that participants’ involvement in the study could become known to others and that social harms may result. Social harms that are judged by the IoR/designee to be serious or unexpected will be reported to the PSRT and responsible site IRBs according to their individual requirement s. 
  
9 CLINICAL MANAGEMENT 
Guidelines for clinical management and permanent discontinuation of study product are outlined in this section. In general, the IoR/designee has the discretion to permanently discontinue study product use at any time if he/she feels that continued product use would be harmful to the participant or interfere with treatment deemed clinically necessary. IoRs/designees will document all permanent discontinuations on applicable CRFs.  
 
 
 
MTN -039,  Version 1.0 72  March 6, 2019  9.1 Grading System  
 
AE severity grading is described in Section 8.4.3 . 
 
9.2 Dose Modification Instructions  
 
No dose modifications will be undertaken in this study.   
 
9.3 General Criteria for Permanent Discontinuation of Study Product  
 
A participant will be permanently discontinued from product use by the IoR/designee for 
any of the following reasons:  
• Acquisition of HIV infection; for those who acquire HIV , study product should be 
held beginning immediately upon recognition of the first positive/ reactive HIV test  
• Pregnancy or breast feeding  
• Anogenital STIs  
• Participant is unable or unwilling to comply with required study procedures, or otherwise might be put at undue risk to their safety and well -being by continuing 
product use, according to the judgment of the IoR/designee.  
• Reported use of or need for PrEP or PEP. Participants who experience a known 
or potential HIV exposure during study participation or have a recognized risk of exposure and thus need PEP or PrEP will have study product permanently discontinued and will be referred for PEP or PrEP initiation. Those who need PEP will be encouraged to start it as quickly as possible and within 72 hours of potential 
exposure. Since continued study follow -up would be of no benefit following 
permanent discontinuation of study product use, these participants will be exited from the study.      
• Anticoagulant  use (e.g., heparin, Lovenox, warfarin and Plavix)  
• Use of certain CYP3A inhibitors and inducers (as specified in Table 8 and Table 
9) 
• Participant develops a Grade 4 adverse event.  
 
9.4 Follow -up in Response to Observed Adverse Events  
 
Grade 1 and Grade 2 Unrelated  
In general, a participant who develops a Grade 1 AE, regardless of relationship to study product, may continue product use. Participants who develop a Grade 2 AE that is judged 
by the IoR/designee to be unrelated to study product may also continue product use. If the IoR/designee opts to temporarily hold study product, the PSRT must be notified.   
 
Grade 2 Related  and Grade 3  
For participants who develop a Grade 2 AE that is judged by the IoR/designee to be 
related to product  or any Grade 3  AE, study product must be held and the IoR must 
consult with PSRT regarding provision of the second dose.  
Grade 4 
For participants who develop a Grade 4 AE study product  must be permanently 
discontinued and the PSRT notified.  
 
 
MTN -039,  Version 1.0 73  March 6, 2019   
9.5 Pregnancy  
 
Female participants will be encouraged to report all signs or symptoms of pregnancy to 
study staff. The IoR/designee will counsel any participant who becomes pregnant regarding possible risks to the fetus according to site SOPs. The IoR/designee also will refer the participant to all applicable services; however, sites will not be responsible for paying for pregnancy -related care.  
 A participant who becomes pregnant during study participation will have study product 
discontinued and will be terminated from  the study, as per  Section 7.5.2
. The study site 
will make every reasonable effort to contact participants and collect infant outcome at approximately one year after delivery for those pregnancies that result in live birth. A 
participant who is pregnant at study termination will continue to be followed until the pregnancy outcome is ascertained (or, in consultation with the PSRT, it is determined that the pregnancy outcome cannot be ascertained).  
 
9.6 Criteria for Early T ermination of Study Participation  
 Participants may voluntarily withdraw from the study for any reason at any time. IoRs/designees also may withdraw participants from the study to protect their safety and/or if they are unwilling or unable to comply with required study procedures, after consultation with the PSRT. Participants also may be withdrawn if CONRAD, NIAID, 
MTN, government or regulatory authorities, including the FDA and Office for Human Research Protections (OHRP), or site IRBs terminate the study  prior to its planned end 
date. Every reasonable effort is made to complete a final evaluation of participants who withdraw or are withdrawn from the study prior to completing follow -up (see details 
regarding the Early Termination Visit in Section 7
). Study staff members will record the 
reason(s) for all withdrawals in participants’ study records.  
   
10 STATISTICAL CONSIDERATIONS  
 
10.1 Overview and General Design  
 
MTN -039 is a phase 1, open label, single- arm, two -period trial designed to characterize 
the safety and PK profiles of the TAF/EVG Insert , 20/16 mg administered rectally  at two 
dose levels (one insert in the first period and two insert s in the second period) . Twenty 
HIV-uninfected individuals 18 years of age or older  will receive a single dose (one insert) , 
then allow  time for adequate washout before application of the two- insert dose.  Samples 
will be taken over a 3- day period after each dose application.  
 
 
 
MTN -039,  Version 1.0 74  March 6, 2019  10.2 Study Endpoints  
 
Primary Endpoints  
 
Consistent with the primary study objectives to (1) evaluate the safety of the TAF/EVG  
Insert when applied rectally at two dose levels and (2) characterize the systemic and 
rectal  pharmacokinetics of the TAF/ EVG Insert(s) following rectal application, the 
following endpoints will be assessed:  
 
• Safety  
All Grade 2 and higher AEs  
 
• Pharmacokinetics  
EVG  concentrations  in: 
o Blood  
o Rectal fluid  
o Rectal mucosal tissue homogenates   
 
TAF and TFV concentrations in: 
o Blood  
o Rectal fluid  
 
TFV-DP concentrations in:  
o Rectal mucosal tissue homogenates  
o Rectal mucosal tissue cell  isolates  
 
10.3 Primary Study Hypotheses  
 
MTN -039 hypothesizes that TAF and EVG will be safe when applied to the rectum and 
well-tolerated among healthy men and women who have a history of receptive anal 
intercourse (RAI).  
 
10.4 Sample Size and Power Calculations  
 
Safety Endpoints  
 The proposed total sample size for assessing safety is approximately N=20 participants.  This sample size is based upon the size of similar Phase 1 studies of microbicides for HIV prevention.  
 As a means to characterize the statistical properties of this study,  Table 17 below presents 
the probability of observing zero, at least one, and two or more safety endpoints among the 20 participants for various “true” event r ates:  
 
Table 17: Analysis of Safety Event Frequency  
Event Rate  P (0 events | n=20)  P (>1 event | n=20)  P (>2 events | n=20)  
1% 81.8 18.2 1.7 
 
 
MTN -039,  Version 1.0 75  March 6, 2019  If the true rate of a safety endpoint is 5%, the probability of observing that endpoint in at 
least one out of 20 participants is 0.64.  
 An alternative way of describing the statistical properties of the study design is in terms of the 95% confidence inte rval for the true rate based on the observed data. Table 18 
below shows the exact 2- sided 95% confidence intervals for the probability of an event 
based on a particular observed rate. If none of the 20 participants receiving a particular dose (one insert or two inserts) experience a safety event, then the 95% exact 2- sided 
upper confidence bound for the true rate of such events for that dose is 16.8%.  
 
Table 18: Exact 2 -sided 95% Confidence Intervals Based on Observing a Particular Rate of 
Safety Endpoints among 20 Participants  
Observed event rate  Confidence interval (%)  
0/20 (0%)  0.0, 16.8  
1/20 (5%)  0.1, 24.9  
2/20 (10%)  1.2, 31.7  
3/20 (15%)  3.2, 37.9  
  Additional participants may enroll in the study, at the discretion of the protocol team, to replace currently enrolled participants lost to follow -up or to permanent product 
discontinuation. Thus, if additional participants are recruited for this purpose, the total 
sample size at the end of the study may slightly exceed 20 participants who received either dose of TAF and EVG . 
 
10.5 Randomization Procedures  
 There will be no randomization to dose of TAF and EVG  (one insert or two inserts) in this 
open- label, single -arm, and two- period trial. However, upon enrollment , participants will 
be randomly assigned to one of two sample collection schedules for the collection of rectal tissue (collected with flexible sigmoidoscopy), rectal fluid, and cervicovaginal fluid (if applicable) : 
Group 1: Visits 3, 5, 7, and 9  
Group 2: Visits 4, 6, 8, and 10  
Note : Both groups 1 and 2 will provide blood at Visits 3- 10. A t Visits 3 and 7, both 
groups will provide rectal fluid and cervicovaginal fluid (if applicable) – Group 1 at 
2 and 6 hours post -dose, and Group 2 at 4 hours post -dose.  
 Randomization will be stratified by sex at birth to incorporate at least three participants 
assigned female sex at birth in each group.  
 The randomization scheme will be generated and maintained by the MTN SDMC.  
 5% 35.8 64.2 26.5 
10% 12.2 87.8 60.8 
15% 3.9 96.1 82.4 
20% 1.2 98.8 93.0 
25% 0.3 99.7 97.6 
 
 
MTN -039,  Version 1.0 76  March 6, 2019  10.6 Participant Accrual, Follow -up and Retention 
 
Based on previous studies of rectal products with similar eligibility requirements, the 
accrual of approximately 20 eligible participants will take approximately 6- 8 months. 
Individuals lost to follow -up or to permanent product discontinuation may be replaced after 
statistical and team input have been received. However, every effort will be made to complete the regularly scheduled safety evaluations and retain all enrolled participants in follow -up to minimize possible bias associated with loss -to-follow -up. 
 
10.7 Data and Safety Monitoring and Analysis  
 10.7.1   Study Monitoring Committee  
 
No Data and Safety Monitoring Board oversight is planned for this study. The MTN SMC 
will conduct interim reviews of participant safety data and study progress, including rates of participant accrual, retention, completion of primary and main secondary endpoint assessments, and study or lab issues. These reviews will take place approximately every 
4-6 months, or as needed.  At the time of this review, or at any other time, the SMC may 
recommend that the study proceed as designed, proceed with design modifications, or 
be discontinued.  
 10.7.2   Primary Analysis  
 
When the use of descriptive statistics to assess group characteristics or differences is 
required, the following methods will be used: for categorical variables, the number and percent in each category; for continuous variables, the mean, median, standard deviation, quartiles and range (minimum, maximum). Within- treatment group assessment of the 
change from the baseline measurement to a follow -up measurement will be analyzed 
using McNemar’s test (for categorical response variables) or the paired t -test or Wilcoxon 
signed- ranks test (for continuous variables).  
 
Safety Endpoints  
All visits in which a participant has been exposed to the study product will be included in the primary analyses of safety. Secondary intent to treat analyses may also be performed. The number and the percentages of participants experiencing each safety endpoint (see Section 10.2
) will be tabulated by dose (one insert or two inserts). Each participant will 
contr ibute once in each category (i.e., only for highest severity AE for each participant) 
for the calculation of event rates for each dose.  
 To assess the overall tolerability of the two doses (one insert or two inserts), participants in each dose may be compared for characteristics including safety events and laboratory measurements using descriptive statistics. Due to the small sample size, formal comparisons will not be done.  
 
Pharmacokinetic Analysis  
We will use descriptive statistics for continuous variables as defined above to describe the EVG and tenofovir -related analyte (TAF, TFV) concentrations in blood , rectal fluid, 
and rectal tissue assessed at all scheduled time points.  For each dose (one insert or two 
 
 
MTN -039,  Version 1.0 77  March 6, 2019  inserts), the 1 to 72-hour time points will be used to describe the concentrations beginning 
soon after a dose exposure through time to peak concentrations through initial elimination 
among different matrices.  EVG developmental PK studies are planned to be conducted 
in parallel with this study to inform interpretation of EVG tissue PK and explant results.  
 10.7.3   Secondary and Exploratory Analyses  
 
Acceptability Analysis  
We will use descriptive statistics to summarize overall acceptability of the two dose regimens and to identify  product attributes  considered likely to challenge and/or facilitate 
future sustained use of the TAF/ EVG Insert when applied rectally .  
 
Pharmacok inetic/Pharmacodynamic Analysis  
We will use descriptive statistics for continuous variables as defined above to describe the EVG and tenofovir -related analyte (TAF, TFV) concentrations in cervicovaginal fluid 
at all scheduled time points.  For each dose (one insert or two inserts), the 1 to 72-hour 
time points will be used to describe the concentrations beginning soon after a dose exposure through time to peak concentrations through initial elimination in cervicovaginal fluid.  
 Ex vivo HIV explant data wil l use virus levels to compare baseline levels with virus levels  
on study product. Concentration- response relationships may also be explored using 
appropriate linear and non- linear models. Rectal fluid and cervicovaginal fluid will be 
assessed for anti -HIV activity, and the percent inhibition will be correlated to EVG a nd 
tenofovir -related analyte (TAF, TFV)  concentrations.  
10.7.4  Missing Data  
 
Every effort will be made to complete the regularly scheduled safety and PK evaluations 
and retain all enrolled participants in follow -up over the two dose evaluations lasting 
approximat ely 21 to 77 days total, including washout. Based on previous MTN trials, we 
expect to have minimal missing data. If participants are lost to follow -up or to permanent 
product discontinuation, they may be replaced, as mentioned above. If missing data rates  
are higher than anticipated (over 15%) for a particular dose safety evaluation or for individual pharmacokinetic measure time points, then additional participants may enroll in the study at the discretion of the protocol team .  
  
11 DATA HANDLING AND RECORDK EEPING  
11.1 Data Management Responsibilities  
 Data collection tools will be developed by the MTN SDMC in conjunction with the protocol team. Quality control reports and queries will be routinely generated and provided by the 
SDMC to the study sites for verification and resolution. As part of the study  activation 
process, each study site must identify all CRFs to be used as source documents. Study CRF data will be entered into the MTN -039 database, transferred in compliance with the 
 
 
MTN -039,  Version 1.0 78  March 6, 2019  US-EU Safe Harbor Requirements and the EU Data Protection Directive 95/ 46/EC to the 
MTN SDMC, entered, and cleaned using Medidata Rave, a data management system 
compliant with the International Council on Harmonization (ICH) Good Clinical Practices (GCP) and US CFR guidelines for electronic data capture.  
 Transcriptions of interviews will be generated using the audio files recorded at University of Pennsylvania. Both the audio files and the transcripts will be uploaded and managed 
using a qualitative software package. Interview notes will be kept at the University of 
Pennsylvania in the participant files.  
 
11.2 Source Documents and Access to Source Data/Documents  
 
All study sites will maintain source data/documents in accordance with current DAIDS 
policies. ( https://www.niaid.nih.gov/sites/default/files/daids -sourcedocpolic y.pdf )   
 
Each IoR/designee will maintain, and store securely, complete, accurate and current 
study records throughout the study. In accordance with U.S. regulations, for the 
investigational products tested, IoRs/designees will maintain all study documentation for 
at least two years following the date of marketing approval for the indication in which they 
were studied.  If no marketing application is filed, or if the application is not approved, the 
records will be retained for two years after the investigation is discontinued and the US 
FDA is notified.   
 
Study records must be maintained on site for the entire period of study implementation.  
Thereafter, instructions for record storage will be provided by DAIDS. No study records 
may be moved to an off -site location or destroyed prior to receiving approval from DAIDS.   
 
11.3 Quality Control and Quality Assurance  
 
Study sites will conduct quality control and quality assurance procedures in accordance 
with current DAIDS policies  (https:// www.niaid.nih.gov/sites/default/files/qmppolicy.pdf ). 
  
12  CLINICAL SITE MONITORING 
 Study monitoring will be carried out by Pharmaceutical Product Development, Inc. (PPD) (Wilmington, NC) in accordance with current DAIDS policies. Study monitors will visit 
study sites to do the following:  
 
• Review informed consent forms, procedures, and documentation  
• Assess compliance with the study protocol, Good Clinical Practices (GCP) guidelines, and applicable regulatory requirements (US and non- US), including 
CFR Title 45 Part 46 and Title 21 Parts 50, 56, and 312  
• Perform source document verification to ensure the accuracy and completeness of study data  
• Verify proper collection and storage of biological specimens  
 
 
MTN -039,  Version 1.0 79  March 6, 2019  • Verify proper storage, dispensing, and accountability of investigational study 
products  
• Assess implementation and documentation of internal site quality management procedures  
 
IoRs/designees will allow study monitors to inspect study facilities and documentation (e.g., informed consent forms, c linic and laboratory records, other source documents, 
CRFs), as well as observe the performance of study procedures. IoRs/designees also will allow inspection of all study -related documentation by authorized representatives of the 
MTN LOC, SDMC, LC, CONRAD, NIAID, FDA, OHRP, IRBs , and other local , US or 
international  regulatory authorities. A site visit log will be maintained at study sites to 
document all visits.  
 
 
13  HUMAN SUBJECTS PROTECTIONS 
Site investigators will make efforts to minimize risks to participants. Participants and study 
staff members will take part in a thorough informed consent process. Before beginning the study, IoRs/designees will have obtained IRB approval and the protocol will have been submitted to the FDA. IoRs/designees will permit audits by the NIH, CONRAD, the FDA, 
OHRP, MTN LOC, IRBs, SDMC, and other local, US or international regulatory authorities 
or any of their appointed agents.  
 
13.1 Institutional Review Boards/Ethics Committees  
 The participating institution is responsible for assuring that this protocol, the associated site-specific informed consent forms (ICFs), and study -related documents (such as 
participant education and recruitment materials) are reviewed by an IRB responsible for oversight of research conducted at each study site. Any amendments to the protocol must be approved by the responsible IRBs prior to implementation.  
 
After  the initial review and approval, the responsible IRBs must review the study at least 
annually. Each IoR/designee will make safety and progress reports to the IRBs at least 
annually and within three months after study termination or completion. These repor ts will 
include the total number of participants enrolled in the study, the number of participants who completed the study, all changes in the research activity, and all unanticipated problems involving risks to human subjects or others. In addition, the r esults of all SMC 
reviews of the study will be provided to the IRBs. Study sites will submit documentation of continuing review to the DAIDS Protocol Registration Office (PRO) in accordance with the DAIDS Protocol Registration Policy and Procedures Manual.  
 
13.2 Protocol Registration  
 Prior to implementation of this protocol, and any subsequent full version amendments, sites must have the protocol and the protocol consent forms approved, as appropriate, by its local IRB and any other applicable regulatory entity  (RE). Upon receiving final 
approval, sites will submit all required protocol registration documents to the DAIDS PRO 
 
 
MTN -039,  Version 1.0 80  March 6, 2019  at the RSC. The DAIDS PRO will review the submitted protocol registration packet to 
ensure that all of the required documents have been received.  
 Site-specific ICFs will be reviewed or approved by the DAIDS PRO, and sites will receive 
an Initial Registration Notification when the DAIDS PRO receives a complete registration packet. Receipt of an Initial Registration Notification indicates successful completion of the protocol registration process. Sites will not receive any additional notifications from the DAIDS PRO for the initial protocol registration.
 A copy of the Initial Registration 
Notification should be retained in each site's regulatory files.  
 Upon receiving final IRB and any other applicable RE approval(s) for an amendment, sites should implement the amendment immediately. Sites are required to submit an amendment registration packet to the DAIDS PRO at the RSC. The DAIDS PRO will review the submitted protocol registration packet to ensure that all the required documents have been received. Site- specific ICF(s) will not  be reviewed and approved 
by the DAIDS PRO and sites will receive an Amendment Registration Notification when the DAIDS PRO receives a complete registration packet. A copy of the Amendment Registration Notification should be retained in site regulatory files.  
 For additional information on the protocol registration process and specific documents required for initial and amendment registrations, refer to the current version of the DAIDS Protocol Registration Manual.  
 
13.3 Study Coordination  
 DAIDS holds the Investigational New Drug (IND) application for this study. Assignment of 
all sponsor responsibilities for this study will be specified in a Clinical Trials Agreement (CTA) executed by NIAID and CONRAD.  
 Study implementation will be directed by this protocol, which may not be amended without prior written approval from the Protocol Chair and DAIDS Medical Officer. S tudy 
implementation will also be guided by a common Study -Specific Procedures (SSP) 
Manual that provides further instructions and operational guidance on conducting study visits; data and forms processing; specimen collection, processing, and shipping; AE assessment, management and reporting; dispensing study products and documenting product accountability; and other study operations. Standardized study -specific training 
will be provided to sites by the MTN LOC, SDMC, LC and other designated members of the Protocol Team.  
 Close coordination between protocol team members is necessary to track study progress, respond to queries about proper study implementation, and address other issues in a timely manner. The PSRT will address issues related to study eligibility and AE management and reporting as needed to assure consistent case management and documentation. Rates of accrual, adherence, follow -up, and AE incidence will be 
monitored closely by the team as well as the SMC.  
 
 
 
MTN -039,  Version 1.0 81  March 6, 2019  13.4 Risk Benefit Statement  
 
13.4.1  Risks  
 It is not expected that this trial will expose human subjects to unreasonable risk.  
 
Vaginal Fluid Collection  
Collection of vaginal fluid may cause discomfort or pressure in the vagina or genital area.  
 Phlebotomy  and IV Cannula Placement  
Phlebotomy may lead to discomfort, feelings of dizziness or faintness, and/or bruising, swelling , having a blood clot, excessive bleeding,  and/or infection.  
 
Pharyngeal Swab 
Pharyngeal (throat) swab collection often causes a momentary gagging reflex.  
 
Rectal Enema  
An enema is a standard procedure that may be used prior to insertion of a flexible 
sigmoidoscope since fecal matter can obscure the test. The main risk from having an enema is temporary discomfort.  A hollow tube about the thickness of a pencil will be used to put approximately 120 mL of normal saline 0.9% into the rectum and flush it out again (a larger volume may be required if the initial volume does not produce results), along with any stool that is there. There is a risk of a bloated/cramping feeling. The tube is small, 
but it might cause some anal or rectal discomfort if the participant  has any hemorrhoids 
or other painful conditions.  There is also a remote possibility of rectal perforation 
associated with the use of  an enema.  
    
Finger and Anoscope Rectal Exams  
During rectal exams and collection of rectal fluid and tissue samples , insertion of a finger 
or lubricated anoscope will likely cause some discomfort.  
 
Flexible Sigmoidoscopy and Rectal Biopsy Collection  
Flexible sigmoidoscopy is a commonly practiced endoscopic medical procedure and will not involve any increased risk over usual sigmoidoscopy performed for clinical indications.  There is a low risk of infection, mild rectal irritation, low blood pressure, and feeling a 
sudden urge to defecate during or after the flexible sigmoidoscopy procedure. There is a very low risk of an intestinal tear during the flexible sigmoidoscopy procedure.  
 There is a risk of limited rectal bleeding 1- 2 days after flexible sigmoidoscopy, associated 
with collection of biopsy samples.  The rate of perforation of a hollow viscus following 
endoscopic biopsy occurs less than 88 out of every 100,000 times .
32 A recent 
retrospective analysis of approximately 1,000 research flexible sigmoidoscopies (including collection of rectal biopsies) conducted at the University of Pittsburgh demonstrated an overall adverse event rate of 1.6%. The majority of AEs were gastrointestinal in nature and of mild/moderate severity .
33  
 Participants will be instructed to refrain from sexual intercours e and counseled not to use 
aspirin (over 81 mg per day) and non-steroidal anti -inflammatory drugs (NSAIDS) within 
 
 
MTN -039,  Version 1.0 82  March 6, 2019  72 hours  prior to and following a tissue sample collection visit.   If participants engage in 
sexual intercourse before the biopsy has healed they may experience some temporary 
discomfort.  If participants are sexually active they may also be at increased risk for STIs 
and HIV acquisition, if exposed. There is a small risk of infection and heavier bleeding. Participants will be instructed to contact the clinic if symptoms are bothersome, if heavy bleeding is noted or if the participant develops any abnormal odor or discharge from the rectum.  
 
Rectal Fluid Collection  
There is the risk of mild discomfort in addition to a slight risk of bleeding with the insertion 
of rectal swabs and sponges for collection of rectal fluid.  
 
Other Risks  
Disclosure of HIV and STI status may cause worry, sadness or depression. Disclosure of HIV-positive status has been associated with depression, suicidal ideation, and denial as 
well as social isolation. Trained counselors will be available to help participants deal with these feelings.  
 Participation in clinical research includes the risks of l oss of confidentiality and discomfort 
with the personal nature of questions when discussing sexual behaviors.  
 Sexual partner notification in response to diagnosed STI or HIV infection could cause problems in participants’ relationships. Participants also could have problems in their partner relationships associated with study -required abstinence.  
 
 
Site staff will make every effort to protect participant privacy while in the study.  Although study site s will make every effort to protect participant privac y and confidentiality, it is 
possible that participants' involvement in the study could become known to others, and that social harms may result (i.e., because participants could become known as HIV -
positive or at "high risk" for HIV infection).  For example, participants could be treated unfairly or discriminated against, or could have problems being accepted by their families and/or communities.   
 Risks Associated With EVG Insert
8 
If administered rectally, an insert containing EVG may cause the following:  
• Rectal urgency  
• Rectal irritation  
• Rash  
• Exacerbation of hemorrhoid symptoms  
 Risks Associated With Oral EVG
7 
These risks are based on the safety assessment of EVG oral tablets when co-administered with other ARVs:  
 Most Common Adverse Reactions  (All grades, incidence ≥10%) in subjects receiving 
EVG  were :  
• Headache  
• Diarrhea 
 
 
MTN -039,  Version 1.0 83  March 6, 2019  • Nausea  
• Fatigue 
 
Other  Common Adverse Reactions  (All grades, incidence ≥1% and <10%) were:  
• Depression  
• Insomnia  
• Abdominal pain  
• Vomiting  
• Dyspepsia 
• Rash   
 Uncommon Adverse Reactions (All grades, incidence ≥0.1% and <1%) in patients with 
a pre- existing history of depression or psychiatric illness were:  
• Depression  
• Insomnia  
• Suicidal ideation and suicide attempt  
 Risks Associated With TAF
12 
These risks are based on the safety assessment of TAF oral tablets from previous randomized, double- blind, active- controlled trials:  
 Most Common Adverse Reactions  (All grades, incidence ≥5%)  were :   
• Headache  
• Abdominal pain  
• Cough 
• Back pain  
• Fatigue 
• Nausea  
• Arthralgia  
• Diarrhea 
• Dyspepsia  
 Other  Common Adverse Reactions  (All grades, incidence ≥1% and < 5%) were:  
• Vomiting  
• Rash   
• Flatulence  
 There is a theoretical risk of the development of HIV drug resistance to tenofovir or elvitegravir if the participant acquires HIV infection around the time of study drug administration.  
 
Risks Associated With Rectally -Applied Drugs      
In previously completed studies involving repeated use of rectally -applied gel products, 
the following AEs were observed. These side effects may or may not be associated with 
the use of TAF/ EVG  Insert  administered rectally :  
 More Common Adverse Reactions  (incidence ≥5%) were :  
 
 
MTN -039,  Version 1.0 84  March 6, 2019  • Flatulence  
• Defecation urgency  
• Diarrhea  
 
Less Common Adverse Reactions ( incidence < 5%) were :  
• Abdominal distension  
• Abdominal bloating  
• Abdominal pain/cramps  
• Tenesmus  
• Irritation in the rectum  
• Rash  
• Worsening of existing problems due to hemorrhoids  
 13.4.2  Benefits  
 Participants in this study may experience no direct benefit. Participants and others may benefit in the future from information learned from this study. Specifically, information learned in this study may lead to the development of safe and effective interventions to prevent HIV acquisition and transmission. Participants also may appreciate the opportunity to contribute to the field of HIV prevention research.  
 Participants will receive HIV/STI risk reduction counseling, HIV and STI testing, physical and r ectal examination, and routine laboratory testing related to blood, liver, and kidney 
function. Participants may be provided or referred for STI treatment free of charge, and STI testing and treatment may be offered and/or referrals may be provided (for their partners). For other medical conditions identified as part of the study screening and/or follow -up procedures, participants will be referred to other sources of care available in 
their community. Some volunteers may have the opportunity to access expedient treatment and decreased morbidity due to early diagnosis and treatment of abnormalities identified during tests, examinations and referrals.  
 
13.5 Informed Consent Process  
 Written informed consent will be obtained from each study participant prior to scre ening. 
Written informed consent also will be obtained for long -term specimen storage and 
possible future testing, although consent for long -term specimen storage is not required 
for study participation. In obtaining and documenting informed consent, IoRs and their designees will comply with applicable local and US regulatory requirements and will adhere to GCP and to the ethical principles that have their origin in the Declaration of Helsinki. Study staff must document the informed consent process in accordance with the Requirements for Source Documentation in DAIDS Funded and/or Sponsored Clinical Trials (https://www.niaid.nih.gov/sites/default/files/daids -sourcedocpolicy.pdf ). 
Participants will be provided with copies of the ICF if they are willing to receive them.  
 In addition to the ICF, the Protocol Team will work with study staff and community representatives to develop appropriate materials about the study and a standardized approach to the informed consent process to be implemented at study sites, which will be 
 
 
MTN -039,  Version 1.0 85  March 6, 2019  detailed in the SSP Manual.  
 
The informed consent process will cover all elements of informed consent required by research regulations. In addition, the process specifically will address the following topics of importance to this study:  
 
• The unknown safety and unproven efficacy of the study product  
• The need to abstain from sexual intercourse for protocol defined periods  
• The importance of participants in all study groups to the success of the study  
• The importance of adherence to the study visit and procedures schedule  
• The potential medical risks of study participation (and what to do if such risks are experienced)  
• The potential social harms associated with study participation (and what to do if such harms are experienced)  
• The real yet limited benefits of study participation  
• The distinction between research and clinical care 
• The right to withdraw from the study at any time  
 
13.6 Participant Confidentiality  
 
All study procedures will be conducted in private, and every effort will be made to protect 
participant privacy and confidentiality to the extent possible.  Study sites will implement 
confidentiality protections that reflect the local study implementation plan and the input of 
study staff and community representatives to identify potential confidentiality issues and 
strategies to address them.  
 
All study -related information will be stored securely. All participant information will be 
stored in locked areas  with access limited to study staff. All laboratory specimens, study 
data, and administrative forms will be identified by coded number only to maintain 
participant confidentiality. All records that contain names or other personal identifiers, 
such as locat or forms and informed consent forms, will be stored securely. All local 
databases will be secured with password- protected access systems. Forms, lists, 
logbooks, appointment books, and any other listings that link participants’ identification 
numbers to identifying information will be stored in a locked file in an area with limited 
access. Participants’ study information will not be released without their written 
permission, except as necessary for review, monitoring, and/or auditing by the following:  
• Representatives of the US Federal Government, including the US FDA, the US 
OHRP, NIH and/or contractors of the NIH, and other local , US or international 
regulatory authorities  
• PPD 
• Representatives of CONRAD, including study monitors  
• Representatives of the MTN LO C, SDMC, and/or LC Study staff  
• Site IRBs  
 The MTN has a Certificate of Confidentiality from the US Department of Health and Human Services that is applicable to this study. This Certificate protects study staff from being compelled to disclose study -related information by any US Federal, State or local 
 
 
MTN -039,  Version 1.0 86  March 6, 2019  civil, criminal, administrative, legislative or other proceedings. It thus serves to protect  
the identity and privacy of study participants.  
 
13.7 Special Populations  
 
13.7.1  Children 
 
The NIH has mandated that children be included in research trials when appropriate. This study meets “Justifications for Exclusion” criteria for younger children as set forth by the NIH. Specifically, “insufficient data are available in adults to judge potential risk in children” and “children should not be the initial group to be involved in research studies.” This study does not plan to enroll children under 18 years old.  
 
13.8 Compensation 
 Pending IRB approval, participants will be compensated for time and effort in this study, and/or be reimbursed for travel to study visits and time away from work. Site specific reimbursement amounts will be specified in the site specific ICF.  
 
13.9 Communicable Disease Reporting  
 Study staff will comply with local requirements to report communicable diseases, including HIV -1 identified among study participants to health authorities. Participants will 
be made aware of reporting requirements during the informed consent process.
 
 
13.10  Access to HIV -related Care  
 13.10.1  HIV Counseling and Testing 
 HIV test- related counseling will be provided to all potential study participants who consent 
to undergo HIV -1 screening to determine their eligibility for this study, and to all enrolled 
participants at each follow -up HIV -1/2 testing time point. Testing will be performed in 
accordance with the algorithm in Appendix II
. Counseling will be provided in accordance 
with standard HIV counseling policies and methods at sites and additionally will emphasize the unknown efficacy of the study products in preventing HIV -1 infection. In 
accordance with the policies of the NIH, participants must receive their HIV -1/2 test 
results to take part in this study.   
 
13.11  Study Discontinuation 
 This study may be discontinued at any time by NIAID, the MTN, CONRAD, the US FDA, 
the OHRP, other government or regulatory authorities, or site IRBs.  
   
 
 
MTN -039,  Version 1.0 87  March 6, 2019  14  PUBLICATION POLICY  
 
DAIDS/NIAID and MTN policies and a CTA between NIAID and CONRAD will govern 
publication of the results of this study. Any presentation, abstract, or manuscript will be submitted by the investigator to the MTN Manuscript Review Committ ee, DAIDS, NIAID, 
and NIMH for review prior to submission.  
  
15 APPENDICES 
  
 
 
MTN -039,  Version 1.0 88  March 6, 2019  APPENDIX I:  SCHEDULE OF STUDY VISITS AND EVALUATIONS 
  
Screening    
Visit 1              Enrollment          
Visit 2             
(Day 0)  Dosing               
Visits 3, 7  24 hours 
Post-
Dosing  
Visits 4 and 
8 Other Post -
Dosing   
Visits 5, 6, 9, 
and 10  Final 
Contact /Early 
Termination  
Visit 11  
ADMINISTRATIVE AND REGULATORY  
Obtain written informed 
consent  X      
Assign a unique Participant 
Identification (PTID) number  X      
Assess and/or confirm 
eligibility  X X     
Collect demographic 
information  X      
Collect/review/update locator 
information  X X X X X X 
Random assignment of 
sampling schedule   X     
Provide reimbursement  X X X X X X 
Schedule next visit/contact  * * X X X * 
BEHAVIORAL/COUNSELING  
HIV pre - and post -test 
counseling  X X * * * * 
HIV/STI risk reduction 
counseling  X X * * * * 
Protocol counseling  X X X X X  
Behavioral assessment 
(CASI)   X     
Behavioral assessment (Brief 
CASIs)     X    
Behavioral IDI      X (Visit 10)   
CLINICAL  
Collect/review/update 
concomitant medications  X X X X X X 
Collect/review/update medical 
history  X X X X X X 
Perform physical exam  
(Targeted at Visits 3 -10) X X * * * * 
Perform genital exam  * * * * * * 
Perform pelvic exam ▲ * * * * * * 
Perform rectal exam  X X X X X * 
Treat or prescribe treatment 
for RTI/UTI/STIs  * * * * * * 
Provide available test results  X X X X X X 
Collect /update  AEs   X X X X 
LABORATORY  PHARYGEAL  
NAAT for GC/CT  X * * * * * URINE  NAAT for GC/CT ▼ X * * * * * 
Pregnancy test ■ X X * * * * 
Urine dipstick/culture  * * * * * * 
 
 
MTN -039,  Version 1.0 89  March 6, 2019   
Screening    
Visit 1              Enrollment          
Visit 2             
(Day 0)  Dosing               
Visits 3, 7  24 hours 
Post-
Dosing  
Visits 4 and 
8 Other Post -
Dosing   
Visits 5, 6, 9, 
and 10  Final 
Contact /Early 
Termination  
Visit 11  BLOOD  CBC with differential and 
platelets  X * * * * 
(required at 
visit 10)  * 
Chemistries (AST/ALT/creatinine) X * * * * 
(required at 
Visit 10)  * 
Syphilis serology  X * * * * * 
Coagulation (PT/INR)  X      
Plasma for archive   X     
HIV-1/2 test  X X * * * 
(required at 
Visit 10)  * 
Blood for PK   X X  X X   PELVIC ▲ NAAT for GC/CT/TV  X * * * * * 
CVF for PK    X ** ☼ X ⌂  
CVF for PD   X ♣ (2 hrs 
post-
dose)  ☼ X ⌂  
CVF for microflora   X ♣ (2 hrs 
post-
dose)  ☼   ANORECTAL  NAAT for GC/CT  X * * * * * 
Rectal fluid for PK    X ** ☼ X ⌂  
Rectal fluid for PD   X ♣ (2 hrs 
post-
dose)  ☼ X ⌂  
Rectal fluid for 
microbiome   X ♣ (2 hrs 
post-
dose)  ☼   
Rectal enema prior to 
biopsy collection   X   X ⌂  
Rectal tissue for PK    ♣ (2 hrs 
post-
dose)  ☼ X ⌂  
Rectal tissue for PD   X ♣ (2 hrs 
post-
dose)  ☼ X ⌂  
Rectal tissue for 
biomarkers   X ♣ (2 hrs 
post-
dose)  ☼   
STUDY PRODUCT SUPPLY  
Administration of study 
product    X    
Offer condoms  X X X X X * 
Offer lubricant    X    
Provide home enema kit   X   X  
(Visit 6 only)   
*  If indicated  
▲Participants assigned female sex at birth and if anatomy allows  
▼If pelvic GC/CT cannot be performed  
■ Participants  of childbearing potential  
 All participants will have blood collected at 1, 2, 4, and 6 hours following product administration  
 
 
MTN -039,  Version 1.0 90  March 6, 2019   
Screening    
Visit 1              Enrollment          
Visit 2             
(Day 0)  Dosing               
Visits 3, 7  24 hours 
Post-
Dosing  
Visits 4 and 
8 Other Post -
Dosing   
Visits 5, 6, 9, 
and 10  Final 
Contact /Early 
Termination  
Visit 11  
⌂ Group 1  will have biopsies, rectal fluid and cervicovaginal fluid (if applicable) at 48 hours (Visits 5 and 9) following 
each administration of product; Group 2 will have biopsies , rectal fluid and cervicovaginal fluid (if applicable) 
collected at 72 hours (Visits 6 and 10) following each administration of product.  
♣ Group 1 only  
☼ Group 2 only  
** Group 1: 2 and 6 hours post -dose; Group 2: 4 hours post -dose 
Note: All sampling times are approximate; allowable windows are provided in the MTN -039 SSP manual.  
 
 
 
MTN -039,  Version 1.0 91  March 6, 2019  APPENDIX II:  ALGORITHM FOR HIV TESTING FOR SCREENING AND FOLLOW -
UP 
 
 
START 
Immunoassay
Sample 1 
HIV  Confirmation 
Test 
 
Is this a 
Screening 
Participant
?-
+ or Ind
- or Ind
+Yes+
Sample 2
HIV Confirmation 
Test - or IndNoReport as 
HIV Uninfected 
Not eligible for 
enrollment
Report  as HIV
 Infected Consult LC
Consult LC
Ind: Indeterminate test results 
LC: Laboratory Center
 
  
 
 
 
MTN -039, Version 1. 0 92  March 6, 2019  
 
 APPENDIX III: SAMPLE INFORMED CONSENT FORM (SCREENING, 
ENROLLMENT, LONG -TERM STORAGE AND FUTURE TESTING)  
 
DIVISION OF AIDS, NIAID, NIH  
 
MTN -039 
Version 1.0 
March 6, 201 9 
 
A Phase 1 Open Label Safety and Pharmacokinetic Study of Rectal 
Administration of a  Tenofovir Alafenamide/Elvitegravir Insert at Two Dose Levels  
 PRINCIPAL INVESTIGATOR:  [Site to insert] 
PHONE : [Site to insert]  
Short Title for the Study:  Safety and PK Study of TAF/EVG Administered Rectally  
 INFORMED CONSENT  
 IMPORTANT INFORMATION ABOUT THE RESEARCH STUDY  
 You are being asked to take part in this research study because you are a healthy, HIV -
negative adult,  18 years of age or older and reported at least one experience of 
consensual receptive anal sex in your lifetime. Approximately 20 people will participate in 
this study at two sites in the United States. National Institute of Health’s Division of AIDS  
(DAIDS)  is the sponsor of this Microbicide Trials Network (MTN) study. At this site, the 
person in charge of this study is [INSERT NAME OF PRINCIPAL INVESTIGATOR] . 
 Important things you should know:  
• The study product in this clinical trial is an insert that contains tenofovir alafenamide (TAF) and elvitegravir (EVG). The insert resembles  a tablet  and 
dissolve s quickly once inside the body . It contains 20 mg TAF and 16 mg EV G. 
Both drugs are used to treat HIV and are now being tested to see if they also prevent HIV.  
• The purposes of this study are:  
o T o find out if it is safe to apply the TAF/EVG Insert in the rectum.  
o To better understand the way the body absorbs, distributes, and gets rid of 
TAF and EVG when the insert is  used in the rectum.  
o T o understand whether you find it acceptable to use the insert when applied 
to the rectum.  
• If you qualify and choose to participate, you will receive two doses of the TAF/ EVG 
Insert, 20/16 mg . The first dose will be one insert and the second dose will be two 
inserts. After each dose, you will have laboratory tests  and clinical evaluations or 
exams for research purposes and to make sure you do not have any side effects. 
The s econd dose will be administered 7-49 days (1- 7 weeks ) after the first one. 
You will be randomly assigned to one of two sampling schedules  for the lab tests.  
 
 
 
MTN -039, Version 1. 0 93  March 6, 2019  
 
 • Y ou will be asked to attend 10 clinic visits at this study clinic and will be followed 
for approximately 6- 13 weeks. The total length of your participation in this study 
will be about 4 months.  
• At some of the clinic visits, the following will occur (other things may happen that are not listed here but are in the detailed descriptions of the study procedures):  
o A physical and/or rectal  exam will be performed;  
o Blood will be obtained to test for HIV and/or other sexually transmitted infections (STI)  and for research purposes ; 
o Urine will be collected to test for infections  and (if applicable) pregnancy;  
o R ectal and vaginal fluids will be collected for research purposes and to test 
for STIs (if applicable). At 5 of the 10 visits, rectal tissue will also be 
collected ;  
o You will be asked to complete 3 short interviews and a longer interview at 
Visit 10 . 
• Some common side effects  from the use of TAF and/or EVG in oral forms include : 
headache, diarrhea, nausea, fatigue, abdominal pain, cough, back pain, vomiting 
and rash. Uncommon adverse reactions include depression, insomnia and suicidal thought s and attempt s in patients with a history of depression or psychiatric illness.
 
• T here are no direct benefit s for taking part  in this study, but information learned 
from this study may help in the development of ways to prevent the spread of HIV in the future. You will receive HIV/STI risk reduction counseling, HIV  and STI 
testing, physical and rectal examinations, and routine laboratory testing.  
• If you decide not to join this study : there are methods available to prevent sexually 
transmitted HIV , including condom use during sex and/or the use of daily oral 
Truvada® for pre -exposure prophylaxis (PrEP) or post-exposure prophylaxis 
(PEP). Study staff can provide you with additional information about PrEP and PEP if you are interested.   
 Please take time to read this entire form and ask questions before deciding whether to 
take part in this study. If you do decide to take part in this study, you will sign your name on this form. A copy of this form will be offered to you. Signing this consent form does not mean you will be able to join the study. You must first complete the screening tests and exams to see if you are eligible. It is important to know that your participation in this research is your decision and taking part in this study is completely voluntary. You may decide to stop being in the study at any time.   
 What  is the study product?   
Elvitegravir (EVG) is an anti -HIV medication that is FDA approved for oral use in 
combination with other medications for the treatment of HIV. EVG works in a specific way to potentially prevent HIV  from making copies of itself, thereby stopping the spread of HIV 
in the human body.  
 Oral EVG has been tested in combination with other medications in large clinical studies 
for treatment of HIV infection. These studies have shown that EVG in combination with 
other drugs is generally safe, with the most frequently reported adverse events being 
 
 
 
MTN -039, Version 1. 0 94  March 6, 2019  
 
 related to the stomach and intestines. EVG in the form of an insert  has been tested in 
animals in the vagina and in the rectum for drug absorption and safety with no findings of 
concern.  
 Tenofovir alafenamide (TAF ) is a  medication  that is FDA approved for the treatment of 
chronic hepatitis B or in combination with other medications for the treatment of HIV. TAF 
also inhibits the replication of HIV virus, therefore stopping the spread of HIV in the human 
body.  
 TAF has been tested in clinical studies for safety and efficacy alone and as part of combination therapy that includes EVG. Similarly, study results indicated that TAF taken alone or in combination with other anti -HIV medications is generally safe.  
  Researchers now would like to learn about the safety of the TAF/ EVG Insert applied 
rectally and how the body absorbs, distributes, and gets rid of TAF and EVG.  In this study, 
TAF and EVG are being tested for the first time in humans as a rectally -applied insert.    
 
Who will be in this research study and what will I be asked to do if I join?  
The study includes a total of 10 clinic visits and one final contact, including the Screening Visit which is taking place today. All clinical visits will take place at this study clinic.  
 Study Visit Schedule    
 
 Screening Visit :   
 The procedures done today will take about [SITES TO INSERT TIME] . Multiple visits may 
be conducted to complete all required screening procedures.  
 You will:  
• Answer questions to confirm you are able and willing to join the study  
• Answer questions about where you live, your medical history, including what medications you are taking    
• Provide study staff your contact information (i.e. where you live and how we can contact you)  

 
 
 
MTN -039, Version 1. 0 95  March 6, 2019  
 
 • Be asked to abstain from some medications during your participation in the study:  
 Blood thinners  
 Non-study related rectally -administered medications and any products 
containing N -9 
 Certain medications that might interact with TAF or EVG  
 Medications used for PrEP (oral Truvada® or other PrEP ) or PEP (post -
exposure prophylaxis) . However, if you need medication due to a 
known or potential exposure to HIV, you should take it but let the study 
staff know as soon as possible  
• Talk with study staff about sexually transmitted infections (STIs), HIV, HIV/STI testing, and ways to avoid HIV and other infections passed through sex   
• Have a physical exam  
• If applicable, h ave your urine or vaginal fluid collected (via a swab) to test for 
sexually -transmitted diseases and other infections  
• Provide a blood sample [SITES TO INSERT AMO UNT] : 
o To test the health of your blood, liver and kidneys  
o To test for infections that typically are passed through sex, including HIV and syphilis  
 You will be told your test results as soon as they are available. You 
will talk with the study staff about the meaning of your results, how 
you feel about them, and learn about ways to prevent HIV and other sexually transmitted infections. Sometimes HIV tests are not clearly positive, but also not clearly negative. In that case, we will do more tests until we are sure of your status. To participate in the study, you must receive the results of your HIV test. If the test shows you have HIV, you cannot join the study. We will refer you to available sources of medical care and other services you may need.  
• Have a throat swab (like a Q -tip) collected, to test for infections passed through 
sex 
• Have a rectal examination. Rectal fluid will be collected with a swab;  these will be 
used to test for sexually transmitted infections (STIs). To examine the rectum, study staff will insert a short hollow tube called an anoscope.  The c linician will 
insert the swab through the hollow tube to collect the sample.  
• If applicable:  
o Your urine will be tested for pregnancy  
 If you are pregnant you cannot join this study  
 Staff will discuss with you ways to avoid getting pregnant  
• Be treated or referred for treatment of sexually transmitted infections, and/or be referred for any other care if needed  
• Receive your test results, when available. It is expected that all of your results will be available by [SITES TO SPECIFY TIMEFRAME] .     
• Be offered male condoms  
• Be compensated for your visit  
• Schedule your next visit to enroll in the study, if you are willing and eligible.  
 
 
 
MTN -039, Version 1. 0 96  March 6, 2019  
 
  You will be asked to abstain from the following activities at timepoints specified during the study:  
 
Activity:  Abstain For How Long?  
• Receptive  intercourse  
o Anal 
o Oral 
• Receptive an al or genital 
stimulation (e.g., fingers, partner 
placing their mouth on your  anal or 
genital area)  
• Inserting any non- study products 
or objects into your rectum, including:  
o Fingers  
o Rectal medications  
o Enemas  
o Lubricants  
o Sex toys (dildos, anal 
plugs, etc.)  • 72 hours (3 days) prior to each clinic 
visit 
• 72 hours (3 days) following each clinic visit 
 
• Receptive vaginal intercourse  
• Inserting non- study products or 
objects into your vagina, including:  
o Fingers  
o Spermicides  
o Vaginal medications 
(including hormones)  
o Vaginal douches  
o Lubricants  
o Vaginal moisturizers  
o Sex toys (vibrators, dildos, 
etc.) • 72 hours (3 days) prior to each clinic 
visit 
 
• Using aspirin (greater than 81 mg) 
and non- steroidal anti -
inflammatory drugs (NSAIDS)  • 72 hours (3 days) prior to tissue 
sample collection visit  
• 72 hours (3 days) following tissue sample collection visit  
 
If you do not think you can be sexually abstinent for the required length of time 
before and after study visits, you should not join this study.   
 
If you decide not to join this study , blood and other samples collected at this visit will not 
be kept or used for any tests other than those listed above.  
 Enrollment Visit:  
 Your Enrollment Visit (the visit where you enter the study) will take about [SITES TO 
INSERT TIME.]   
 
 
 
MTN -039, Version 1. 0 97  March 6, 2019  
 
  The following procedures are specific to the Enrollment Visit, which will take place up to 45 days after your Screening Visit .  
 You will:  
• Answer questions to confirm you are able and willing to join the study  
• Update your contact information  
• Be assigned to a study sample collection sequence  
o You will be assigned to one of two groups for timing of sample collection 
(rectal fluid and vaginal fluid [if applicable ] and rectal tissue) by random 
chance (like a roll of the dice) . Neither you nor the study staff can control 
which group you will be assigned to.  
o At some of your study visits after the Enrollment Visit, these samples may be collected at approx imately 2, 4, and/or 6 hours after receiving the 
TAF/ EVG Insert(s), and approximately 24, 48, or 72 hours later, depending 
on the timing of sample collection you have been assigned to. This table shows the different times when each group has samples collec ted: 
 
Visit  Post -
Dose 
Hours  Rectal Tissue  Rectal Fluid  Vaginal fluid 
 Group 
1 Group 
2  Group 
1 Group 
2  Group 
1 Group 
2 
Dosing Visits  
(Visits 3 and 7)  
 2 X  X  X  
4    X  X 
6   X  X  
24-hour Post -
Dosing Visits  
(Visits 4 and 8)  
 24  X  X  X 
48-hour Post -
Dosing Visits  
(Visits 5 and 9)  
 48 X  X  X  
72-hour Post -
Dosing Visits  
(Visits 6 and 10)  
 72  X  X  X 
 o You will be able to find out today at which visit(s) you will have these 
samples collected and how long each study visit will last.  
o These samples will help researchers learn how the body absorbs, 
distributes, and gets rid of TAF and EVG . 
 
 
 
MTN -039, Version 1. 0 98  March 6, 2019  
 
 • Talk with study staff about the following:  
o The instructions and procedures of the study and how to follow the study guidelines, including  the sexual abstinence requirement and use of non-
study products/objects.  
o Sexually transmitted infections (STIs), HIV, HIV/STI testing, and ways to avoid HIV and other infections passed through sex   
• Discuss any health problems you may have had in the past or since your last visit (including what medications you are taking)  
• Discuss with study staff the initiation of any new medication, over the counter drug 
or food supplement product  (vitamins, nutritional supplements and herbal 
preparations ).  
• Complete a brief computer -administered self -interview  (CASI) . This will take  
approximately 20- 30 minutes. You will be asked some questions about your 
experience and comfort in using rectal products, as well as douching or other rectal 
hygiene practices, among other things.   
• Provide a blood sample [SITES TO INSERT AMOUNT] : 
o In case there’s a question about your test results at a later time  
o To test your blood for HIV, the virus that causes AIDS  
o To see if there is study drug  in your body prior to the use of study product   
• Have a physical exam  
• In preparation for the rectal sample collection, you will have an enema.  
o During an enema, a hollow tube about the thickness of a pencil will be used to put some saline solution (salt water) through your anus and squeeze it into your rectum to flush it out and cleanse the bowel of fecal matter (stool). 
An enema is standard procedure prior to insertion of a flexible sigmoidoscope, since fecal matter can obscure the test. This may need to be repeated so that any stool that is there is removed  
• Have a rectal  exam where rectal fluid and tissue samples will be collected.  
o To collect rectal fluid samples: Study staff or the clinician will insert a short hollow tube called an anoscope inside your rectum and insert swabs and/or sponges through the hollow tube to c ollect the sample.  
o To collect rectal tissue samples: A flexible sigmoidoscopy will be performed.  
  A flexible sigmoidoscope is a flexible, hollow tube that is placed 
inside your rectum so that the study clinician can take samples of tissue.   
 The study cli nician will collect approximately 11 tissue samples, each 
about the size of a grain of rice  
• If applicable:  
o Have a urine test for pregnancy and discuss with study staff ways to avoid getting pregnant  
o Have a swab inserted in the vagina to collect  fluid for r esearch purposes    
• Be given test results, if available 
• Be given male condoms, if you need them  
 
 
 
MTN -039, Version 1. 0 99  March 6, 2019  
 
 • Be given a home enema kit. Study staff will tell you how to use the kit at home 
the evening prior to Dosing Visit 3 . 
• Be reimbursed for your visit  
• Schedule your next visit, if applicable.  
 Dosing Visits (Visits 3 and 7) : 
 All participants will receive a single TAF/ EVG Insert at Visit 3, and two TAF/ EVG Inserts 
at Visit 7 , administered by study staff. Visits 3 and 7 will take approximately [SITES TO 
INSERT AMOUNT OF TIME] . 
You will:  
• Update your contact information  
• Review the instructions and procedures of the study and how to follow the guidelines, including about sexual abstinence and insertion of non- study products 
or objects  
• Discuss any health problems you may have had since your last visit (including what medications you are taking)  
• Have study insert(s) administered by study staff  
• Have blood samples collected [SITES TO I NSERT AMOUNT]   
o At approximately 1 hour, 2 hours, 4 hours, and 6 hours after each dose  
o An intravenous cannula (IV tube) may be placed for up to 6 hours after administration of the insert(s) for the blood draws. These samples will be collected to help researchers better understand how the study drug is processed by the body.  
• Have a rectal examination and have rectal fluid and tissue collected using the anoscope and flexible sigmoidoscope  
o For Group 1 participants, both rectal fluid and tissue samples wi ll be 
collected at 2 hours after each dose of study insert(s) and only rectal fluid will be collected at 6 hours after each dose of study insert(s). At 2 hours, the study clinician will also collect approximately 22 tissue samples, each 
about the size of a grain of rice 
o For Group 2 participants, only rectal fluid sample will be collected at 4 hours after each dose of study insert(s).   
•  If applicable:  
o Have vaginal fluid collected with a swab  
o For Group 1 participants, vaginal fluid sample will be collected at 2 hours and 6 hours after each dose of study insert(s).   
o For Group 2 participants, vaginal fluid sample will be collected at 4 hours after each dose of study insert(s).   
• Discuss with study staff about any problems that you may be experiencing as a result of administration of the study insert(s), or as a result of procedures 
performed during your visit  
• Be provided with any available test results and with treatment or a referral for treatment if your test results indicate that you require it  
 
 
 
MTN -039, Version 1. 0 100  March 6, 2019  
 
 • Be given male condoms, if you need them  
• Be reimbursed for your visit  
• Schedule your next visit or contact.  
 24-Hour Post -Dosing Visits (Visits 4 and 8) : 
 You will be asked to attend a 24- Hour Post -Dosing Visit (Visits 4 and 8) approximately 24 
hours (1 day) after each dosing visit . Each visit will take between [SITES TO SPECIFY 
TIMEFRAME]  to complete.  
At these visits, you will:  
• Update your contact information  
• Review the instructions and procedures of the study and how to follow the guidelines, including about sexual abstinence and insertion of non- study products 
or objects  
• Discuss any health problems you may have had since your last visit (including what medications you are taking)  
• Complete a brief computer -administered self -interview. This interview may take 
approximately 10 - 15 minutes. You will be asked questions about your thoughts 
on the study product, what might make the product more appealing to use and your experience with the insert administration in the clinic.  
• Have a rectal examination and have rectal fluid and tissue collected using the anoscope and flexible sigmoidoscope (Group 2 participants only) . The study 
clinician will collect approximately 22 tissue samples, each about the size of a grain 
of rice .  
• If applicable ( Group 2 participants only ) 
o Provide a small amount of vaginal fluid via swab for research purposes  
• Provide a blood sample [SITES TO INSERT AMOUNT] : 
o To help researchers to better understand how the body absorbs, distributes, 
and gets rid of the study drug  
• Speak with study staff about any problems that you may be experiencing as a result of administration of the study insert(s), or as a result of procedures performed during your visit  
• Be given any available test results  
• Be given condoms, if you need them  
• Be reimbursed for your visit  
• Schedul e your next visit or contact.  
 48-Hour Post -Dosing Visits (Visits 5 and 9) : 
 You will be asked to attend a 48- Hour Post -Dosing Visit (Visit s 5 and 9)  approximately 48 
hours (2 days) after each dosing visit . Each visit will take between [SITES TO SPECIFY 
TIMEFRAME]  to complete.  
 At these visits, you will:  
 
 
 
MTN -039, Version 1. 0 101  March 6, 2019  
 
 • Update your contact information  
• Talk with study staff about the instructions and procedures of the study and how to follow the guidelines, including about sexual abstinence and insertion of non-study products or objects  
• Discuss any health problems you may have had since your last visit (including what medications you are taking)  
• Have a rectal examination and have rectal fluid and tissue collected using the anoscope and flexible sigmoidoscope (Grou p 1 participants only)  
o In preparation for the tissue collection you will have an enema (rectal lavage).    
o The study clinician will collect approximately 15 tissue samples, each about 
the size of a grain of rice.  
• If applicable ( Group 1 participants only)  
o Provide a small amount of vaginal fluid via swab for research purposes  
• Provide a blood sample [SITES TO INSERT AMOUNT] :  
o To help researchers to better understand how the study drug is processed by the body  
• Discuss with study staff about any problems that you may be experiencing as a result of administration of the study insert(s), or as a result of procedures performed during your visit  
• Be given any available test results  
• Be given condoms, if you need them  
• Be reimbursed for your visit  
• Schedule your next visit or contact.  
 72-Hour Post -Dosing Visits (Visits 6 and 10)  
 You will be asked to attend a 72-Hour Post -Dosing Visit (Visit s 6 and 10)  approximately 
72 hours (3 days) after each dosing visit . Each visit will take between [SITES TO 
SPECIFY TIMEFRAME]  to complete.  
 At these visits, you will:  
• Update your contact information  
• Talk with study staff about the instructions and procedures of the study and how to follow the guidelines, including about sexual abstinence and insertion of non-study products or objects  
• Discuss any health problems you may have had since your last visit (including what medications you are taking)  
• Have an in- depth interview (at Visit 10 only). This interview may take approximately 
30 - 45 minutes . You will be asked questions about your thoughts on the study 
product, if the product is acceptable to you, what might make the product more appealing to use and your experience with the insert administration in the clinic, among other topics.  This conversation will be audio- recorded to make sure to 
record your words exactly how you said them . The audio recording, notes, and 
 
 
 
MTN -039, Version 1. 0 102  March 6, 2019  
 
 analyses from these materials will be kept confidential and will only use study numbers or made up names, and the hardware will be physically protected in a locked area. This means that no one other than the study team will have access to your responses. The information that links you to the research materials w ill be 
kept in a secure location that will be accessed only by members of the MTN -039 
study team for the purposes of this research.  
• Have a rectal examination and have rectal fluid and tissue collected using the anoscope and flexible sigmoidoscope (Group 2 participants only)  
o In preparation for the tissue collection you will have an enema (rectal lavage).    
o The study clinician will collect approximately 15 tissue samples, each about 
the size of a grain of rice.  
• If applicable ( Group 2 participants only)  
o Provide a small amount of vaginal fluid via swab for research purposes  
• Provide a blood sample [SITES TO INSERT AMOUNT] :  
o To test the health of your blood, liver and kidneys (Visit 10 only)  
o To test your blood for HIV, the virus that causes AIDS (Visit 10 only)  
o To help researchers to better understand how the body absorbs, distributes, and gets rid of the study drug  
• Discuss with study staff about any problems that you may be experiencing as a result of administration of the study insert(s), or as a result of procedures performed during your visit  
• Be given any available test results  
• Be given condoms, if you need them  
• Be given a home enema kit  at Visit 6 . Study staff will tell you how to use the kit at 
home the evening prior to Dosing Visit 7.  
• Be reimbursed f or your visit  
• Schedule your next visit or contact.  
 Final Contact (Visit 11)  Your Final Contact will take place approximately 3- 7 days following Visit 10 . This 
visit/contact will take approximately [SITES TO SPECIFY TIMEFRAME]  to complete and 
can be conducted over the phone .  
 At this visit, you will:  
• Update your contact information  
• Discuss any health problems you may have had since your last visit (including what medications you are taking)  
• Discuss any problems that you may be experiencing as a result of using the study insert(s) or as a result of procedures performed during the study  
• Be reimbursed for your visit, if required  
• Schedule your next visit or contact (if necessary)  
• Be given any available test results  
 
 
 
MTN -039, Version 1. 0 103  March 6, 2019  
 
 • Be given male condoms, if y ou need them.  
 It is important that you remember that at any time during the study, study staff can answer any questions you may have about the procedures mentioned above or any other aspect of this study.  
 Other Procedures  
In addition to the procedures listed above, it is possible that study clinicians may need to perform additional tests, if necessary (e.g., if you report having symptoms of a urinary, genital, or other infection and/or other issues). These tests might include the following:  
• P hysical exam  
• Pelvic exam  
• Genital exam  
• Rectal exam  
• Test rectal or throat samples for STIs  
• Test cervix/vaginal samples for STIs 
• Test your urine for STIs or other infections  
• Test your blood for STIs  
• Test your blood to check the health of your blood, liver and kidneys  
• Give you treatment or refer you for treatment of STIs or other issues, if needed.  
 Further you may need to provide additional samples if any of the above procedures need to be repeated due to issues with sample processing, and/or testing or shipping.  
Additional testing may be performed as part of quality control.  
 What are the possible risks, side effects, and discomforts of this research study?  
It is not expected that participation into this study will expose you to unreasonable risks.  
 Risks from study drug  
The following side effects have been associated with the use of EVG in participants in other studies in which the drug was taken by mouth. These side effects may or may not be associated with the use of EVG when the drug is taken rec tally:  
 
Most Common Adverse Reactions  occurring in 10% or more of participants receiving EVG 
by mouth:  
• Headache  
• Diarrhea 
• Nausea  
• Tiredness  
 
 
 
 
MTN -039, Version 1. 0 104  March 6, 2019  
 
 Other Common Adverse Reactions  occurring in between 1% and 10% of participants 
receiving EVG by mouth:  
• Depression  
• Inability to sleep  
• Pain in abdomen  
• Vomiting  
• Indigestion  
• Rash  
 
Uncommon Adverse Reactions  occurring in between 0.1% and <1% of participants 
receiving EVG by mouth:  
• Depression  
• Inability to sleep  
• Suicidal thoughts and suicide attempt in patients with a history of depression 
or psychiatric illness  
 
The following side effects have been associated with the use of TAF in participants in 
other studies in which the drug was taken by  mouth. These side effects may or may not 
be associated with the use of TAF when the drug is taken rectally:  
 
Most Common Adverse Reactions  occurring in 5% or more of participants receiving TAF :   
• Headache  
• Abdominal pain  
• Cough 
• Back pain  
• Fatigue 
• Nausea  
• Joint pain  
• Diarrhea 
• Dyspepsia  
 
Other Common Adverse Reactions  occurring in between 1% and 5%  of participants 
receiving TAF : 
• Vomiting  
• Rash   
• Flatulence  
 There is a theoretical risk of the development of HIV drug resistance to tenofovir or elvitegrav ir if the participant acquires HIV infection around the time of study drug 
administration.  
 It is also possible that you may have an allergic reaction to the study product. Signs of allergic reaction may include: rash, dizziness, itching, muscle aches, nausea, fainting, facial flushing, chest tightness, cough, hives, fever, and shortness of breath.  
 
 
 
MTN -039, Version 1. 0 105  March 6, 2019  
 
  Risks from rectally -applied drugs  
The following side effects have been associated with the repeated use of rectally -applied 
gel in other studies. These side eff ects may or may not be associated with the use of 
TAF/ EVG  Insert  administered rectally:  
 
More Common Adverse Reactions  occurring in 5% or more of participants:  
• Passing gas from the intestinal tract  
• A sudden, almost uncontrollable, need to relieve the bowels  
• Diarrhea (loose, frequent stools)  
 
Less Common Adverse Reactions  occurring in less than 5% of participants:  
• Abdominal bloating, feeling full, or a sense of abdominal pressure and/or pain  
• Feeling a constant need to pass stools, despite an empty bowel 
• Irritation in the rectum  
• Rash  
• Worsening of existing problems due to hemorrhoids  
 Risks from phlebotomy and IV cannula placement (blood tests)   
• You may feel discomfort.  
• You may feel dizzy or faint.  
• You may have a bruise, swelling, small clot, or infection where the needle goes in your arm.  
• You may have excessive bleeding.  
 Risks of throat swab  
• A throat swab often causes a momentary gagging reflex.  
 Risks of enemas  
• The main risk from having an enema is temporary discomfort. A hollow plastic tube about the thickness of a pencil will be used to administer about 120- 125 mL of 
enema fluid into the rectum.  
• You may experience some mild discomfort and a bloated or “crampy”  feeling.  
• If you have any hemorrhoids or other painful conditions, you might feel anal or rectal discomfort.  
• There is also a remote possibility of rectal perforation associated with the use of an enema.  
 
Risks of finger and anoscope rectal exams 
• During rectal exams and collection of rectal fluid and tissue samples, insertion of a finger or lubricated anoscope will likely cause mild discomfort.  
 Risks of rectal swab/sponge insertion  
 
 
 
MTN -039, Version 1. 0 106  March 6, 2019  
 
 • Insertion of rectal swabs and sponges may cause mild discomfort, in addition to a slight risk of bleeding.  
 Risks of flexible sigmoidoscopy  
• A flexible sigmoidoscopy is a commonly practiced medical procedure where a flexible tube with a small camera attached is used to look inside the rectum and lower colon. The procedures done in this study will not involve any increased risk over usual flexible sigmoidoscopy performed for clinical indications (for routine medical diagnosis or treatment).  
• The risks associated with these procedures include mild discomfort, a sudden urge to relieve the bowels, the feeling of having a “bloated stomach”, low blood 
pressure, light bleeding following a bowel movement, abnormal odor or discharge from the rectum, as well as flatulence (gas passed through the anus/rectum) following the procedure.  
 Risks of endoscopic biopsy  
• Endoscopic biopsies (biopsies done using a slender, lighted optical tube) to collect rectal tissue samples are painless and heal quickly within 3 days.  
• On extremely rare occasions, the endoscopic procedure or biopsies may lead to 
pain, infection (sepsis), bleeding or perforation (small hole or tear) of the stomach 
or intestines. Perforation occurs less than once out of every 1,000 procedures 
(88/100,000 procedures). If this extremely rare complication occurs, antibiotics and surgery to repair the tear may be necessary.  
• If you engage in sexual intercourse before the biopsy has healed, there exists the risk of temporary discomfort, and increased risk of STIs  and HIV infection . 
 (If applicable) Risks of vaginal swab  
• During vaginal fluid collection, you may feel discomfort or pressure in your vagina or genital area.  
 Other Possible Risks:  
• You may become embarrassed and/or worried when discussing your sexual practices, ways to protect against HIV and other infections passed through sex, 
and your test results.  
• You may feel anxious while waiting for your test results, and after receiving them. Trained study counselors will help you deal with any feelings or questions you have.  
• Finding out your HIV status could cause depression and/or suicidal thoughts.  It 
could also cause problems between you and your partner(s). If you have any problems, study counselors will talk with you and/or your partner to try to help resolve them.  
• It is possible that you and/or your partner(s) may experience problems in your relationship(s) associated with maintenance of the study -required abstinence.  
 
 
 
MTN -039, Version 1. 0 107  March 6, 2019  
 
 • It is possible that others may learn of your participation here and, because of this, may t reat you unfairly or discriminate against you. For example, you could have 
problems getting or keeping a job, or being accepted by your family or community.   
• The interviews that take place at some of your clinic visits will be computer -
administered and questions of a personal nature may be asked. Responding to these questions may make you uncomfortable. You may choose not to answer any question that makes you uncomfortable.   
 We will make every effort to protect your privacy and confidentiality during the  study visits. 
Your visits will take place in private. Any names that might be mentioned during the interview will NOT be retained.  Instead a generic description will be used in the records (i.e., if you refer to a friend’s name, “FRIEND1” will be noted).  
 What are possible benefits from taking part in this study?  
• There are no direct benefits for taking part in this study, but you or others may have future benefit from information learned in this study. You may also learn more about HIV and other diseases and ways to protect yourself from infection.   
• It is important that you know that you will not be paid any additional money (beyond the reimbursement described below for study participation) if the study product being studied is eventually licensed for use.  
• You will have physical and rectal exams. You will also have tests to check the overall health of your liver, kidneys, and blood cells. If these tests show that you might have any health problems, you will be told about medical care and other services av ailable to you. This will be available to you even if you do not enroll in 
this study. This study cannot provide you with general medical care, but study staff will refer you to other available sources of care.  
• You will get counseling and testing for HIV and STIs. If you have infections passed through sex, other than HIV infection, you will be offered medicine to treat them or provided information for where you may receive treatment, and study staff will discuss options available for counseling and treatme nt of your partner. This 
treatment or referral for treatment is available to you even if you do not enroll in this study.   
• If you become infected with HIV, you will need to receive care from your own health care provider or we will provide you with a referral. This study does not provide medication for treatment of HIV/AIDS.    
• You will receive free male condoms, if you need them.  
 Will this study product prevent HIV infection? 
We do not know if the drug s contained within the insert work to protect men and women 
from getting HIV. This study is not testing to see if TAF/ EVG Insert prevents HIV infection. 
Researchers are continuing to study TAF and EVG to learn more about how they work in 
humans to protect against HIV infection. There are two known effective ways to reduce your risk of contracting HIV: the use of condoms and/or the use of oral pre- exposure 
prophylaxis (PrEP) medication, Truvada® , or post -exposure prophylaxis (PEP) .  PrEP is 
 
 
 
MTN -039, Version 1. 0 108  March 6, 2019  
 
 an HIV prevention method in which people who do not have HIV take an oral tablet to reduce their risk of becoming infected. Study staff can provide you with additional information about PrEP and PEP if you are interested in learning more. If you are 
interested in these alternative options , you may also want to discuss them with your 
doctor. If you are currently taking PrEP or PEP or plan to take PrEP in the near future, 
you will not be eligible for this study.   
 What if there is new information learned during this study?  
We will tell you about new information from this or other studies that may affect your willingness to stay in this study. You will also be told when study results may be available, and how to learn about them.  
 A description of this clinical trial will be available on http://www.ClinicalTrials.gov. This Web site will not include information that can identify you. At most, the Web site will 
include a summary of the results. You can search this Web site at any time.  
 Is it possible that I may be taken out of the study without my consent? 
A study clinician may need to remove you from the study early without your permission if:  
• The study is cancelled by the US FDA, US NIH, CONRAD (the organization that supplies the rectal insert), the US Office for Human Research Protections (OHRP), 
MTN, the local or other government or regulatory agency, or the Institutional 
Review Board (IRB). An IRB is a committee that watches over the safety and rights of research participants.  
• The Study Monitoring Committee (SMC) recommends that the study be stopped early . A SMC reviews the progress of the study and the kinds of effects that people 
report while they are participating in the study.  
• You are found to be infected with HIV (see “If You Become Infected With HIV” section below) or an STI  in your anal or genital area. 
• (Females) You become pregnant or are breastfeeding (see “If You Become Pregnant” section below).  
• If you start on medication for PEP or PrEP  
• You report the use of the following prohibited medications:  
o Anticoagulants (e.g., heparin, Lovenox, warfarin and Plavix)  
o Certain CYP3A inhibitors or inducers (e.g., grapefruit, Prozac, Zoloft, 
Prednisone, Prilosec)  
• A study clinician decides that using the study would be harmful to you, for example you have a bad reaction to the study insert(s).  
• Other reasons that may prevent you from completing the study successfully, such as you are not able to reliably keep appointments.  
 
If You Become Infected With HIV  
Your participation in this study will not cause HIV infection. However, there is always a chance that through sexual activity or other activities (e.g., needle sharing 
for recreational  drug use) you may become infected with HIV. In the unlikely event 
 
 
 
MTN -039, Version 1. 0 109  March 6, 2019  
 
 that you become infected with HIV, study staff will give you counseling and refer you to available medical care and other services you may need. The study does not pay for this care. Tests will be performed to see if you have HIV drug resistance. This will allow your doctor to know what HIV drugs would be best for the treatment of your type of HIV. If the HIV test shows that you have been infected 
with HIV, you will stop using the study insert. You may be referred to other research studies. Continued study participation would be of no added benefit to you, so your participation in the study will be discontinued.  
 
(If applicable) If You Become Pregnant  
The study insert is not a birth control method. You must agree to use an effective method of birth control such as birth control pills or another hormonal -based 
method, or  an intrauterine device (IUD), unless you or your partner have been 
sterilized (i.e., no longer able to become pregnant), and/or you only have sex that cannot lead to pregnancy (no penile- vaginal intercourse) . You should use an 
effective method of contraception at least 30 days prior to enrollment or abstain from penile- vaginal intercourse 90 days prior to enrollment.    
 
We do not know what effect TAF/ EVG Insert has on pregnancy, including its effect 
on the fe tuses of women who use the rectal insert when pregnant, or the babies of 
women who use the insert when breastfeeding. Because of this, pregnant women and women who are breastfeeding may not join this study. Women who join this study will have pregnancy tests while in the study.  
 
If you become pregnant during the study, study staff will refer you to available medical care and other services you or your baby may need. The study does not pay for this care. You will stop using the insert and you will exit the study. We will 
contact you to find out about your pregnancy and the outcome of your pregnancy. The outcome of your pregnancy is important to study staff; therefore, your pregnancy will be followed until the results of your pregnancy are known. If you becom e pregnant and you deliver a baby from that pregnancy, we will contact you 
approximately one year after your delivery to collect information about the health of your baby.  
 
If you are removed from or choose to leave this study, you will be asked to complete the procedures described for Visit 1 1, if you are willing to do so. The study clinician will ask 
you to stop using the study insert but continue to come in for follow -up visits and 
procedures if you have a bad reaction to the insert.  
 Will there be any payments if I take part in this research study?  
[SITES TO INSERT INFORMATION ABOUT LOCAL REIMBURSEMENT:]  You will 
receive [ SITES TO INSERT AMOUNT $] for your time, effort, and travel to and from the 
clinic at each scheduled visit. You may receive [ SITES TO INSERT AMOUNT $] for any 
visits which occur in between your normally scheduled visits.  
 
 
 
 
MTN -039, Version 1. 0 110  March 6, 2019  
 
 What are the costs?  
[SITES TO COMPLETE ACCORDING TO SITE CAPACITY]  There is no cost to you for 
study related visits, physical/rectal examinations, laboratory t ests or other procedures. 
Treatments available to you from the study site for infections passed through sex will be given to you free of charge or you will be referred for available treatment for the duration of the study.  
 Are there any other studies if I  cannot join this one?  
There may be other studies going on at this study clinic or in the community for which you may be eligible. If you wish, we will tell you about other studies that we know about. There may also be other places where you can go for HI V counseling and testing. We will tell 
you about those places if you wish. If you choose not to take part in this study, it will have no effect on the regular medical care available to you at this clinic or elsewhere.  
 Who will know about my participation in this research study?  
Any information about you obtained from this research will be kept as private as possible. All records related to your involvement in this research study will be kept in a [ SITES TO 
INSERT ]. Your identity on these records will be indicated by a number rather than by your 
name, and the information linking these numbers with your name will be kept separate from the research records.  We will keep the audio recordings and materials from all 
interviews and discussions confidential and will only use study numbers or fake names.  
[Sites to modify with their site- specific source documentation storage duration 
requirements if required by their IRBs/IECs: All original study documents that provide 
information about you for this study will be kept  for at least two years after either the study 
insert is approved for use or research on the insert is stopped.]  
 Efforts will be made to keep your information confidential. However, it is not possible to guarantee confidentiality. Your personal information may be disclosed if required by law. Any publication of this study will not use your name or identify you personally. The study staff may use your personal information to verify that you are not in any other research studies. This includes studies conducted by other researchers that study staff know about.  
 Your records may be reviewed by:  
• Study staff  
• Site Institutional Review Boards  
• PPD (a contract research organization that monitors clinical trials for safety and data quality)  
• Representatives of CONRAD, the nonprofit organization that supplies the study rectal 
insert  
• Representatives of the US Federal Government, including the US Food and Drug Administration (FDA), US Office for Human Research Protections (OHRP), NIH, and/or contractors of NIH  
• Other local , US and international regulatory authorities.  
 
 
 
MTN -039, Version 1. 0 111  March 6, 2019  
 
  [Sites to include/amend the following:]  [LOCAL/STATE/NATIONAL ] regulations 
require study staff to report the names of people who test positive for HIV and other infections  passed during sex to the [LOCAL HEALTH AUTHORITY ]. Outreach workers 
from the [LOCAL HEALTH AUTHORITY ] may then contact you about informing your 
partners, since they also should be tested. If you do not want to inform your partners yourself, the outreach workers will contact them, according to the confidentiality guidelines of the [HEALTH AUTHORITY ]. 
 [Sites to include/amend the following:]  
The researchers will do everything they can to protect your privacy. In addition to the efforts of the study staff to help keep your personal information private, we have obtained a Certificate of Confidentiality from the US Federal Government. This Certificate protects study staff from being forced to tell people who are not connected with this study, such as the court system, about your participation or information you give for study purposes.  
With limited exceptions, researchers may not disclose names, information or documents containing information you give for study purposes. This Certificate does  not expire.   
 However, if the study staff learns of possible child abuse and/or neglect or a risk of harm to you or others, they will be required to tell the proper authorities . Also, we may have to 
release your information if the organization that is funding this study , [Funding Agency ], 
requests the information, or if the FDA, EMA or other regulatory body tells us to release this information. This Certificate does not prevent you from releasing information about yourself and your participation in the study.  
 What if I am injured as a result of participating in this study?  
[SITES TO SPECIFY INSTITUTIONAL POLICY:] It is unlikely that you will be injured as 
a result of study participation. If you are injured, the [institution ] will give you immediate 
necessary treatment for your injuries. You [will/will not ] have to pay for this treatment. 
You will be told where you can receive additional treatment for your injuries. The U.S. National Institutes of Health (NIH) does not have a mechanism to pay money or give other forms of c ompensation for research related injuries. You do not give up any legal rights 
by signing this consent form.  
 May I withdraw my consent for participation in this research study? [SITE TO SPECIFY INSTITUTIONAL POLICY :] Taking part in this study is completel y 
voluntary. You may choose not to take part in this study or leave this study at any time. If you choose not to participate or to leave the study, you will not lose the benefit of services to which you would otherwise be entitled at this clinic, nor will the confidentiality of the care provided for you here be affected. You should feel free coming back to this facility even if you decide not to participate in this study. If you want the results of the study after the study is over, let the study staff members know.  
 What do I do if I have questions?  
 
 
 
MTN -039, Version 1. 0 112  March 6, 2019  
 
 If you ever have any questions about the study, or if you have a research- related injury, 
you should contact [insert name of the investigator or other study staff]  at [insert 
telephone number and/or physical address ]. 
 If you have questions about your rights as a research participant, you should contact [insert name or title of person on the IRB or other organization appropriate for the site] at [insert physical address and telephone number].  
 
 
 
 
MTN -039, Version 1. 0 113  March 6, 2019  
 
 CONSENT FOR LONG -TERM STORAGE AND FUTURE TESTING OF 
SPECIMENS  
There might be a small amount of blood, rectal tissue, rectal fluid, or vaginal fluid left over after we have done all of the study -related testing. We would like to ask 
your permission to store these leftover samples and related health information for 
use in future studies, such as future research to fight HIV and other related 
diseases. This health information may include personal facts about you such as your race, ethnicity, sex, medical conditions and your age range.   
 
If you agree, your samples and related health data will be stored safely and securely at facilities that are designed so that only approved researchers will have access to the samples. Some employees of the facilities will nee
d to have access to your 
samples to store them and keep track of where they are, but these people will not have information that directly identifies you.  The de -identified data and specimens 
could then be used for future research by our research team or ot her researchers 
without notifying you or asking your permission for this use.  Your biospecimens will 
never be used for commercial profit.    
 
The type of testing planned for your leftover specimens is not yet known. However, samples may be used by the MTN Laboratory Center to complete additional quality 
assurance testing, ensuring that the tests work correctly and supply accurate data.  
No genetic testing on either a limited set or the full set of genes or sequencing (for 
example, the mapping of all of your  genes, also known as whole genome 
sequencing) is planned for leftover samples that are stored for the purposes of 
future research. It is important that you know that any future testing or studies 
planned for these specimens must be approved by an Institutional Review Board before they can be done.   
 
You can still enroll in this study if you decide not to have leftover samples stored for future studies.  If you do not want the leftover samples stored, we will destroy them. You can withdraw your consent for  the storage and future testing of specimens at 
any time by providing your request in writing to the person in charge of this study.  
However, researchers will not be able to destroy samples or information from 
research that is already underway.  
 _______________   
Initials and Date  I DO agree to allow my biological specimens and health 
data to be stored and used in future research studies.  
 _______________    
Initials and Date  I DO NOT agree to allow my biological specimens and 
health data to be stored and used in future research 
studies.  
 
   
 
 
 
MTN -039, Version 1. 0 114  March 6, 2019  
 
 SIGNATURES - VOLUNTARY CONSENT  
 [INSERT SIGNATURE BLOCKS AS REQUIRED BY THE LOCAL  IRB/EC]:  If you have 
read this consent form, or had it read and explained to you, and you understand the information, and you voluntarily agree to the study, please sign your name or make your mark below.  
 ____________________ ________________________ ______________  
Participant Name   Participant Signature/Mark   Date  
(print)  ____________________ ________________________ ________ ______  
Study Staff Conducting  Study Staff Signature   Date  
Consent Discussion (print)  
  ____________________ ________________________ ______________  
Witness Name (print)  Witness Signature    Date  
      
 
 
 
 
 
 
 
MTN -039, Version 1. 0 115  March 6, 2019  
 
 REFERENCE LIST  
 
1. McGowan I. Microbicides for HIV prevention: Reality or hope? Current Opinion in 
Infectious Diseases 2010;23:26 -31. 
2. Leynaert B, Downs AM, de V, I. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on 
Heterosexual Transmission of HIV. Am J Epidemiol 1998;148:88 -96. 
3. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, Buchbinder, S.P. Per -
contact risk of human immunodeficiency virus transmission between male sexual partners. 
American Journal of Epidemiology 1999;150:306 -11. 
4. Carlos JA, Bingham TA, Stueve A, et al. The role of peer support on condom use among Black and Latino MSM in three urban areas. AIDS Education and Prevention 2010;22:430-
44. 
5. Gorbach PM, Manhart LE, Hess KL, Stoner BP, Martin DH, Holmes KK. Anal intercourse 
among young heterosexuals in three sexually transmitted disease clinics in the United 
States. Sexually Transmitted Diseases 2009;36:193- 8. 
6. Ray AS, Fordyce MW, Hitchcock MJ. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Antiviral Res 2016;125:63- 70. 
7. Gilead Sciences I. Gilead Sciences. VITEKTA- elvitegravir tablet, film coated:  Package 
insert (2012). 2012.  
8. CONRAD. Investigator's Brochure: Elvitegravir Vaginal Insert 8mg. 2017.  
9. CONRAD. In vitro Dissolution of Elvitegravir Insert. 2017.  
10. Ramanathan S, Mathias AA, German P, Kearney BP. Clinical pharmacokinetic and 
pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 
2011;50:229 -44. 
11. CONRAD. A 14 -Day Rectal Irritation and Pharmakinetic Study of Elvitegravir in Rabbits - 
Draft Pathology Report (MPI Study Number: 1645- 114). 2017.  
12. Gilead Sciences I. VEMLIDY Packet Insert. 2018.  
13. Gilead Sciences I. GENVOYA Packet Insert. 2017.  
14. CONRAD. Investigator's Brochure: Tenofovir Alafenamide/Elvitergravir (TAF/EVG) Combo Vaginal Insert. 2018.  
15. Murakami E, Wang T, Park Y, et al. Implications of efficient hepatic delivery by tenofovir alafenamide (GS -7340) for hepatitis B virus therapy. Antimicrob Agents Chemother 
2015;59:3563 -9. 
16. Babusis D, Phan TK, Lee WA, Watkins WJ, Ray AS. Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS- 7340. 
Molecular pharmaceutics 2013;10:459- 66. 
17. Prathipati PK, Mandal S, Pon G, Vivekanandan R, Destache CJ. Pharmacokinetic and 
Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded 
Nanopartic les in Humanized Mice Model. Pharm Res 2017;34:2749- 55. 
18. Dobard C, Peet MM, Nishiura K, al. e. Dose -Ranging Pharmacokinetic Assessment of 
Vaginally Administered EVG/TAF Inserts in Macaques for PrEP.  HIVR4P; 2018 October 21-25; Madrid, Spain.  
19. CONRAD. A 14 -Day Vaginal Irritation and Pharmakinetic Study of Elvitegravir and 
Tenofovir Alafenamide Fumarate in Rabbits (Study No. 1645- 116) Draft Report. 2018.  
20. CONRAD. A 14 -Day Rectal Irritation and Pharmakinetic Study of Elvitegravir and 
Tenofovir Alafenamide Fumarate in Rabbits (Study No. 1645- 117) Draft Report. 2018.  
21. CONRAD. A 14 -day rectal irritation and pharmacokinetic study of Elvitegravir and 
Tenofovir Alafenamide fumarate in rabbits (Study No. 1645- 117)2018.  
 
 
 
MTN -039, Version 1. 0 116  March 6, 2019  
 
 22. Unger NR, Worley MV, Kisgen JJ, Sherman EM, Childs -Kean LM. Elvitegravir for the 
treatment of HIV. Expert Opin Pharmacother 2016;17:2359 -70. 
23. Cottrell ML, Garrett KL, Prince HMA, et al. Single -dose pharmacokinetics of tenofovir 
alafenamide and its active metabolite in the mucosal tissues. J Antimicrob Chemother 
2017;72:1731 -40. 
24. Agarwal K, Fung SK, Nguyen TT, et al. Twenty -eight day safety, antiviral activity, and 
pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. Journal of hepatology 2015;62:533 -40. 
25. Markowitz M, Zolopa A, Squires K, et al. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse 
transcriptase inhibitor tenofovir, in HIV -infected adults. J Antimicrob Chemother 
2014;69:1362 -9. 
26. Ruane PJ, DeJesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10 -day monotherapy 
in HIV -1-positive adults. J Acquir Immune Defic Syndr 2013; 63:449 -55. 
27. Gaur AH, Kizito H, Prasitsueubsai W, et al. Safety, efficacy, and pharmacokinetics of a 
single -tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir 
alafenamide in treatment -naive, HIV -infected adolescents: a single- arm, open- label trial. 
Lancet HIV 2016;3:e561 -e8. 
28. Pozniak A, Arribas JR, Gathe J, et al. Switching to Tenofovir Alafenamide, Coformulated 
With Elvitegravir, Cobicistat, and Emtricitabine, in HIV- Infected Patients With Renal 
Impairment: 48- Week Results From a Single -Arm, Multicenter, Open- Label Phase 3 
Study. J Acquir Immune Defic Syndr 2016;71:530 -7. 
29. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil 
fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment 
of HIV -1 infection: two randomised, double- blind, phase 3, non- inferiority trials. Lancet 
2015;385:2606 -15. 
30. Zhang W, Littlefield S, McCormick T, et al. Development and Proof -of-Concept Clinical 
Evaluation of a Freeze- dried Topical Microbicide Insert for On- demand HIV Prevention.  
HIV R4P; 2016.  
31. Dobard C, Sharma S, Martin A, et al. Durable protection from vaginal simian- human 
immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J Virol 2012;86:718- 25. 
32. Gatto NM, Frucht H, Sundararajan V, Jacobson JS, Grann VR, Neugut AI. Risk of 
perforation after colonoscopy and sigmoidoscopy: a population- based study. J Natl 
Cancer Inst 2003;95:230 -6. 
33. Chiu WK, Brand R, Camp D, et al. The safety of multiple flexible sigmoidoscopies in 
clinical trial participants (Poster).  HIV Research for Prevention (HIV R4P) 2016; 2016 10/11/2016; Chicago, IL, USA; 2016.  
 
MTN -039, Version 1.0, LoA #04 30 September 2021  Page 1 of 4 
 LETTER OF AMENDMENT # 04 TO: 
 
MTN-039 
 
A Phase 1 Open Label Safety and Pharmacokinetic Study of Rectal 
Administration of a Tenofovir Alafenamide/Elvitegravir Insert at Two Dose Levels  
 
Version 1.0, dated March 6,  2019  
 
DAIDS Protocol # 38470  
IND # 145334  
 
Date of Letter of Amendment: 30 September 2021  
______________________________________________________________________  
 
Site Instruction  
The following information impacts the MTN -039 study and must be forwarded to your Institutional Review 
Board (IRB)/Ethics Committee (EC) as soon as possible for their information and review. The f ollowing 
information does not impact the sample informed consent.  Upon receiving final IRB/EC and any other 
applicable Regulatory Entity (RE) approval(s) for this LoA, sites should submit a LoA registration packet 
to the DAIDS Protocol Registration Office (PRO) at the Regulatory Support Center (RSC). Sites will 
receive a registration notification for the LoA once the DAIDS PRO verifies that all the required LoA 
registration documents have been received and are complete. A copy of the LoA registration notification 
along with this letter and any IRB/EC correspondence should be retained in the site’s regulatory files.  
 
Summary of Revisions  
This LoA  does not impact the overall design or the study visit schedule for MTN -039. The primary 
purpose of this LoA is to  clarify sample testing for tenofovir alafenamide ( TAF) and tenofovir diphosphate 
(TFV-DP) concentrations as primary endpoints in the protocol. This LoA will add rectal mucosal tissue 
homogenates to sample testing to measure TAF concentrations and remove rectal mucosal tissue 
homogenates from testing to measure TFV -DP concentrations.   
 
Unless otherwise noted below , text to be deleted is noted by strikethrough, text to be added is noted in 
bold , and text in bold italics  is not to be added, but to serve as a clarification of the implementation item 
in question. 
______________________________________________________________________  
 
Detailed Listing of Revisions  
 
The following revis ions (1-4) were made to add rectal mucosal tissue homogenates to sample 
testing to measure TAF concentration and remove rectal mucosal tissue homogenates from 
testing to measure TFV -DP concentration .   
 
1. In the second to fourth  bullet  lists of pharmacokinetics in the “Primary Endpoints” sub-
section of Protocol Summary :  
 
Pharmacokinetics  
• EVG concentrations in:  
o Blood  
o Rectal fluid  
o Rectal mucosal tissue homogenates  
MTN -039, Version 1.0, LoA #04 30 September 2021  Page 2 of 4 
  
• TAF and TFV concentrations in  
o Blood  
o Rectal fluid  
o Rectal mucosal tissue homogenates 
 
• TFV-DP concentration in:  
o Rectal mucosal tissue homogenates  
o Rectal mucosal tissue cell isolates  
 
• TFV concentrations in  
o Rectal mucosal tissue homogenates  
 
2. In the second to fourth  bullets of pharmacokinetics in the “Primary Endpoints” sub-
section of Section 4.2, Summary of Major Endpoints:   
 
Pharmacokinetics  
• EVG concentrations in:  
o Blood  
o Rectal fluid  
o Rectal mucosal tissue homogenates  
 
• TAF and TFV concentrations in  
o Blood  
o Rectal fluid  
o Rectal mucosal tissue homogenates  
 
• TFV-DP concentration in:  
o Rectal mucosal tissue homogenates  
o Rectal mucosal tissue cell isolates  
 
• TFV concentrations in  
o Rectal mucosal tissue homogenates  
 
3. In the second to fourth bullets of pharmacokinetics in the “Primary Endpoints” sub-
section of Section 10.2, Study Endpoints:   
 Pharmacokinetics  
• EVG concentrations in:  
o Blood  
o Rectal fluid  
o Rectal mucosal tissue homogenates  
 
• TAF and TFV concentrations in  
o Blood  
o Rectal fluid  
o Rectal mucosal tissue homogenates  
 
• TFV-DP concentration in:  
o Rectal mucosal tissue homogenates  
o Rectal mucosal tissue cell isolates  
MTN -039, Version 1.0, LoA #04 30 September 2021  Page 3 of 4 
  
• TFV concentrations in  
o Rectal mucosal tissue homogenates  
 
4. In the “Rectal Tissue” column in Table 16: Specimens to be Collected to Assess Safety, 
PK and Ex Vivo Antiviral Activity , of Section 7.10, Pharmacokinetics (PK) and 
Pharmacodynamics (PD):   
 
Study Visit  Specimens collecte d for PK, PD and mucosal safety  
 Blood  Rectal Fluid  Rectal Tissue  CVF  
Visit 3  & Visit 7 -  
Samples 
collected at 1, 2, 
4 and 6 hours    • Blood for PK  
 
  Group 1 at 2 -hour  
• RF for microbiome  
• RF for PK  
• RF for PD  
 
Group 1 at 6 -hour  
• RF for PK  
 
Group 2 at 4 -hour  
• RF for PK  
 Group 1 only at 2 -hour  
• 7 samples for biomarkers  
• 4 samples for PD  
• 11 samples for PK  
o 1 for EVG  
o 1 for TAF and  TFV and TFV-
DP 
o 1 for backup  
o 8 for MMC isolation  Group 1 at 2 -hour  
• CVF for microflora  
• CVF for PK  
• CVF for PD  
 
Group 1 at 6 -hour  
• CVF for PK  
 
Group 2 at 4 -hour   
• CVF for PK  
 
 
5. Protocol Signature Page was updated to include Letter of Amendment # 04; it is 
appended to the end of this document.  
 
 The above information, as well as the changes from L oA#01, LoA#02 and LoA#03, will be 
incorporated into the next version of the protocol at a later time if it is amended.  
  
MTN -039, Version 1.0, LoA #04 30 September 2021  Page 4 of 4 
 MTN -039 
 
A Phase 1 Open Label Safety and Pharmacokinetic Study of Rectal Administration of  
a Tenofovir Alafenamide/Elvitegravir Insert at Two Dose Levels  
 
INVESTIGATOR SIGNATURE FORM  
Version 1.0; March 6, 2019  
Letter of Amendment #01; 20 September 2019  
Letter of Amendment #02; 23 March 2020  
Letter of Amendment #03; 24 July 2020  
Letter of Amendment #04; 30 September 2021  
 
 
A Study of the Microbicide Trials Network  
 
Funded by:  
Division of AIDS (DAIDS), US National Institute of Allergy and Infectious Diseases  
US Eunice Kennedy Shriver National Institute of Child Health and Human Development  
US National Institute of Mental Health  
US National Institutes of Health (NIH)  
 
IND Holder:  
DAIDS (DAIDS Protocol ID: 38470)  
 
I, the Investigator of Record, agree to conduct this study in full accordance with the provisions  
of this protocol and all applicable protocol -related documents. I agree to conduct this study  
in compliance with United States (US) Health and Human Service regulations (45 CFR 46);  
applicable U.S. Food and Drug Administration regulations; standards of the Interna tional  
Conference for Harmonization Guideline for Good Clinical Practice (E6); Institutional Review  
Board/Ethics Committee determinations; all applicable in- country, state, and local laws and  
regulations; and other applicable requirements (e.g., NIH, DAIDS) and institutional policies.  
 I agree to maintain all study documentation for at least two years after the last approval of a  
marketing application in an ICH region and until there are no pending or contemplated  
marketing applications in an ICH region or at least two years have elapsed since the formal  
discontinuation of clinical development of the investigational product. These documents  
should be retained for a longer period, however, if required by the applicable regulatory  
requirements or by an agreement with the sponsor. DAIDS will inform the  
investigator/institution as to when these documents no longer need to be retained  
 I have read and understand the information in the Investigator's Brochure(s), including the  
potential risks and side effects of the products under investigation, and will ensure that all  
associates, colleagues, and employees assisting in the conduct of the study are informed  
about the obligations incurred by their contribution to the study.  
 ____________________________  
Name of Investigator of Record (print)  
 
 
____________________________    ______________________________  
Signature of Investigator of Record    Date  